Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2016 Nov 15;37(3):514–626. doi: 10.1002/med.21420

Nanotechnology in Glycomics: Applications in Diagnostics, Therapy, Imaging, and Separation Processes

Erika Dosekova 1, Jaroslav Filip 2, Tomas Bertok 1, Peter Both 3, Peter Kasak 2, Jan Tkac 1,
PMCID: PMC5659385  EMSID: EMS74624  PMID: 27859448

Abstract

This review comprehensively covers the most recent achievements (from 2013) in the successful integration of nanomaterials in the field of glycomics. The first part of the paper addresses the beneficial properties of nanomaterials for the construction of biosensors, bioanalytical devices, and protocols for the detection of various analytes, including viruses and whole cells, together with their key characteristics. The second part of the review focuses on the application of nanomaterials integrated with glycans for various biomedical applications, that is, vaccines against viral and bacterial infections and cancer cells, as therapeutic agents, for in vivo imaging and nuclear magnetic resonance imaging, and for selective drug delivery. The final part of the review describes various ways in which glycan enrichment can be effectively done using nanomaterials, molecularly imprinted polymers with polymer thickness controlled at the nanoscale, with a subsequent analysis of glycans by mass spectrometry. A short section describing an active glycoprofiling by microengines (microrockets) is covered as well.

Keywords: nanotechnology, nanomaterials, glycomics, glycan sensing, glycan enrichment and active glycoprofiling, glycan‐based vaccines/therapeutics, cell tissue targeting/imaging and drug delivery

1. NANOTECHNOLOGY

The term nanotechnology was first used in 1974 by Professor Nario Taniguchi,1 but the idea and concepts behind nanoscience began more than a decade earlier with a talk by Professor Richard Feynman, “There´s Plenty of Room at the Bottom.”2 In this talk, the process by which science could control and manipulate single atoms was described. The real breakthrough in nanoscience came in 1981,3 when the scanning tunneling microscope was developed, enabling the observation of individual atoms, and after the invention of atomic force microscopy (AFM), nanotechnology as a scientific discipline was born. Currently, nanotechnology covers processes for the design, preparation, and application of extremely small things. Materials and structures could be designated as “nano” only if their size (at least one dimension) is within the range of 1 to 100 nm.4 The discovery of nanomaterials, such as fullerenes5 and graphene,6 awarded the Nobel Prize to theirs discoverers. Nanomaterials now form a large family of materials, including metal/semiconducting nanoparticles (NPs), quantum dots (QDs), nanowires, fullerenes, graphene and its derivatives, graphene QDs, and carbon nanotubes (CNTs, Fig. 1).7, 8 It is not only the size of nanomaterials that matters, but their remarkable physical and chemical properties are gaining increasing attention from scientists both from fundamental and application points of view, using nanomaterials in biology, chemistry, and applied physics.9 14 An interesting feature of nanomaterials is that their dimension is similar to that of biomolecules, such as DNA/RNA, proteins, lipids, and carbohydrates, with numerous applications in biology and biomedicine as well.9 14

Figure 1.

Figure 1

Various forms of nanomaterials, which can be integrated with biomolecules for applications in glycomics with their size related to other objects of our world, micro‐ and nano‐world.

2. GLYCOMICS

For quite a long time, carbohydrates were considered only as reservoirs of energy and as building blocks providing the organisms strength, that is, cellulose and chitin, which are the most abundant polymers on Earth.15 Glycans are complex carbohydrates consisting of saccharide units that link together and are attached to proteins and lipids to form glycoproteins and glycolipids, respectively (Fig. 2).16 Glycans are bound to proteins during co‐ and posttranslational modifications via a multistep enzymatic process in the endoplasmic reticulum and Golgi apparatus.17 Glycans can be classified into several categories based on the bond between a glycan and a protein: N‐glycans (via –NH2 group to asparagine), O‐glycans (via –OH group to serine, threonine, or hydroxylated amino acids), and less‐abundant forms of glycans, such as C‐glycans (C—C bond via tryptophan) and the quite unusual S‐glycans (C—S bond via cysteine).18, 19 Moreover, glycans can be branched by the formation of biantennary, triantennary, and more complex antennary structures.20, 21

Figure 2.

Figure 2

The challenges in glycan analysis and separation due to complex and heterogeneous structure of glycans as a result of a variable monosaccharide composition, branching, and multiple glycosylation sites of glycoconjugates. Structure of the most common carbohydrates moieties within glycans is shown as well.

Glycomics as a scientific discipline studying the structure and function of glycans is a younger sister of more developed genomics and proteomics. There are several reasons why glycomics is still behind genomics and proteomics: (i) glycans and glycoconjugates are more structurally complex than proteins and DNA/RNA; (ii) it is quite challenging to determine glycan identity/sequences using traditional instrumental techniques; and (iii) glycan biosynthesis cannot be predicted from a template as in the case of DNA and proteins. In addition, the chemical synthesis of oligosaccharides is very challenging (protection of all functional groups with a variety of protecting groups in order to generate the site‐specific deprotection of those which are intended to form a chemical bond) and represents yet another obstacle to obtain valuable intermediate or incomplete structures. Despite intensive research in genomics and proteomics, there are still many questions that cannot be answered by analyzing genome and proteome alone, and glycomics has to be added into the equation. Currently, it is estimated that 70% of human cytosolic proteins and 80% of membrane proteins are glycosylated, underlining the important involvement of glycans within the human body.16

The function of glycans in living organisms has been revealed at an amazing pace with involvement of glycans in cell—cell and host—pathogen interactions, the binding of cells to the extracellular matrix, the immune response, the differentiation of cells, and other physiological and pathological processes.22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33 Since glycosylation involves numerous proteins during synthesis, including transport proteins, glycosyltransferases/glycosidases, and other glycan‐processing enzymes, depending on the actual physiological state of the cell, distinct glycoforms of the same protein within a particular cell can be formed.34 Each form of such protein can possess different properties, such as distribution in the cell, folding, or stability; thus, glycan alterations can influence the physiological functions of proteins and can indicate pathological processes as well.35 The correlation between diverse forms of cancer and altered glycan structures has been intensively studied. An increasing amount of evidence suggests that the occurrence of a certain glycan structure correlates with cancer invasiveness, the presence of tumor circulating cells, and the ability to metastasize distant organs.35, 36, 37, 38, 39 Thus, glycoproteins can be used as cancer biomarkers for screening, diagnostic, predictive, and monitoring purposes.40 Changes in protein glycosylation have also been observed in other pathological processes, such as inflammatory and autoimmune diseases, and in processes of aging.41, 42 Changes in the glycosylation of immunoglobulin G (IgG) are influenced by pregnancy and gender,43 which should to be considered in future studies.

Several methods have been developed for structural glycan analysis. The most common method is mass spectrometry (MS) in combination with other separation techniques, including a battery of electrophoretic and chromatographic methods and nuclear magnetic resonance. Instrumental techniques can be effectively applied for glycan analysis, but the identification of glycan isoforms and the linkages between carbohydrates within a glycan structure are not trivial issues.44 Moreover, such an analysis requires sophisticated instrumentation and skilled operators to correctly interpret data with low analysis throughput. Moreover, various pretreatment steps (glycan release, enrichment, and modification) are needed prior to analysis.

Lectins are carbohydrate‐binding proteins other than enzymes or antibodies and other than carbohydrate sensor/transport proteins45 with potential therapeutic applications.46 Lectins as natural glycan‐recognizing proteins can be effectively applied to analyze glycans because they can detect intact glycans still attached to proteins or even cells.47, 48, 49, 50 The first step toward the effective utilization of lectins in glycan analysis and for diagnostic purposes was the introduction of lectin microarrays/biochips.51, 52, 53, 54 Glycan microarrays are a valuable tool in glycomics for the identification of glycan‐binding proteins,55, 56 and together with lectin microarrays, such highly parallel analyses with a minute consumption of reagents had led to numerous important discoveries regarding glycan involvement in various cellular processes. However, the main disadvantages of microarray‐based analysis are the low sensitivity of detection with a rather high limit of detection (LOD) and the need to fluorescently label either the ligand or sample.51, 52 This is why alternatives to glycan/lectin microarrays with a biosensor detection platform as a viable option have been intensively sought.57, 58, 59

Because of the above‐mentioned importance of glycans in pathological processes, there is substantial interest in visualizing them directly within intact cells and tissues. Numerous strategies have been developed to achieve this, using glycan interactions to allow for a targeted delivery of an imaging probe to a chosen cell/tissue; hence, a precise and accurate detection of, for example, tumors or other cells/tissues with specific receptors was possible. Moreover, when a therapeutic agent is selectively delivered to a targeted cell/tissue, a significant reduction in adverse side effects can be achieved. Chemotherapy is good example of this approach—cytotoxic agents are delivered to and released only in tumor tissues, while healthy cells are not affected. Recently, a theranostic approach has been frequently used, relying on particles selectively delivering both an imaging probe and a drug to a targeted cell/tissue. Furthermore, the specificity of these interactions can be used to design vaccines and novel therapeutic approaches, as glycans bound to receptors that are naturally targeted by pathogens prevent the first step of infection (e.g., pathogen binding). Finally, a partial functional restoration of glycosidases used to cure “liposomal storage diseases” (e.g., Gaucher disease) mediated via glycan interactions has been described as well.

3. NANOTECHNOLOGY IN GLYCOMICS

One of the earliest efforts to describe the beneficial properties of nanomaterials in the field of glycomics was published by Reichardt et al. in 2013, applying nanomaterials as support for the delivery of vaccines, cellular imaging, biosensors/diagnostics, glycan isolation, and enrichment.9 Since this review was published, there has been an explosion of papers focusing on the integration of nanomaterials in the field of glycomics (Scheme 1), and in this article, we would like to provide a summary of the achievements in this field in the last 3 years (from 2013).

Scheme 1.

Scheme 1

Overview of different nanomaterials (outside the blue circle) used in combination with biomaterials/biomolecules (inside the blue circle) for various applications (in yellow circle) reviewed in this study. The figure was redrawn from 7. Copyright (2014), with permission from Elsevier.

In the sections describing the integration of nanomaterials within various types of transducers, you will find a comprehensive review of recently developed biosensors, bioanalytical devices, and protocols for the detection of various analytes, including viruses and whole cells, together with their main characteristics (Section 4.). It is divided into subsections according to nanomaterials used, that is, metal NPs (Section 4.A), hybrid nanomaterials (Section 4.B), carbon nanomaterials (Section 4.C), QDs (Section 4.G), and others—mostly glycopolymers (Section 4.D) and synthetic receptors (Section 4.E), used as an immobilization platform or as a part of an amplification strategy. Some of these applications have been summarized in recent reviews.7, 60

Sections describing the application of nanomaterials for various biomedical applications will basically cover the progress in the fabrication of glycan‐based NPs that can either induce an immune response (vaccines against viral and bacterial infections and, more recently, even against cancer cells) or possess another therapeutic effect, including antibacterial effect or enzyme inhibition (Section 5.). An extensive section covering glycan‐targeted nanocarriers for drug delivery (Section 6.A); therapeutic purposes prepared from carbonaceous, metallic, or polymeric nanomaterials (Section 6.B); and advances in in vivo imaging (Section 6.C), that is, the selective delivery of imaging probes, is provided as well. There are also sections and subsections dealing with the application of carbon, metal, polymer, and magnetic NPs (MNPs) for nuclear magnetic resonance imaging (NMRi) and another subsection focused on other imaging methods besides fluorescence and NMRi (Section 6.C). There are only two review papers either not comprehensively covering the application of a diverse range of NPs—covering biomedical applications only of gold‐ and polymer‐based glyconanoparticles61—or not focused on recent developments in this field.62

The final part of the paper will describe various ways for glycan release (Section 7.A) and enrichment (Section 7.C), which can occur in a timely way with a minute consumption of precious samples using various nanomaterials (Sections 7.D7.K). Glycan‐enrichment procedures performed directly on matrix‐assisted laser desorption/ionization (MALDI) plates (Section 8.) will be provided as well. The application of nanomaterials or nanoporous materials for matrix‐free MS (Section 8.) will also be described. This section will also discuss the preparation of molecularly imprinted polymers (MIP) with polymer thickness controlled at the nanoscale for the selective affinity‐like enrichment of specific glycoproteins (Section 7.E). Moreover, active glycoprofiling by microengines/microrockets (Section 9.) will be covered as well. Only one review paper has focused on the application of nanotechnology in glycan enrichment; it was published in 2014 and only covers advancements in the field until the end of 2013.63

4. NANOGLYCOSENSING

Glycan moieties attached to protein backbones or lipids are destined mostly for the cell surface. Since glycosylation is the most common co‐ and posttranslational modification of proteins, it is also increasingly recognized as a phenotype modulator of various pathological changes on cell surfaces, mostly during cancer development,35, 64 and glycomics is thus believed to soon provide relevant information and detection strategies for glycan‐based diagnostics.65 A relatively small amount of glycans within a sample of interest could be present (e.g., a prostate‐specific antigen [PSA] contains only one glycan per molecule).66 Thus, for the structural analysis and identification of glycans using mainly MS, capillary electrophoresis, and liquid chromatography,67 enrichment methods must be performed prior to analysis.63 For the analysis alone, the use of glycosylated nanomaterials has gained increasing attention in recent years because NPs decorated with suitable biorecognition ligands, that is, glycan structures in a multivalent form similar to the glycocalyx structures on cell surfaces,68 could be used for the detailed study of glycan—lectin (Latin: legere—to choose, to read) interactions.69 The following section describes in detail the most recent progress in the area of glycosensing using various nanostructures, including (but not limited to) metal, carbon, and polymer nanomaterials with respect to the analytical performance of such devices for the analysis of glycoproteins, lectins, viruses, and bacteria or for dynamic N‐glycan evaluation on cell surfaces.

A. Metal Nanomaterials

Different lectins, which are ubiquitously found in nature, often provide a model system for studying glycan—protein interactions. These interactions play a pivotal role in viral infections, cell adhesion, and the differentiation and progression of various diseases and are thus of great interest for many clinical applications. Despite this fact, they have attracted much less attention than antibodies.70 The most commonly used NPs are gold NPs (AuNPs) because they can be easily prepared and modified using standard thiol chemistry (a covalent‐like modification).4, 71 The synthesis, modification, and engineering of different (glyco)NPs, including metal, magnetic, and carbon NPs and QDs with a focus on biosensing applications, have been reviewed elsewhere.60, 72, 73

1. Optical Biosensors

Moreover, using precisely engineered inter‐NP spacers (e.g., polymer grafts), it was possible to control the degree of plasmonic coupling between NPs.74 This principle was demonstrated with poly[(lactose)mb‐(pyridine)n] and bivalent galactose‐binding lectin from Ricinus communis (RCA120, M w = 120 kDa) on gold nanorods (AuNRs), where the authors claimed to develop a protein assay with an LOD for lectin down to pictogram per milliliter (fM range).74

Other study75 focused on the preparation of a sandwich configuration with graphene oxide (GO) and phenoxy‐derivatized dextran (conjugated together through π—π stacking interactions) deposited on gold substrate for specific Concanavalin A (Con A) binding with a final amplification of the signal using dextran‐capped AuNPs. This system was, however, less sensitive than a previous one, offering an LOD of 0.39 μg mL−1 (3.75 nM), but still with a 28.7‐fold increase in sensitivity compared to a direct assay (without any amplification reagent).75 The application of different graphene‐based interfaces for the surface plasmon resonance (SPR) analysis of biospecific interactions between different ligand—receptor couples was recently reviewed.76

Since the change in the localized SPR (LSPR) signal of metal NPs is not very sensitive and provides only a little information about the nature of interacting molecules, Craig et al. aimed to develop an on/off surface‐enhanced Raman scattering (SERS) aggregation system for picomolar Con A detection. The authors took advantage of the multivalent character of the interaction (since Con A is a homotetrameric molecule at a physiological pH with four glycan‐binding sites) with aggregated NPs producing a strong electromagnetic field between their interfaces, resulting in an increased SERS intensity.77 The LOD for this system was as low as 40 pM for the chosen silver NPs (AgNPs) because they provided a tenfold increase in scattering efficiency compared to AuNPs.77 Plasmonic and, in general, label‐free methods are of a particular interest for glycan‐lectin‐based biosensing because of a negative effect of lectin/glycan labeling on the biorecognition. In 2015, a novel approach called plasmon waveguide resonance was introduced based on glass prisms coated with 50 nm silver and 460 nm silica layers derivatized with mannose and lactose using CuI‐catalyzed Huisgen azide‐alkyne cycloaddition (CuAAC).78 In addition to “click chemistry” based techniques, photocoupling reactions with underivatized glycans represent an alternative approach comparable to CuAAC.79

AuNPs can be easily covalently attached on a plane gold surface via thiol linkers containing an –SH or –NH2 head group for sensitive glycoprotein detection using immobilized lectin molecules,80 providing an increased surface area for immobilization, as well as for the suppression of steric hindrance between lectin molecules because of the spherical shape of AuNPs. This effect proved to be so crucial that prepared impedimetric, a Sambucus nigra agglutinin (SNA) based biosensor, was more sensitive, with an LOD 3 orders of magnitude lower (shift from fM to aM range for the detection of sialylated glycoprotein fetuin) even though the total amount of lectin on the surface was lower in the NP‐based 3D configuration compared to the 2D (planar gold) configuration.81 Most often, metal NPs are used as signal amplifiers. NPs decorated with saccharide structures (d‐maltoheptaose as the largest carbon source among maltodextrins that can be transported to Escherichia coli cytoplasm) promote particle internalization for silica, magnetic, silica‐coated MNPs and silica‐coated QDs.82

Other optical detection platforms are based on colorimetric bioassays. The possibilities for the improvement of the selectivity and sensitivity of such assays for the detection of lectins, toxins, and viruses were recently reviewed.83 Besides lectins, different toxins possess the ability to specifically bind various saccharide residues. Within the so‐called AB5 bacterial toxin family (which also includes cholera toxin, shiga and shiga‐like toxins, and pertussis toxin), a protein is produced by enterotoxic E. coli causing “traveller´s diarrhoea”: heat‐labile enterotoxin. Poonthiyil et al. prepared an efficient colorimetric sensor using 12 nm AuNPs with attached thiol‐modified galactose moieties binding to the B‐subunit of heat‐labile enterotoxin (while the A‐subunit is typically the one causing a particular disease among all members of this family) that is able to detect the toxin down to 100 nM.84

Glycan‐decorated AuNPs may also be used for the rapid evaluation of viral hemagglutinin´s specificity because viral pathogens use lectins encoded by their own or host genome to replicate and spread85; these AuNPs can also be used in antiviral drugs strategies. In general, avian‐adapted influenza viruses prefer α2,3‐linked sialic acid (ligands commonly found in the intestinal epithelia of birds), and human‐adapted viruses bind preferentially to α2,6‐linked sialic acid. Using host cell receptors as biorecognition elements immobilized on AuNPs, it was possible to easily and rapidly evaluate a potential threat to the human host without using complex immunoanalytical strategies. Since influenza hemagglutinin molecules contain several binding sites (Fig. 3), the aggregation of NPs occurred with a red‐to‐purple shift.86

Figure 3.

Figure 3

A hemagglutinin from H1N1 Influenza A virus (complexed to three molecules of 3´‐sialyllactose, denoted with yellow arrows), an interaction used to bound virus to glycan epitopes of host cells (http://pdb.org, code 3HTO).

This is an alternative to using highly specific monoclonal antibodies, where an LOD of 7.8 hemagglutinin units (i.e., 7.8×106 particles) was achieved recently for human H3N2 influenza A virus without any additional amplification.87 By using the epitope glycan structures, however, knowing the exact influenza subtype is not required. Moreover, glycans‐based biosensors can benefit from the multivalent character of the protein—glycan bond.88, 89, 90 For instance, NPs modified with thiolated monovalent and trivalent α2,6‐linked sialic acid and thiolated polyethyleneglycol (PEG) were successfully used to discriminate between human influenza virus X31 (H3N2) and avian RG14 (α2,3‐sialic acid binding H5N1 strain) virus with an LOD of 2.55 μg mL−1. In addition, the trivalent configuration provided more rapid results and a greater sensitivity for plasmonic detection relying on glycoNPs’ aggregation compared to a monovalent configuration.91 As shown in this and other studies, when self‐assembled monolayers (SAMs) on gold surfaces are used, the concentration of a diluting thiol as well as its functional head group and length are crucial for assay performance. Finally, using glycan‐modified nanostructured surfaces, it is also possible to reliably detect any new and, for people, potentially pathogenic viral strains without needing any other reagents just by investigating the specificity of the viral strains toward the human glycan epitopes present in exposed epithelia. SAMs as a form of nanotechnology4 allow the fine‐tuning of other surface properties, such as wettability and adsorption processes,92 in addition to tuning interfacial chemical reactivity toward the subsequent covalent immobilization of biomolecules.

2. Electrochemical Biosensors

Among others, electrochemical methods (e.g., increasingly popular electrochemical impedance spectroscopy [EIS], suitable for single‐molecule to whole‐cell detection)93 are highly sensitive for providing an alternative platform for viral hemagglutinins or whole‐particle detection down to attomolar detection limits or single‐viral particles, respectively.94, 95 Tung et al. prepared a nanostructured (gold nanohemisphere‐modified) biosensor surface.96 The impedimetric biosensor with enhanced sensitivity due to increased surface reaction area was used for the ultra‐weak binding of C‐type lectin domain family 5, member A and mosquito‐borne dengue virus particles, causing hemorrhagic fever and shock syndrome, with tens of millions infected people every year.96 Another ultrasensitive attomolar detection of human H1 and avian H5 viral hemagglutinin was successfully performed on a field‐effect transistor (FET) based device (Fig. 4), modified with 3‐aminooxypropyltriethoxysilane (using standard silane coupling) and the simple glycan blotting of two different trisaccharide receptors (α2,3‐ and α2,6‐sialyllactose).97 It is worth mentioning here that the above‐mentioned PEG molecules have become a gold standard for surface modification (even in a microarray format)98 for the suppression of nonspecific interactions and for the stabilization of NPs when used for biosensing applications.99 However, the introduction of glycan moieties, such as N‐acetylglucosamine (GlcNAc) and lactose, on the surface of AuNPs and AuNRs was proposed to be an alternative to PEG stabilization, ensuring colloidal stability in protein‐rich media and preventing phagocytosis by macrophages, but at the same time exhibiting an excellent sensitivity toward carbohydrate‐binding proteins.100 In addition to PEG, zwitterionic thiol derivatives (e.g., carboxy‐ or sulfobetaine derivatives in single‐component SAMs and mixed binary SAMs)101, 102 are promising ways to prepare nanostructured interfaces resisting nonspecific interactions.103

Figure 4.

Figure 4

A field‐effect transistor (FET) biosensor device for detection of viral hemagglutinins down to attomolar level using glycoblotting protocol; (A) typical scheme and picture of the described device and (B) modification scheme of FET device surface using silane chemistry. The slight difference in the glycan epitope (3´‐ vs. 6´‐sialyllactose) is enough to distinguish between Influenza viruses able to infect a human and other types of Influenza. Reprinted with permission from 97. Copyright 2013 American Chemical Society.

The multivalent amplification effects of glycan—receptor interactions are naturally present in biological systems, for example, complexly branched glycans on glycoproteins or densely packed rafts of glycolipids. Therefore, synthetic multivalent saccharides (among others) have often been used to mimic nature.104 Good examples are synthetic polymers, such as poly(acrylamidophenyl‐α‐mannose‐co‐acrylamide) attached to AuNPs,105 layer‐by‐layer modifications of MNPs coated with polysaccharide shells of hyaluronan and chitosan.106 These polymers were applied for the selective enrichment of glycoconjugates in more complex biological samples106 and for the non‐covalent modification of hydrophobic, dodecanethiol‐stabilized AuNPs (synthesized by Brust—Schiffrin method107) by multivalent glycocalixarenes with four mannose units to improve targeting efficiency toward intact cells.108 Glycan parts of different enzymes frequently serve as models to study interactions with lectins. A practical application for the food industry and agriculture is an electrochemical device based on palladium NPs (PdNPs) as catalysts for the 3,3´,5,5´‐tetramethylbenzidine sulfate/H2O2 system with immobilized mannose‐binding jacalin‐related lectin from rice (Oryza sativa, a bioprobe) for the electrochemical detection of Magnaporthe oryzae (also M. grisea) chitinase (a biochemical marker) during early rice infections. The use of a magnetic‐controllable electrode together with magnetic bead based PdNPs allows the detection of chitinase down to 17 pg mL−1 (approximately 420 fM). Moreover, using chronopotentiometry, it was possible to detect chitinase 2 days after rice infection, while a standard enzyme‐linked immunosorbent assay (ELISA) could detect the chitinase only 4 days after infection.109 In addition to NPs and nanorods, nanoporous materials, for example, nanoporous gold in combination with square‐wave voltammetry (SWV)110 and nanoporous gold monoliths in combination with thermogravimetric analysis,111 were used to effectively and sensitively detect glycan—protein interactions, for example, to detect high‐mannose glycan‐containing ovalbumin molecules.112

In situ glycosensing on the cell surface may play an important role in determining the physiological status of the whole cells in the biopsy samples acquired from patients suffering from various diseases. EIS was used to detect human colon cancer DLD‐1 cells with an LOD of 40 cells mL−1 by bovine serum albumin (BSA) incorporated Ag nanoflowers on a glassy carbon electrode (GCE) with a 3D porous architecture and a large surface area and the retention of immobilized cells activity after binding (attributed to the presence of BSA as a biocompatible support).113 After the conjugation of the cells with the selected lectin (SNA in this case), the average number of sialic acid molecules on a single living cell was counted as approximately 2.16 × 1012.113 Su et al. developed a novel lab‐on‐a‐paper device for the electrochemical sensing of K562 cancer cells with an LOD of 400 cells mL−1 and a wide linear range spanning 5 orders of magnitude based on a macroporous Au‐paper electrode.114 Given that the volume used for incubation was as low as 10 μL of cell suspension, the LOD of the device was approximately 4 cells. An in situ monitoring of multiglycan expression in response to drug treatment was achieved using differential pulse voltammetry (DPV) and horseradish peroxidase (HRP) labeled wheat germ agglutinin (WGA), peanut agglutinin, Dolichos biflorus agglutinin, and Con A. A similar device designed by the same group later that year based on an aptamer modified 3D macroporous Au‐paper electrode was developed in a microfluidic format to screen anticancer drugs (Fig. 5).115 This device could also detect as little as 350 cells mL−1 (very similar to a previous case, e.g., approximately four cells in 10 μL) using the biosensor signal generated using an HRP‐labeled annexin V bioprobe. This bioprobe specifically interacts with membrane phosphatidylserine molecules (in the presence of Ca2+ ions), whose externalization cannot proceed in healthy and necrotic cells, thus providing a highly specific response toward apoptotic cells (translocation from the inner to the outer leaflet of the membrane is an important indicator of apoptosis).115 Recent advances in electrochemical cytosensing amplified by nanostructures and nanocrystals were reviewed by Hasanzadeh et al.116

Figure 5.

Figure 5

Schematic presentation of a macroporous Au paper electrode (μPECD); (A) cells are incubated with HRP‐folic acid conjugate, (B) folding of μPECD and clamping the μPECD between circuit boards (front (C) and reverse side (D)) and finally the detection principle (E), where a is o‐phenylenediamine and H2O2, b is 2,2´‐diaminoazobenzene and c is the final product of the reaction. The real size of the device is compared to a Chinese 1 yuan coin. Reprinted from 115. Copyright 2014, with permission from Elsevier.

No doubt the most commonly investigated and the most commercially successful biosensors are those for glucose detection based mostly on glucose oxidase (GOx) enzyme, despite the fact that even enzyme‐free nanostructured sensors have been described.117 However, the synergistic effect of an NP catalyst with a conducting hydrogel heterostructure‐based interface118 and the dependence of the sensor performance on NP shape were demonstrated only recently.119 Li et al. not only described a simple glucose detection, but went even further with the imaging of intracellular glucose consumption in living cancer cells.120 Their system is based on apo‐GOx (an inactive form of GOx) modified AuNPs and fluorescein isothiocyanate (FITC) dextran. In the presence of glucose in the environment, the quenched fluorescence of FITC‐dextran is recovered as glucose exhibits greater affinity than dextran to apo‐GOx . The LOD of 5 nM, along with the introduction of apo‐GOx instead of GOx, means no consumption of O2 with subsequent H2O2 production (causing cellular damage) and makes this assay a simple, sensitive, and “biofriendly” method for various disease diagnoses and metabolomics studies.120 Even though glucose is an important molecule for diagnostics of different conditions and cell metabolism and its importance is highlighted in many sections throughout this review, glucose as a monosaccharide is not considered as a glycan and thus glucose‐based biosensors are not discussed here in more details.

It is quite difficult to analyze electrochemically inactive glycans and oligo‐ and polysaccharides using electrochemical methods.121 However, Paleček and his team recently published several papers about the deacetylation of N‐acetylated glycans to make the –NH2 groups free and thus electrochemically active122 and about the modification of glycans with Os(VI)L complexes for subpicomolar detection.123 Most recently, a paper about the label‐free electrochemical detection of interaction between Con A lectin and a glycoprotein on an atomically smooth mercury electrode was described.124

B. Hybrid Nanomaterials and Nanocomposites

Very often, not only single nanomaterials but also combinations of two materials where at least one is a nanomaterial are used for bio‐ and cytosensing.125 AuNPs, forming novel nanocomposites with other materials, are often used as signal amplifiers. Poly(ethylenimine) (PEI)‐reduced GO (rGO) and hollow AuNPs deposited on GCE with immobilized GOx as recognition elements significantly improved the signal intensity of the luminol/H2O2 electrochemiluminiscent (ECL) system for Con A detection down to 0.31 ng mL−1 (approximately 3 pM).126 Chen et al. developed a sandwich electrochemiluminiscent biosensor with a Con A‐integrating AuNP‐modified Ru(bpy)3 2+‐doped silica nanoprobe and a multiwalled CNTs (MWCNTs) modified electrode with another Con A on the surface (Fig. 6).127 They were able to detect myelogenous leukemia K562 cells with an LOD of 600 cells mL−1 and, more importantly, to dynamically observe the cell surface glycoprofile during different phases of growth in vitro in response to external stimuli—glycan release by peptide‐N‐glycosidase (PNGase) F or incubation with the N‐glycan inhibitor tunicamycin.127

Figure 6.

Figure 6

A schematic illustration of electrochemiluminiscent ECL biosensor for dynamic evaluation of cell surface N‐glycan expression; (A) fabrication procedures of Con A‐modified NPs presenting the lectin molecules in a multivalent manner and (B) ECL biosensor for cytosensing and evaluating cell surface N‐glycans, while the signal is reflecting the action of various inhibitors or glycosidases compared to untreated cells. Reprinted with permission from 127. Copyright 2013 American Chemical Society.

The same team later that year published another study describing competitive recognition and a signal amplification strategy using AuNPs modified with GOx.128 They counted all of the mannose moieties on a single K562 cell (1.8 × 1010) and again demonstrated the importance of the multivalent character of glycan—protein interactions, as the apparent dissociation constant between GOx‐Au and Con A nanoprobes was 1.64 nM—approximately 5 orders of magnitude lower than in the interaction of Con A with mannose.128 The low LOD for K562 (50 cells mL−1 with a working volume of 200 μL and a linear response of up to 800 cells mL−1) was achieved using a graphene‐hemin‐AuNRs ternary composite as a peroxidase mimetic.129 For influenza detection, a nanohybrid of the Pt NPs (PtNPs), porous ZnO spheres and hemin was synthesized for an amplified electrochemical immunosensor (Fig. 7).130 Briefly, by the in situ generation of a redox probe by alkaline phosphatase (i.e., the release of 1‐naphthol from inactive 1‐naphthyl phosphate) and the excellent behavior of the Pt‐pZnO‐hemin nanocomposite applied as a signal enhancer, the influenza antigen was successfully detected on an antibody‐modified electrode in a sandwich configuration using DPV with an LOD of 0.76 pg mL−1 and with a linear range spanning 4 orders of magnitude.130

Figure 7.

Figure 7

(A) A scheme for preparation of a Pt‐pZnO‐hemin conjugate with a secondary antibody (green) and alkaline phosphatase (yellow). (B) A working principle of the proposed biosensor for influenza antigen detection using a primary antibody (purple) immobilized on an AuNPs modified electrode. Reprinted from 130. Copyright 2016, with permission from Elsevier.

More recently, He et al. introduced a novel sandwich strategy for a dual‐potential responsive, ECL biosensor for simultaneous cytosensing and surface N‐glycan evaluation.131 At a potential of 1.25 V, chemiluminescence was generated by Ru(phen)3 2+ ECL probes intercalated in the grooves of double‐stranded DNA consisting of a DNA aptamer for MCF‐7 (breast cancer) cell recognition and a complementary capture DNA strand and immobilized on electrochemically reduced MoS2 nanosheets. In the presence of cells, the capture DNA and the ECL probe were released from the electrode interface. The sandwich was then completed by a Con A‐conjugated AuNP‐modified graphite‐C3N4 to detect cell surface mannose units at a negative potential of –1.6 V.131 Zhang et al. published a paper on an ECL biosensor based on PEI‐rGO and hollow AuNPs.126 The interaction between AuNPs and the—NH2 groups of PEI was used for AuNP and GOx immobilization in this case, where GOx served as a producer of H2O2 for the luminol/H2O2 ECL system. In the presence of Con A, a decrease in the ECL intensity was observed, with an LOD down to 310 pg mL−1 (approximately 3 pM) and with a linear range from 1 to 20 ng mL−1. The authors claimed that they developed an assay with a nearly 1000‐fold improved detection limit for Con A compared to previously published methods.126 The same team prepared a similar device using a nanocomposite consisting of C60 fullerene and rGO as a detection interface and hollow Au nanosphere‐conjugated GOx as a label.132 The interaction of GOx with the electrode interface was mediated by phenoxy‐derivatized dextran, which served as a recognition element for Con A. Using a luminol/H2O2 based ECL system, the LOD for Con A was estimated to be 30 pg mL−1 (approximately 288 fM) with a linear range spanning 3 orders of magnitude (from 0.1 to 100 ng mL−1).132

Multivalent recognition and dual‐signal amplification strategies with Con A‐conjugated poly(amidoamine) (PAMAM) on a chemically rGO interface and HRP‐aptamer‐AuNPs nanoprobes were reported to detect CCRF‐CEM (human acute lymphoblastic leukemia) cells down to 10 cells mL−1 with excellent selectivity and could dynamically evaluate surface N‐glycans.133 Graphene could also be used as a support in combination with other metal NPs for biosensing applications. For instance, an rGO‐ and AgNP‐based nanocomposite was used as a redox probe together with phenoxy‐derivatized dextran and GOx as biorecognition elements for sensitive Con A detection on GCE.134 Different electrochemical techniques, that is, cyclic voltammetry, DPV, and EIS, were used for signal generation with an LOD for Con A as low as 0.67 ng mL−1 (approximately 6.44 pM) and with a linear range from 2.0 to 322 ng mL−1. Furthermore, the device was successfully used in diluted real human sera with recoveries from 92 to 108% and showed no major interference from BSA, cytochrome c, or phytohemagglutinin, suggesting possible applications for rapid and reliable clinical diagnostics.134 Another example of the application of a nanocomposite for biosensing purposes is an rGO‐tetraethylene pentamine‐1‐butyl‐3‐methylimidazolium hexafluorophosphate hybrid composite.135 A dense adsorption of bimetallic AuPtNPs, subsequently used for SNA lectin immobilization, was achieved by free –NH2 groups from tetraethylene pentamine. This biosensor was used for the electrochemical detection of α2,6‐sialylated glycan down to 3 fg mL−1 and showed a wide linear range covering 8 orders of magnitude. As in a previous case, the recovery when analyzing real human sera was very similar, that is, with a range from 100.8 to 101.4% for Neu5Ac‐α2,6‐Gal‐β‐MP glycoside (4‐methoxyphenyl group via O‐glycosidic linkage) spiked to a final concentration of 1 pg mL−1 to 100 ng mL−1.135

Because α2,6‐sialylated glycans might play an important role in clinical diagnostics using various biomarkers (e.g., on PSA),136 new methods for their ultrasensitive detection are still emerging.137 For example, the nanocomposite composed of graphite oxide, Prussian blue, and PTC‐NH2 (ammonolysis product of 3,4,9,10‐perylenetetracarboxylic dianhydride) was used on a GCE to immobilize AuNPs through free –NH2 groups and SNA‐I lectin for the DPV analysis of α2,6‐bound sialic acid on serum glycoproteins down to 0.03 pg mL−1 with a linear range spanning 5 orders of magnitude.138 Although many different and successful strategies and protocols have been proposed relaying on different electroanalytical approaches for the analysis of complex glycan structures, the main challenge to be addressed for the application of affinity biosensors for real sample analysis is the efficient blocking of nonspecific interactions on the biorecognition interface, although BSA could be effectively applied as a blocking agent in some cases. Additionally, it is necessary to note that despite the fact that SNA lectin is routinely used to detect α2,6‐bound sialic acid, according to some specialized vendors, there is a minor α2,3‐sialic acid binding activity present as well.139

C. Carbon Nanomaterials

Engineered carbon nanomaterials (nanotubes, graphite, fullerenes, and graphene as main matrices for the conjugation of biomolecules) can be successfully applied for the preparation of biosensors.140 There are different conjugation techniques for the functionalization of carbon structures with carbohydrates; the most common is the use of a carboxylic group formed on carbon surfaces using strong acidic oxidation with the subsequent conversion of –COOH groups to acyl chlorides, direct (carbodiimide activated) amidation, or ligation with an azide (Staudinger ligation).141 Single‐walled CNTs (SWCNTs) were also functionalized through microwave‐assisted functionalization using perfluorophenyl azides with mannose and galactose.142 This interface provided a reliable platform for agglomeration studies using FITC‐Con A lectin, specifically binding to α‐d‐mannopyranoside and, to a lower extent, to α‐d‐glucopyranoside residues, but not to Gal‐modified SWCNTs.142 Through phenylacetylene‐SWCNTs and few‐layer graphene flakes, Ragoussi et al. prepared a carbohydrate‐modified (α‐d‐mannosyl glycodendron‐bearing) carbon nanostructures for Con A detection (using AFM, fluorescence, and UV/VIS studies), connected by means of CuAAC “click reaction” mechanism.143 This group even managed to capture and observe the same object for their AFM study, leading to a reliable height profile analysis of the nanostructures before and after treatment.143 Other detection platforms may be useful for studying glycan—lectin interactions using graphene‐modified surfaces. For SPR‐based experiments, graphene was grown through chemical vapor deposition (CVD) on polycrystalline Cu foils in a five‐step process on a 50‐nm‐thick Au film as single and double layers.144 A simple immersion of this interface into a 100 nM mannose solution was sufficient for the mannose modification of the interface through the interaction of carbohydrate with the aromatic ring structure of graphene. Using mannose‐specific Lens culinaris agglutinin and GlcNAc‐ and sialic acid‐specific Triticum vulgaris agglutinin, it was shown that noncovalent surface modification by a simple mannose adsorption allowed the tuning of surface selectivity towards a specific receptor in a simple manner, allowing an LOD of approximately 1 μg mL−1 (low nM range) for lectins with a linear range of up to 1000 μg mL−1.144 However, electrochemical and ECL‐based devices are more sensitive than optical platforms.

Since the Nobel Prize in physics in 2010, graphene has become an increasingly popular material and has recently been applied for biosensing purposes, as well as for glycomics, mainly in cytosensing applications using different detection strategies. As already discussed in Section B..B regarding nanohybrids, the combination of different materials, the preparation of nanocomposites, and the very frequent utilization of a sandwich format analysis is common for biosensor construction. It has been previously reported that polymer dendrimers (e.g., PAMAM in this case) provide excellent support for the immobilization of glycans, allowing them to interact with proteins involving a multivalency effect. Molecular recognition using so‐called corona‐phase complexes consisting of synthetic polymers and CNTs, where the two components show affinity toward a selected analyte only if they stick together via surface forces stabilizing them and giving the polymer its final configuration (with a possibility to predict recognition specificity in advance), was also reported.145 SPR gold surface coated with rGO (electrophoretically deposited) can be easily modified by a simple immersion in a solution of a particular polymer to prepare strongly negative (poly(sodium 4‐styrenesulfonate)) or positive (PEI) surfaces, as well as a surface modified by different saccharide moieties (mannose, lactose) through π–π stacking and electrostatic interactions. Subramanian et al. modified SPR chips with rGO to study the affinity of three different pathogenic E. coli strains to surfaces mediated by the presence of different adhesins on a bacterial cell membrane because those are responsible for the colonization of different epithelial structures and surfaces.146 The modified SPR interface interacted strongly with highly pathogenic E. coli 107/86 strain in a quantitative manner with a linear response spanning 7 orders of magnitude and with an LOD of ∼100 cfu mL−1 (cfu—colony‐forming units) for bacterial strains 107/86 and UTI89.146

ECL methods based on carbon nanomaterials could be used for cytosensing applications, as well. The simplest sandwich configuration, in which GO‐modified GCE served to immobilize the antibodies of interest (anti‐PSA in this case for the specific biorecognition of membrane PSA) and with a subsequent surface blocking by the use of BSA, was used to detect PC‐3 (prostate cancer) cells down to 260 cells mL−1.147 With a linear range spanning almost 2 orders of magnitude, ruthenium complex‐labeled WGA served as a signal probe.147 A similar concept used for the impedimetric detection of HL‐60 (human promyelocytic leukemia) cells down to 500 cells mL−1 was based on a graphene surface modified by carboxymethyl chitosan.148 This composite served to support the layer‐by‐layer assembly of PEI and folic acid for the fabrication of a label‐free cytosensor. Folic acid served as a biorecognition element because the overexpression of folate receptors often occurs in some tumor cell lines.148

Graphene may be successfully utilized in various forms in biosensing technologies using not only plane graphene sheets but also monolithic and macroporous graphene foam. Such a 3D matrix (grown by CVD) was used to prepare an immunosensor for carcinoembryonic antigen (CEA, a tumor biomarker).149 Briefly, a graphene substrate was used for the polymerization of dopamine, which subsequently served as a matrix for noncovalent Con A immobilization and interaction with HRP‐labeled anti‐CEA as a biorecognition element bound to Con A via a glycan part of HRP. After the surface was blocked by HRP, various electrochemical methods (mainly DPV using an electrochemical mediator) were used to detect CEA down to 90 pg mL−1 (approximately 500 fM), and the biosensor did not show any response toward other biomolecules, such as BSA, PSA, HRP, or glucose. Noncovalent graphene modification could be achieved not only by unmodified saccharides,144 but as well as using “clickable” monosaccharide derivatives, such as azido galactosides immobilized on an alkynyl anthraquinone‐modified graphene electrode for the label‐free EIS detection of cancer cells.150

D. Other Nanostructures, Glycopolymers, and Boronic Acid Derivatives

Commonly used nanomaterials in glycomics in addition to metal and carbon nanostructures are glycopolymer‐based micelles, vesicles, or nonspherical NPs that are able to interact with lectins as multivalent ligands in a manner similar to natural glycoproteins.48 Block copolymers often self‐assemble into diverse morphologies in solution depending on their properties, providing a promising bottom‐up engineering strategy for different applications of such nanostructures.61 Polymer scaffolds may also be effectively glycosylated in vitro using a wide variety of available glycosyltransferases to prepare glycan structures mimicking those present in nature for the biorecognition of multivalent glycans by their specific lectin receptors.151 Any information contained in the “sugar code” must be controlled with an extreme precision during glycopolymer preparation in laboratories for diagnostic and other purposes because every small difference in vivo may significantly affect a biorecognition event and lead to structural and functional abnormalities in the organism. Therefore, structural control of carbohydrate sequences during the synthesis of glycomimetics and multivalent glycopolymers is of highest importance to obtain reliable data.152, 153 Such synthetic glycopolymers are promising tools for use in emerging biomedical applications and research, including biosensing, biomolecular recognition, and vaccine development.154, 155

Multivalency and complexity of lectin—glycan interactions are applied in numerous processes in nature. For the study of such a complex combination of binding mechanisms in real time, dendrimers may serve as useful tools to evaluate the binding capacity of lectin receptors and the effect of avidity. Mannosylated gallic acid‐triethylene glycol‐based dendrimers in combination with SPR provided important structural data for studying biorecognition between Con A and mannose‐modified dendrimers.156 An amphiphilic block copolymer consisting of hydrophilic lactose and hydrophobic pyridine was synthesized via reversible addition‐fragmentation chain transfer polymerization.157 Glycosurface prepared on Au quartz crystal microbalance (QCM) chips was used to reliably detect RCA120 in the nanomolar concentration range without any significant binding of BSA as a nonspecific probe.157 Moreover, the authors in this study calculated the K A for the system, obtaining a value of 6.3 × 106 M−1; this value is normally in the range of 103 M−1 for monovalent lactose and its receptor. A similar value of K A (same order, 2.3 × 106 M−1) was obtained in another study using QCM and RCA120 lectin binding to galactose‐containing gradient glycopolymer synthesized by RAFT polymerization.158 By synchronizing enzymatic monomer transformation with polymerization, the authors obtained a gradient sugar distribution in a final amphiphilic polymer.158 The lowest detectable concentration (5 μg mL−1) was again in the low nanomolar region. Superior lectin binding was achieved for the gradient polymer compared to the statistical glycopolymer, underlining the relevance of multivalency in the case of lectin—glycan interactions.158 Glycoconjugated amphiphilic polymers can also be used for the encapsulation of fluorescent QDs.159 Prior to its encapsulation, amphiphilic poly(isoprene)‐b‐poly(ethylene glycol) diblock copolymer was covalently modified by a carbohydrate moiety (d‐manno‐heptulose, d‐glucose, d‐galactose, bis(nitroso)‐streptozotocin, or d‐maltose) using Huisgen‐type click chemistry, and interaction with Con A was studied again using the SPR method, showing enhanced affinity constants due to multivalent binding effects.159 Supramolecular structures, which are of high importance in nanotechnology these days, may also be prepared by click chemistry reactions, as in the work published by Assali et al., in which the authors managed to synthesize poly(diacetylene)‐based nanomaterials with different morphologies.160 Neoglycolipids with an amide bond between the hydrophilic and hydrophobic parts of the amphiphilic molecule formed 3D micelles, while triazole‐containing ones (obtained by “click‐reaction”) allowed 1D nanotube formation.160 Block glyco‐copolymers may also be used for cell imaging and as an effective drug delivery system (see Section 6.). They may also enhance the uptake of drug‐loaded micelles by cells, as in the case of the increased uptake of doxorubicin‐loaded sugar (glucose or maltose as a biorecognizable hydrophilic block modification) and poly(4‐substituted‐ε‐caprolactone) copolymer micelles by HeLa cells, compared to free doxorubicin.161

Since glycans are the most complex biomolecules, there is a need for high‐throughput methods for their analysis. In addition to commercial microarrays, a novel super‐microarray (containing many microarrays on the same slide) for lectin glycan sensing was recently developed. Such arrays use glycan‐labeled dye‐doped silica NPs (SiNPs) and a set of lectins immobilized on epoxy slides with poly(dimethylsiloxane) as an insulator, allowing the generation of many individual lectin microarrays, which significantly increase the assay throughput and, due to the multivalency of glycan‐modified NPs, also increase the affinity (over the free glycan and corresponding lectin) by 4–7 orders of magnitude.162 Moreover, fluorescently labeled NPs offer higher stability and fluorescence compared to free organic dyes. Although glycans‐modified NPs have previously been prepared, the first attempt to prepare carbohydrate‐modified SiNPs was published recently by Ahire et al.163 d‐mannose‐capped SiNPs (prepared from amine‐terminated NPs using N,N´‐dicyclohexylcarbodiimide) were used to detect Con A when the interaction caused the aggregation of NPs. To show their biochemical activity, the photoluminescence of these NPs after interacting with MCF‐7 human breast cancer cells was also investigated.163 For electrochemical analysis, conductive polymers are highly relevant for the enhanced sensitivity of detection when used as a solid‐state redox probe. Thiophene containing fused quinone moieties were electrochemically polymerized on a gold electrode surface to couple thiol‐modified mannose.164 Such electropolymerization created a thin film on a solid surface with the ability to control its thickness very precisely up to several nanometers with subsequent application to construct microsensors. This new glycosurface allowed the detection of two major bacterial cell surface biomarkers—namely, fimbriae proteins on bacterial pili and lipopolysaccharides (LPSs) on Gbacteria (by Con A‐mediated binding), using SWV and QCM methods down to 25 and 50 cells mL−1, respectively.164 Moreover, it was quite simple using this method to selectively distinguish between G‐ and G+ bacteria.164

E. Synthetic Receptors for Glycosensing

Common biorecognition elements for the sensitive detection of various analytes (biomolecules, viruses, or even bacteria) include antibodies and less common nucleic acid aptamers. In the past decade, carbohydrates have been increasingly studied due to their presence on the surfaces of proteins and cells. For the purpose of glycocode deciphering, lectins from various sources are commonly used.22 Boronic acids also bind saccharides via reversible interactions, mostly with linear diols or even cis‐1,2‐diols on five‐membered rings or 1,3‐diols to form five‐ or six‐membered rings.165, 166 Fluorescent diboronic acid compounds with dipeptide linkers were synthesized to discriminate cell‐surface Lewis X (Lex) trisaccharide present on Chinese hamster ovary (CHO) CHOFUT4 cells at micromolar concentrations.167 The control cells (without glycan expression, HEP3B cells predominantly expressing Ley, B16FUT3 cells expressing sialyl Lewis a (Lea) and COLO205 cells expressing sLex and sLea but no Lex) were not labeled,167 suggesting the possibility of preparing compounds with a specificity toward glycans comparable to that of naturally occurring lectins. As previously mentioned (Section 4.A.2), pathogenic agents, such as viruses and bacteria, use their envelope proteins (agglutinins) and adhesin lectins to recognize and attach themselves to host cells and tissues via glycans. This principle was used to prepare a novel electrochemical displacement sensor based on three different boronic acid derivative tracers (containing a ferrocene molecule).168 The displacement of tracers by Con A lectin molecules or E. coli cells led to a decrease in the electrochemical signal monitored by SWV. Moreover, the use of thiolated mannose‐OEG conjugate ensured low nonspecific interactions. Con A could be detected with an LOD of 1 μg mL−1 (approximately 9.6 nM, with a linear range spanning ∼2 orders of magnitude), and E. coli cells could be counted down to 600 cells mL−1.168 The novel tracer used in this study, 2‐hydroxymethyl phenyl boronic acid derivative, binds to mannose even at a neutral pH, expanding the application of the system toward real biological samples (e.g., urine).168 To date, many synthetically prepared “boronolectins” showed only a moderate fluorescence enhancement with a requirement of significant amount of co‐solvents in aqueous solution (i.e., dimethylsulfoxide and ethanol). A newly engineered boronolectin derived from tricarbocyanine combined with a boronic acid fragment linked by a piperazine unit exhibited improved certain properties, such as excellent water solubility and sensitive fluorogenicity, upon binding to carbohydrate moieties under a physiological pH.169 To conclude, because boronic acid derivatives are able to successfully mimic lectins as natural glycan decipherers, they may be used not only to detect various analytes but also to selectively bind to free viral particles to inhibit their progression and surface adhesion, as in the case of lipid nanocapsules functionalized with amphiphilic boronic acid for hepatitis C virus inhibition, similar to cyanovirin‐N or griffithsin (both potent HIV inhibitors).170 Their use as ultrasensitive solid‐phase microextraction probes for in vivo and in vitro sensing purposes in biofluids and even semisolid biotissues was also demonstrated.171

F. Naked‐Eye Detection Using Nanostructures

AuNPs modified with different saccharide moieties (lactose, arabinose, cellobiose, sucrose, mannose, glucose, and galactose) were applied by Jayawardena et al. to successfully distinguish among four different lectins with different specificities.172 Con A, soybean agglutinin, Griffonia simplicifolia agglutinin, and Arachis hypogaea peanut agglutinin were detected by observing a red shift in the λmax of the LSPR absorption (LSPR on NPs, as opposed to propagating SPR biosensors).172 Such a library‐oriented approach of glycan‐decorated NPs was later used to prepare polymer‐stabilized glyco‐AuNPs for a rapid, high‐throughput, and 96‐well microplate‐compatible evaluation and identification of pathogenic lectins without a need for any infrastructure because the output of these measurements (red‐to‐blue color shift upon AuNP aggregation) was monitored by a digital camera (Fig. 8).173 Plasmonic metal NPs thus have great potential for their use in biosensor technology due to their sensitive spectral response to the local environment of NPs.174

Figure 8.

Figure 8

An overview of the colorimetric detection principle of lectin–glycan interactions with naked eye by glyco‐AuNPs aggregation due to lectin interaction. In case of an aggregation of NPs (in presence of lectin molecules), red‐to‐blue shift in color occurred. Reproduced from 173, with permission of the Royal Society of Chemistry.

SPR, however, lacks the higher throughput capability compared to lectin microarrays. This drawback was overcome recently175 by establishing a lectin microarray based on a multiplexed SPR interface for the simultaneous measurement of up to 96 interactions by the immobilization of 18 different unmodified lectins (at different dilutions), including controls. A microarray GOAL (Glyco‐gold NP‐based Oriented immobilized Antibody microarray for Lectin) assay was also introduced as a novel approach for the naked‐eye detection of lectin‐carbohydrate interactions after silver enhancement using oriented, surface‐immobilized anti‐lectin antibodies.176 Moreover, these modified AuNPs were highly stable and resistive to any nonspecific protein adsorption.176

Human IgGs are extremely important markers of various diseases, which can be applied in a quantitative and qualitative manner because these glycoproteins are responsible for an effective immune response. The glycan part of human IgG was shown to be associated with autoimmune disease progression, mainly rheumatoid arthritis,16, 101 where the N‐linked biantennary complex glycan in the Fc region is terminated with galactose or even GlcNAc, while in healthy individuals, IgG´s glycan can be terminated with sialic acid.177 The GalNAc biosensor based on poly(diacetylene) nanovesicles developed by Hao et al. was applied for a noninvasive and real‐time colorimetric analysis of galactose‐deficient IgA1 (playing an important role in the pathogenesis of glomerulonephritis—IgA nephropathy) using nanovesicles modified with Helix aspersa agglutinin for naked‐eye detection.178

In addition to glycoproteins, other glycoconjugates, such as glycolipids, were recently used for sensing applications. A fluorescent glycolipid monomer was synthesized using conjugation between 1‐pyreneboronic acid and a glycolipid based on a condensation reaction between d‐glucose and oleic acid for the qualitative and chiral sensing of 80 nmol of amino acids (l‐ and d‐tryptophan and phenylalanine) by the naked eye (Fig. 9).179 In order to study carbohydrate–carbohydrate or carbohydrate–protein interactions using glycolipids, three different strategies could be utilized: (i) insertion of a synthetically prepared glycolipid into a lipid matrix, (ii) preparation of glycolipids that aggregate to form liposomes or micelles, and (iii) modification of a hydrophobic surface by a desired sugar derivative.180

Figure 9.

Figure 9

Photographs of the aqueous dispersions of the D‐vesicles (self‐assembled morphology of synthesized fluorescent glycolipid monomer c = 1.5 mmol, average of 48 nm in diameter) in the presence and absence of amino acids (80 nmol) for the naked‐eye detection. Reproduced from 179 with permission of the Royal Society of Chemistry.

G. Quantum Dots (QDs)

QDs have also attracted considerable attention in many different fields, including bioimaging and the detection of various analytes, mainly because of their tunable optical size‐dependent properties.181 In recent years, the importance of detecting various forms of viruses has emerged with a focus on the identification of various glycoforms present on viral surfaces. A two‐step procedure was developed for virus detection, including the isolation of viral hemagglutinins by glycan‐modified paramagnetic beads, labeling hemagglutinins with CdS QDs with their subsequent electrochemical detection by voltammetry using 3D printed microfluidic chips.182 The other detection principle employed by Chen and Neethirajan was based on a homogenous fluorescence quenching principle.183 They used a sandwich configuration (antibody‐modified AuNPs and glycan‐conjugated QDs) to entrap influenza A hemagglutinins in between these two probes. As a result, a fluorescence decrease due to a nonradiative energy transfer between these two probes was observed. Of course, QDs could be conjugated with a diverse range of different structures in the same way as for the other above‐mentioned nanomaterials. The conjugation of CdSeTe@ZnS‐SiO2 QDs modified with 3‐aminophenylboronic acid was used to monitor changes in the relative amount of sialic acid on K562 cell surfaces after a 3´‐azido‐3´‐deoxythymidine treatment, showing a significant increase in sialic acid expression.183 Another paper184 aimed to develop a photoelectrochemical biosensor using low‐toxic Ag2S QDs for glucose detection as well as for the detection of MCF‐7 breast cancer cells down to 32 μM and 98 cells mL−1.

5. CARBOHYDRATE‐BASED VACCINES, ADJUVANTS, AND THERAPEUTICS

With ongoing progress in glycomics, NPs displaying glycan moieties have been gradually recognized as potential therapeutic agents. There are numerous reviews mapping this broad research field. Hence, the commercialization and real application of developed glyco‐based vaccines are well documented. For example, in a recent study,185 a list of glycoconjugates that were already approved or used in clinical trials as vaccines is provided, while other authors have focused on the application of nanomaterials in vaccine design.186, 187

A. Vaccines and Adjuvants

When saccharide‐based vaccines are developed using nanomaterials, the latter components are primarily applied as glycan carriers, acting as effective immunogenic moieties. The first glycan‐based vaccine was Pneumo Vax produced by Merck (Darmstadt, Germany)—an unconjugated capsular polysaccharide isolated from Pneumonia serotypes.188 Capsular antigenic glycans are in fact the only choice in the development of glycan‐based antibacterial vaccines, but the application potential of glycans given by their combinatoric diversity is very large. The immunogenic effect of these vaccines increases significantly by the increased valency of glycans employed, that is, typically by their conjugation to proteins, polymeric scaffolds, or other NPs. As already summarized,188 carbohydrate‐based vaccines were developed against viruses, some prokaryotes and, quite recently but with ever‐growing interest and success, even against cancer cells. Although noncarbohydrate immunogens (i.e., protein‐based antibodies) have been more broadly used for vaccine development, carbohydrate immunogens are similarly important and useful. Recent achievements in the efficient conjugation of the latter immunogens with NPs are discussed in the following sections. In addition, recently reported studies where carbohydrates are used as building blocks (not immunogens) for the development of vaccines are covered as well.

1. Carbohydrate Immunogens Conjugated with Polymers

In order to overcome the low immunogenicity of cancer cells, tumor‐specific or tumor‐associated antigens can be multiplied on the surface of NPs. The administration of such NPs helps the immune system to fight disease in a more efficient way. A multivalent display of antigens allows their better recognition by respective receptors with the subsequent induction of the immune response. It should be noted that natural antigenic carbohydrates (except for zwitterionic glycans) are believed to mostly lack the ability to be displayed on the B‐cell surface via the major histocompatibility complex, resulting in their incapability to activate T cells. This activation was, instead, achieved by displaying parts of carrier proteins co‐delivered in a vaccine. In the following sections, however, glycan‐nano vaccines without peptide adjuvants are also shown to be fabricable. Using “classical” adjuvants, the conjugation of immunogenic synthetic mucin (MUC1, a surface‐displayed glycopeptide typical for tumor epithelial cells) with different NPs was tested intensively. In a recent review paper, a study describing MUC1 conjugated with tetanus toxoid carrier protein was described.189 This combination provided the best performance as judged from the highest production of specific IgGs (see Fig. 10 for the structure of the glycoprotein conjugate) among other reviewed MUC1 vaccines.189 More recently, the same antigen was conjugated with a bacterial lipoprotein—a Toll‐like receptor ligand to boost the elicited immune reaction (Fig. 11).190 The same composition (i.e., MUC1 antigen conjugated to a Toll‐like receptor) amended with a T‐helper‐cell epitope was employed by Abdel‐Aal et al.191 Their conjugate, however, was not multivalent, but it was incorporated into small lamellar vesicles. These vesicles were used to immunize mice that were subsequently exposed to tumor induction. Animals that had been immunized with the best‐performing conjugate exhibited an approximately twofold smaller tumor after 2 weeks compared to other vaccines or a blank.191 Another cancer antigen is the breast cancer cell‐specific hexasaccharide “Globo H,” and its conjugation with diphtheria toxoid CRM197 and α‐galactosylceramide C34 as an adjuvant provided the highest immune response amongst the conjugates tested using different carrier proteins and adjuvants. This effect observed was even higher than for a similar clinical trial phase III vaccine.192 In order to synthesize well‐defined nanoconjugates, a method using the tyrosine‐specific binding of immunogenic glycans present on the surface of CRM197 was developed193, 194 with consequent application in the development of a glycan‐based vaccine eliciting an immune response against Streptococcus infection.195 Similarly, McCarthy et al. developed a chemoenzymatic synthesis of a well‐defined poly(sialic acid)‐tetanus toxoid glycoconjugate.196 These studies have underlined how important it is to develop novel progressive methods for the precise and well‐defined synthesis of glycoconjugates.

Figure 10.

Figure 10

Synthesis and structure of a carrier protein‐mucin vaccine. Conjugation of a sialyl‐Tn MUC1 glycopeptide antigen (19) terminated via a coupling agent (diethyl squarate; 57) with a carrier protein (Tetanus toxoid or BSA) into a final multivalent carbohydrate‐bearing vaccination conjugate (58). Reproduced from 189 with permission of the Royal Society of Chemistry.

Figure 11.

Figure 11

A schematic structure of a vaccine consisting of 4‐valent glycopeptide MUC1 conjugated to a bacterial lipopeptide (Pam3CSK4), a ligand of Toll‐like receptor (TLR2) which helps to elicitate immune reaction. Reproduced from 190 with permission from John Wiley & Sons.

In addition to discovering new possibilities in the synthesis of well‐defined glycoconjugates consisting of already known components, some studies, more biochemical than nanotechnological, have focused on immunogenic efficiency and the synthesis of new poly‐/oligo‐saccharides, mainly derivatives of bacterial cell wall epitopes.197, 198, 199, 200 Similarly, Johannes et al. investigated the increased immunogenicity of fluorinated analogues of tumor‐associated carbohydrate antigens conjugated to a support applicable as a vaccine against human breast cancer.201

Alternatively, carbohydrates were used as building blocks or monomers for supramolecular scaffolds forming vaccine NPs. Since polysaccharides can form polyvalent ions, they can form self‐assembled nanoscaffolds upon mixing with relevant (polyvalent) counterions. Derivatives of chitin, the second most abundant polysaccharide on Earth and a very promising material in this field of research, can be used as very potent vaccine adjuvants. The mucoadhesion of chitin derivatives is helpful in vaccine administration and allows for an increased rate of chitosan‐based NP internalization via mannose‐binding receptors, inducing both the humoral and cellular immune response.202 The latter was found to induce the degradation of the polysaccharide NPs, and chitosan dissolved in cytosol was found to be a more efficient immunogen than whole, nondestructed chitosan NPs.203 The stability of prepared vaccine NPs is also an important issue. For example, a DNA‐based antitumor vaccine was effectively protected against degradation at a low pH when present in alginic acid based NPs.204 Similarly, the coencapsulation of an antigen to be delivered with a commercially available adjuvant (C48/80) into chitosan NPs significantly decreased the dosage needed for the induction of a strong immune response compared to vaccination with a nonencapsulated antigen and an adjuvant.205, 206 A similar effect was observed for dendritic glucan,207 and immunogenic properties have also been assigned to β‐glucans applied for the preparation of antifungal vaccines208 and to polysaccharide based on δ‐inuline, which was utilized as an adjuvant.209 Cholesteryl pullulan was used to entrap an additional immunogen—tumor necrosis factor α.210 The nasal coadministration of such a prepared adjuvant combined with commercial anti‐influenza vaccine significantly elevated the resistance of mice treated against the influenza virus compared to control groups vaccinated without the adjuvant.210

A better administration of tumor‐associated carbohydrate antigens was developed by Zhou et al., who investigated different derivatives of synthetic lipid A.211 These compounds have been previously found as promising adjuvants, but a more efficient synthesis is needed for their wider utilization.211 The efficacy of polysaccharide vaccines can be further improved by the decoration of NPs, with additional glycan moieties with mannose‐coated chitosan particles being a good example.212, 213 Another approach was presented by Fagan et al., who used tetra‐O‐acetyl‐α‐d‐glucopyranosyl bromide as a core structure for the synthesis of dendritic nanoscaffolds displaying multivalent immunogens—streptococcal B‐cell epitope.214

It is also possible to prepare effective conjugates based on polymers and glycans where carbohydrate moieties are not primarily acting as immunogens but rather promote selective delivery and administration. A good example is mannosylated liposomes delivering albumin as a model antigen efficiently to dendritic cells responsible for the induction of humoral and immune responses.215 The presence of mannose receptors on the surface of DC has also been widely used in drug delivery, imaging, and other biomedical applications that are discussed later. The overall therapeutic efficacy of mannosylated liposomes loaded with antitumor antigen and lipidic adjuvant was significantly boosted by the codelivery of small interfering RNA (siRNA) responsible for the downregulation of expression of immunosuppressive interleukins in tumor cells.216 In another approach, Kim et al. developed fiber‐like supramolecular assemblies coated with mannose‐tethered lectin Con A.217 Such protein coating was responsible for the immunogenicity of the fabricated conjugates and confirmed by observed interleukin production after the treatment of T cells with Con A‐coated NPs.217

Carbohydrate immunogens playing a role as adjuvants, that is, helping to elicit a less‐specific immunoresponse, could also be delivered by diverse nanopharmaceutical systems. For example, a synthetic Mycobacterium tuberculosis epitope derivative (a fusion protein) and a glucopyranosyl lipid moiety were tested in liposomes, nanoemulsions, and adjuvants, with a promising immune response induction observed in mice with nanoemulsions selected as the best option for further vaccine approval and trials.218 Controlled selective delivery was also achieved by the conjugation of a bioactive molecule (inhibitor of a transforming growth factor‐β receptor) with mannose‐6‐phosphate‐human serum albumin.219 This carrier reacted selectively with receptors of hepatic stellate cells, while the conjugated inhibitor prevented transforming growth factor‐β‐induced activation, which is a key factor in the development of liver fibrosis.219

2. Metal and Metal Oxide NPs in Recent Vaccine Development

Due to their versatile and reproducible preparation and modification, AuNPs have attracted researchers’ interest as promising therapeutic agents220, 221 with potential especially in vaccine development.186 Although older studies have demonstrated that AuNPs decorated with analogues of viral or tumor cell polysaccharide epitopes were sufficiently immunogenic,221 there is only one recent study describing vaccine design based on AuNPs coated with a carrier protein and an LPS from a nonvirulent bacterial strain Burkholderia thailandensis.222 This glycoconjugate significantly increased the production of LPS‐specific antibodies in nonhuman primates exposed to the virulent bacterial strain B. mallei. In animals vaccinated with the AuNP‐LPS‐based conjugate no signs of bacteria were found, while in non‐vaccinated animals the pathogen cells were detected ‐ 102 (in animals that survived the test) and 104 (not survived animals) cfu per mg of tissue. Such results can be considered promising for the development of an efficient protective antiglanders (glanders = contagious and highly fatal disease, which can affect humans) vaccine for humans.222 Parry et al. showed that an AuNP‐glycan‐based vaccine efficiently induced the immune response even in the absence of peptide or protein adjuvants.223 These authors synthesized polymers displaying glycan units mimicking tumor tissue specific mucin (see Fig. 12). These immunogens were then conjugated in one step with in situ prepared AuNPs. Contrary to unmodified polymers, all glycan conjugates induced an immune response, as evidenced by IgG titres. The authors found out that the optimal number of glycan units per AuNPs‐conjugated polymer chain is 20–25, regardless of the chain length.223

Figure 12.

Figure 12

Preparation and characterization of a carbohydrate Tn‐antigen/AuNPs vaccine (Tn = N‐α‐acetylgalactosamine linked to serine or threonine). Inset figures show representative dynamic light scattering data (top) and TEM image (bottom) of glycoNPs (scale bar = 20 nm). Reprinted with permission from 223. Copyright 2013 American Chemical Society.

Fallarini et al. investigated simple AuNP–glycan conjugates with the aim of understanding the essential components to design an effective vaccine.225 In this study, they compared the effect of NPs decorated with nonimmunogenic mono‐ and disaccharides mimicking parts of the capsular polysaccharides of Neisseria meningitidis bacterium. The conjugate induced an immune cell response, contrary to nonconjugated forms of carbohydrates, and due to the possible intracellular degradation of the glycoconjugate, a disaccharide‐modified conjugate was more efficient.225 Interesting behavior was observed for AuNPs grafted with fucose‐ended linkers. Such AuNP conjugates with a specific glycan surface density were internalized by dendritic cells via their Dendritic Cell‐Specific Intercellular adhesion molecule‐3‐Grabbing Non‐integrin (DC‐SIGN) receptors (see Fig. 13), but without an expected induction of subsequent interleukin production. Observed targeted internalization is a focus for antigen delivery and for the induction of a desired DC‐SIGN‐mediated signaling cascade.224

Figure 13.

Figure 13

A schematic depiction of fucosylated AuNPs interacting with dendritic cell‐specific intercellular adhesion molecule‐3‐grabbing nonintegrin (DC‐SIGN) receptors. Reprinted with permission from 224. Copyright 2014 American Chemical Society.

In order to induce an anticancer immune response, a tumor‐specific antigen (a phospholipid‐functionalized glycopeptide) was used for the formation of a scaffold with an iron oxide core.226 The highest amount of elicited IgG (mean titres ∼81,402) was confirmed after the vaccination of mice by the conjugate having only one carbohydrate antigen per phospholipid‐modified glycopeptide chain while surprisingly, mean titres of only ∼7530 were observed when two glycosyl units were bound to the chain. It should also be noted that the formation of NPs with an iron oxide core significantly increased the IgG titres for free glycosylated phospholipid‐modified peptide chains from ∼5032 to ∼36,600. Furthermore, a complex induction of the immune response leading to tumor cell degradation was observed,226 suggesting that iron oxide NPs can be an alternative to AuNPs for vaccine design. Carbohydrates were used also as adjuvants in AuNP‐based vaccines, with chitosan‐coated AuNPs decorated with plant saponins applied as tetanus toxoid carriers, but the authors did not describe any specific role of chitosan in the fabricated conjugates.227

B. Nonimmunogenic Therapeutic GlycoNPs

In addition to the activation of the immune system with a consequent therapeutic biochemical cascade, a few other therapeutic effects of glycoconjugates were discovered. Such efforts rely on (i) the competitive binding of lectins/glycans on receptors, thus preventing the successful binding of pathogenic viruses/bacteria, and (ii) the ability of glycoconjugates to selectively agglutinate pathogenic particles, thus eliminating their adverse effect. Since the interaction between a carbohydrate‐binding protein and a carbohydrate is not very strong, multivalent recognition entities must be present on a therapeutic NP surface.

There have been numerous reports describing the fabrication of such therapeutics, with the main achievements comprehensively summarized in recent excellent reviews.90, 188, 228, 229, 230, 231 In summary, these papers referred to diverse kinds of multivalent glycoconjugates, that is, based on carbon and metallic NPs, organic supramolecular scaffolds or proteins with many of such conjugates having therapeutic potential. Moreover, novel synthetic and conjugation protocols have been described as well. Interesting conclusions are provided in a review by Jiménez Blanco et al., who suggested that heteroglycoconjugates, compared to homoglycoconjugates, provide additional regulation possibilities, in addition to the already known protein–carbohydrate binding mechanism.232 These findings have been considered in recent developments in the design of nonimmunogenic therapeutic glycoconjugates.

1. Metallic NPs

Few recent studies have focused on the antibacterial properties of AuNPs233 or AgNPs234 coated with 6‐O‐chitosan sulfate. Importantly, these glycoconjugates are not only antibacterial due to the presence of Ag or Au but also anticoagulant, making them almost perfect candidates for the surface coating of, for example, medical devices that need to be kept sterile. Similar, although offering only antibacterial properties, AgNPs and AuNPs have been conjugated with other polysaccharides, for example, starch235 and aminocellulose.236 A similar antibacterial effect has been observed with AgNPs coated with 12‐C‐monosaccharide‐dodecanoic acid237 or with MNPs stabilized by poly(ethylene oxide) and functionalized with a sialic acid derivative.238 While the aforementioned glycoNPs were tested mainly against E. coli, magnetic glycoNPs displaying fucose‐bearing oligosaccharides efficiently block the adhesion of Helicobacter pylori.239

2. Carbon NPs

Carbon NPs are another choice in the fabrication of glycoconjugates with antiadhesive properties. Recent studies include mannose‐bearing diamond NPs exhibiting an excellent inhibition of E. coli type 1 FimH‐mediated adhesion.240, 241 Ragoussi et al. have described similar mannose modification performed on CNTs and graphene sheets but provided only the results of a selective lectin binding test242; the inhibition of bacterial adhesion by such NPs has yet to be assessed. On the other hand, Luczkowiak et al. reported an inhibition of Ebola pseudotype virus binding to DC‐SIGN receptor‐displaying cells.243 In their study, fullerene with 12 mannoses (Fig. 14) was the most effective virus inhibitor, while increasing mannose valency led to decreased inhibition efficiency,243 confirming a need for the controlled synthesis of conjugates with their extensive assessment.

Figure 14.

Figure 14

Structure of multivalent mannosylated fullerene used for inhibition of Ebola‐like virus binding. Reprinted with permission from 243. Copyright 2013 American Chemical Society.

3. Synthetic Polymers

Despite the relative ease of controlled chemical ways of glycosylation of carbon and metallic NPs, polymer scaffolds seem to have been explored the most intensively in this field. One reason may be a wider diversity of synthesized polymeric glycoconjugates available, as shown in the extensive study by Percec et al.244

Recently reported examples of fully synthesized scaffolds include PAMAM dendrimers displaying carbohydrate Lex moieties capable of competitively blocking DC‐SIGN receptors, thus inhibiting the first phase of HIV infection.245 More importantly, the glycodendrimers exhibited a negligible inhibition of langerin, which, contrary to DC‐SIGN, helped to internalize and destroy HIV particles. From the testing of a mini library comprising of third‐, fourth‐, and fifth‐generation glycodendrimers, the latter was found to be approximately twice as efficient in inhibiting the binding of model virus‐like particles compared to the other ones (third and fourth generation). Finally, the conjugate was tested for the inhibition of the real virus influencing DC‐SIGN‐mediated binding and trans‐infection.245 Fucosylated, branched phosphodiester‐based scaffolds were reported to bind efficiently to Burkholderia ambifaria lectin with a promising application as inhibitors of bacterial infection.246 Cholera toxin has been successfully ligated with newly synthesized five‐armed molecular scaffolds, bearing a galactose‐oligomer recognition unit on the end of each arm.247 Pseudomonas aeruginosa lectin A recognition was suppressed by α‐l‐fucoside and by a β‐d‐galacto‐pyranoside dendrimer hybrid, which may be further exploited for the treatment of Pseudomonas aeruginosa‐based infections248, 249 (for Pseudomonas aeruginosa lectin A‐glycan binding AFM images, see250). Yan et al. investigated the influence of multivalency of n‐heptyl‐α‐d‐mannose on the strength of binding to FimH adhesin displayed on type 1 fimbriae of E. coli causing Crohn's disease.251 They found that the linear polymer decorated with numerous n‐heptyl‐α‐d‐mannose moieties was more efficient in the coagulation of bacteria (Fig. 15) compared to monovalent glycoconjugates or polyvalent star‐like particles.251 The potential of multivalent synthetic glycodendrimers was further demonstrated by Ghirardello et al., who reported a 109×106‐fold stronger binding potential (relative potency) to WGA of a 48‐valent GlcNAc dendrimer compared to an unconjugated GlcNAc moiety.252 A relative potency of only 1168 was reported for a 30‐valent N‐acetyl‐d‐lactosamine (LacNAc) “onion peel” like dendrimer compared to the LacNAc monomer, binding specifically to leguminous lectin from Erythrina cristagalli.253

Figure 15.

Figure 15

Glycopolymer‐induced agglutination of type 1 fimbriaeted E. coli (strain UTI89). (A) Fluorescence microscopy pictures of Katushka‐expressing type 1 fimbriaeted E. coli UTI89; (B) exposed to 1 μM of L188; (C) to 3 μM of L188 and resulting in a “bacterial egg” agglomerate with approximate dimensions of 98 × 51 μm. Reprinted with permission from 251. Copyright 2015 American Chemical Society.

In order to protect against eukaryotic parasites, Campo et al. synthesized cyclic triazole‐linked oligomers with pseudo‐glycosidic units with an affinity toward the trans‐sialidase enzyme from Trypanosoma cruzi.254 As a result, the inhibition of the parasite development after their invasion into macrophage cells was observed, but a quite high concentration (250 μM) of the therapeutic oligomer was needed. Nevertheless, these results are only preliminary, and further optimization of oligomer formation (i.e., a pseudo‐glycosidic unit density and its precise location) is needed to increase the inhibition activity.254

4. Biopolymers and Proteins

Galactose units displayed on a branched oligopeptide were efficiently bound to the surface lectin of P. aeruginosa, inhibiting film formation and disrupting existing biofilms.255 Bouckaert et al. explored cyclodextran NPs conjugated with n‐heptyl‐α‐d‐mannose using various spacers as potential FimH agonists.256 They did not observe improved adhesion to the FimH adhesin of E. coli; however, their results suggest that differences in the length of the spacer arm may account for the low undesired affinity for human mannose‐binding lectins.256 A further step in the development of antivirotics and antibacterial drugs that are not based on recently used synthetic antibiotics, to which an increased number of bugs are resistant, was described by the preparation of a cyclopeptide‐based dendrimer decorated by glycan moieties using an oxime ligation.257 The best‐performing, 64‐valent glycodendrimer from the reported library of compounds (Fig. 16) exhibited a 40,000‐fold increased lectin‐binding potency compared to monovalent methyl α‐l‐fucopyranoside.257 Cholera toxin inhibitor with an IC50 value of 100 pM based on a tetravalent neoglycoprotein prepared by a simple chemical modification of an inactive B subunit of cholera toxin was reported by Branson et al.258 The use of cholera toxin protein as a template secured a “… precise fit of the ligand groups with the spacing and configuration of binding sites on wild‐type CTB.”258

Figure 16.

Figure 16

Synthesis and structure of cyclopeptide‐based glycodendrimers. Reproduced from 257 with permission of the Royal Society of Chemistry.

Self‐assembled polymeric particles are the third type of organic nanocarriers covered in this section. For example, vesicles self‐assembled from poly(ethylene oxide) and polycaprolactone and further modified with a sialodendrimer block the cellular recognition of influenza virus via ligation with viral hemagglutinins.259 Authors have reported a decrease in IC50 from 4 mM to 240 μM (per glycan unit) when mono‐ and eight‐valent glycodendrimers were tested, respectively, and a further decrease to approximately 2 μM when the glycodendrimers were conjugated to the polymer vesicles.259 Another type of conjugate was prepared in the form of nanodroplets by crosslinking polymer shells that were ready for subsequent covalent modification.251 Yan et al. decorated such particles with multiple n‐heptyl‐α‐d‐mannose moieties to achieve the efficient coagulation of pathogenic E. coli type 1.251 E. coli’s type 1 fimbrial adhesin (FimH) was also targeted by Wu at al. using mannose‐terminated DNA oligomers.260 Complementary DNA strands conjugated with a second‐generation dendrimer were then applied to assemble mannosylated fibers with the capability of agglutinating E. coli strain ORN178.260 Interestingly, the authors claimed that agglutination ability was independent of mannosyl density on the fiber surface, most likely because of flexible tube‐like NPs.260 Yu et al. prepared nanotubes that were self‐assembled from amphiphilic pillar[5]arene, with glucose acting as the hydrophilic part.261 These glyco‐nanotubes were able to agglutinate E. coli cells more effectively with an increased number of glucose units with the highest agglutination index of 54 (an average number of bacteria connected to each other after successful agglutination).261 Therapeutic potential also can be predicted for self‐assembled oligopeptide‐LacNAc conjugates capable of moderating the activity of galectin, a lectin‐type protein with signaling and other properties.262

5. GlycoNPs for Enzyme Inhibition and Other Therapeutic Functions

Applications of iminosugars for the treatment of lysosome storage diseases (e.g., Gaucher disease or glycosphingolipid lysosomal storage disorder, characterized by a mutation‐based impairment of different glycosidases with a subsequent pathological accumulation of glycolipids) have been investigated in recent years. Iminosugars are selective and reversible inhibitors of glycosidases due to selective binding to their active sites. This binding can help to fold impaired enzymes, thus partially restoring their hydrolytic activity at the higher pH present in lysosomes. Furthermore, the misfolded enzymes “protected” by the bound iminosugar can avoid degradation otherwise induced by a cellular quality control.263 Using this mechanism, iminosugars could be applied for so‐called “pharmacological chaperone therapy,” an emerging way to treat lysosomal storage diseases. The nature of recognition between iminosugar and respective glycosidase differs significantly from that of lectin–glycan binding. This fact raises the question of whether multivalency can increase the inhibition potency of investigated glycomimetics. In fact, previous studies have suggested that multivalent iminosugars lost their inhibition ability, while recent studies using well‐defined and controlled synthesis have reported the opposite.

In the study of Garcia Fernandez et al., a mini library of iminosugar‐based glycomimetics (either monovalent or conjugated to fullerenes) was tested for its potency to inhibit a variety of glycosidases.264 Their results suggested that in some cases, multivalency can “switch on” the inhibition by switching the binding mode, rather than by the sheer presence of a higher amount of recognition moieties.264 In a more recent work, several scaffolds and conjugates displaying deoxynojirimycin, a broad glycosidase inhibitor, were tested.265 Interestingly, the strongest inhibitor (800‐fold stronger than a monovalent analogue) was just a tetravalent iminosugar present on a porphyrin‐based scaffold. The authors suggested that the valency itself did not cause an increased inhibition potential, but rather the spatial conformation of monosaccharides did.265 Moreno‐Clavio et al. tested several l‐fucosidase iminosugar‐based inhibitors with less success.266 Only a sevenfold‐higher inhibition effect on α‐l‐fucosidases was observed when a trivalent scaffold was used compared to a monovalent one.266 On the other side, a relative α‐mannosidase inhibition potency as high as 3000 was reported for the N‐alkyl analogue of 1‐deoxynojirimycin conjugated on a synthetic glycoprotein scaffold (Fig. 17),267 almost 10,000 for the 21‐valent 1‐deoxynojirimycin scaffold268 and higher than 500 for glycocyloclopeptide with seven copies of 1‐deoxynojirimycin.269 In the latter case, the large inhibition potential was obtained only on glycoconjugates with a longer (C9) spacer, while C6 spacers of the same glycoconjugate resulted only in a relative inhibition potency of 42.269

Figure 17.

Figure 17

1‐Deoxynojirimycin‐based glycopolypeptides: synthesis, self‐assembly, and glycosidase inhibition model. CuAAC = CuI catalyzed Huisgen azide‐alkyne cycloaddition. Reproduced from 267 with permission of the Royal Society of Chemistry.

The real therapeutic effect of different 3‐ to 14‐valent iminosugar conjugates was investigated by Joosten et al. through the in vitro measurement of β‐glucocerebrosidase activities in N370S Gaucher fibroblasts.270 The authors reported a “mild, but significant” effect of multivalency. Importantly, the highest inhibition rate was not correlated with the highest chaperoning (therapeutic) effect.270 This report clearly suggests that similar systematic investigations will be necessary to develop efficient NP‐based drugs against lysosome storage diseases.

A similar approach applied for the treatment of lysosome storage diseases was also investigated for the treatment of cystic fibrosis. 1‐Deoxynojirimycin and its derivatives correct a misfolded cystic fibrosis transmembrane conductance regulator protein in a similar manner as the aforementioned chaperone effect of iminosugars towards glycosidases, with a 1000‐fold increased inhibition activity of 3‐valent iminosugar compared to a monovalent analogue control.271

The concept of pharmacological chaperones may sound very promising, but although the activation of glycosidases has been observed, it hardly reached therapeutically sufficient levels, with typically an approximately twofold increase in the activity.272 From this point of view, the work of Brissonnet et al. is noteworthy.273 These authors reported an activity increase as high as 70‐fold of a bacterial mannoside‐phosphorylase using cyclodextran‐based NPs displaying deoxymannojirimycin (more than 100‐valent). Nevertheless, further studies are needed to elucidate the nature of the enzyme activation gain.273

The selective interaction of a disaccharide called Thomas Friedrich antigen (TFag) with specific tumor cells displaying Gal‐3 lectin had a cytotoxic effect on the targeted cells: a conjugate of small AuPs coated with TFag via an amino acid linker was synthesized, and an approximately 100‐fold higher cytotoxicity toward the Gal‐3‐positive cells was achieved compared to monomeric units.274 The main cytotoxic effect of the TFag relied on apoptosis induced by an inhibited Gal‐3 signaling,274 but it is anticipated that the TFag targeting may also work well in drug delivery.

Another glycan with a therapeutic effect is heparan sulfate, a glycosaminoglycan‐based polysaccharide capable of inhibiting protease β‐secretase responsible for the accumulation of plaques causing Alzheimer's disease. Nevertheless, carbohydrate synthesis is rather complicated and expensive. Therefore, a mini library of dendritic polymers bearing multiple copies of different heparan sulfate monomers was recently introduced.275 Some of these conjugates were found to possess inhibition potential equivalent to that of previously tested oligomers, which is an important result for the future development and production of anti‐Alzheimer's disease drugs.275

6. CELL/TISSUE TARGETING

While the previous section covered the therapeutic effects of NPs displaying carbohydrate moieties on their surface, there are even more studies investigating glycoconjugates where a carbohydrate moiety plays a different role—targeting specific tissues or cells based on the selectivity of protein–carbohydrate interactions. This selective targeting has been mostly used for the delivery of (noncarbohydrate) drugs, particles, or compounds suitable for thermodynamic therapy or fluorophores/particles, allowing selective tissue/cell imaging using spectrophotometric and other methods (e.g., magnetic resonance). In fact, selective cell imaging is based on efficient selective targeting; thus, in many studies, both aspects are overlapped.

A. Drug Delivery

From a material point of view, diverse metallic NPs, carbon NPs, and SiNPs conjugated with carbohydrate moieties and drugs to be delivered have been reported in the past. A recent trend (since 2013), however, is the application of polymeric scaffolds or biopolymers, that is, either abundant polysaccharides based on glucose, chitosan, dextrans, or pullulans or protein‐based scaffolds for such purposes.276, 277, 278 Saccharides were applied for the selective internalization of NPs by targeted cells due to receptors displayed on their surfaces with subsequent intracellular drug release. Saccharides were also used to substantially suppress adverse side effects of the treatment by the improved biocompatibility of otherwise hydrophobic, insoluble, or instable substances.

After targeted delivery, drugs must be released from the conjugate to perform their therapeutic effect. Most nanocarriers have been prepared as pH‐sensitive conjugates, taking advantage of different pH values inside many tumor cells, where NP degradation occurs with subsequent drug release. Enzymatic nanocarrier degradation has also been described, as well as the degradation of the conjugate triggered by the presence of specific small molecules (glucose, glutathione, etc.). Irradiation‐sensitive nanocarriers have also been described where on‐demand and “remotely controlled” drug release occurred after near‐infrared (NIR) or UV irradiation.279 In addition to a “model” drug (doxorubicin being one of the most frequently loaded cargoes in nanocarrier studies) or therapeutic proteins, carbohydrate‐based nanocarriers have also been used as nonviral vectors.277

1. Carbon Nanomaterials

Carbon NPs can be divided into four main groups regarding their dimensionality, that is, 0D fullerenes and spherical NPs, 1D nanotubes and nanofibers, 2D graphene sheets and 3D cryogels, aerogels, or foams. Recently, Li et al. compared of all types of carbon NPs for the simple encapsulation of an enzyme with its subsequent intracellular release.280 While three‐dimensional graphene aerogel was suitable for the long‐term release of a cargo (3% in 24 hr), oxidized CNTs and GO provided fast cargo release (15–20% in 4 hr).280 Without any doubts, a comparison of different types of NPs is needed for the development of ultraefficient drug carriers. Unfortunately, there is no recent comparative study focusing on the performance of different types of NPs modified with glycans applied in drug delivery.

Many recent studies have explored the potential of graphene‐based NPs, that is, GO281, 282, 283 or rGO.284, 285 Flakes of the former form of graphene derivative display many oxygen groups, which make GO hydrophilic and easily dispersible in aqueous solutions.286 Furthermore, surface‐displayed oxygen moieties can be used for the covalent conjugation of various ligands. Most recent studies have investigated only slightly different variations of a basic scheme relying on GO nanosheets decorated with hyaluronic acid (HA) securing the selective binding of nanocarriers by CD44 receptors present on the surface of various kinds of tumor cells. Song et al. described the improved solubility of doxorubicin adsorbed on GO sheets and the “shielding” of a GO's surface charge by increasing its hydrophobicity.281 In this study, a complex of GO‐doxorubicin with modified HA was reported to occur via H‐bonds between HA's amine and GO's epoxide group.281 In another study, HA was covalently grafted onto the GO surface via adipic acid dihydrazide.287 This GO–HA conjugate was treated with doxorubicin solution, and the drug was adsorbed onto a GO surface, most likely by hydrophobic and π–π stacking interactions.287 HA could be attached to a GO surface via introduced sulfhydryl groups, forming disulfide bonds that were cleaved by glutathione inside targeted cells.288 A similar approach was tested by Yang et al., who modified the GO surface with carboxymethylated chitosan.289 Amine groups present in chitosan were used for covalent linkage to GO's hydroxyls and helped to sequentially attach HA with the subsequent loading of doxorubicin.289 All of the authors declared the in vivo inhibition of tumor growth after injection of the prepared conjugates; however, the inhibition rate hardly exceeded 50% compared to the control. Thus, such relatively low efficiency of cancer growth inhibition complicates the further commercial exploration of doxorubicin‐based delivery systems. Interestingly, an almost 80% decrease in the size of epidermal tumors in mice was observed 28 days after the injection of the conjugate prepared from rGO (Fig. 18).284 Most probably, higher hydrophobicity of rGO compared to GO allowed the adsorption of a higher amount of doxorubicin. Xu et al. combined the GO‐HA‐doxorubicin delivery system with a photothermal therapy by wrapping AuNPs in GO sheets with the subsequent loading of HA and doxorubicin.290 Drug‐induced cytotoxicity based on a nanoconjugate was comparable to a treatment with the same concentration of unconjugated doxorubicin, but upon laser irradiation, the increased temperature of AuNPs decreased the cell viability of hepatoma cell line Huh7 from 44 to 18%.290

Figure 18.

Figure 18

Schematic depiction of reduced graphene oxide (black support) conjugated with cholesteryl (green), doxorubicin (red), and hyaluronic acid (blue) including hydrophobic and π–π stacking interactions. Reprinted from 284. Copyright 2013, with permission from Elsevier.

GO hydrogel modified with heparin‐mimicking sodium styrene sulfonate was perfectly biocompatible with blood. Such a nanoconjugate could have a broad range of therapeutic applications, including drug delivery.291 Nevertheless, only a nonselective antimicrobial activity of particles loaded with gentamycin sulfate was tested.291

CNTs offer similar surface properties as graphene‐based NPs, and their complexes with HA were also tested for doxorubicin delivery. However, when the drug was complexed with CNTs covalently grafted with PEI and HA, an in vitro study revealed a quite similar viability (approx. 50%) of model tumor cells treated with conjugated or unconjugated doxorubicin (24 hr, ∼4 μM doxorubicin).292 More promising results were obtained with covalently grafted polyethylene glycol derivative to CNTs, crosslinked to a gel form by adding β‐cyclodextrin and treated with camptothecin (a hydrophobic cytotoxic drug).293 An in vitro study showed the significant growth inhibition of a cancer cell line (∼80% inhibition after 7 days compared to cells treated with blank CNT‐polymer gel). The gelation process relayed on the natural ability of cyclodextrins to include certain molecules (PEG moieties, in this case) into their cavity via host–guest interaction. Such an absorption capacity also has great potential for hydrophobic drug loading. Furthermore, the feasibility of precise chemical modification makes cyclodextrins a great tool not only in smart drug development but generally in the molecular fabrication of diverse mechanisms.293 These possibilities have been reviewed, for example, by Martínez et al.294

In addition to carbon, boron nitride nanotubes have also been exploited for drug delivery. Such nanotubes with covalently grafted glycosylated chitosan exhibited low cytotoxicity; therefore, such NPs could be used as nonviral vectors.295 A plasmid gene was more efficiently expressed in human carcinoma epithelial cells (A549) than in control cell lines even though these NPs did not exhibit any specific receptor ligand selectivity.295 Enhanced plasmid expression could be assigned to more efficient endocytosis rather than to the presence of specific receptors in A549 cells.295

An intriguing approach was reported by Zhou et al. by loading doxorubicin into pores of mesoporous carbon NPs.296 These NPs were subsequently grafted by HA, which guided selective drug targeting. Furthermore, HA acted as a “gatekeeper” because it was specifically recognized and degraded by hyaluronidase‐1 after internalization and allowed drug release. In addition to enzymatic degradation, HA coating could also be removed by glutathione due to the nature of a covalent bond between HA and NPs, making drug release more efficient and controllable. The authors reported an IC50 of 8.9 μM for doxorubicin carried by the nanocarrier.296

2. Metal and Metal Oxide NP‐Glycan Conjugates for Drug Delivery

AgNPs able to generate oxidative stress have strong antimicrobial properties. Their modification with glycans represents very simple carbohydrate‐guided therapy applicable in bactericidal surface fabrication (vide supra) and possibly also in cancer treatment. Kennedy et al. revealed that AgNPs modified with a monosaccharide galactose were internalized by model neural and cancer cells more efficiently than mannose and glucose conjugates, but interestingly, the former exhibited lower cell toxicity (approx. fourfold lower EC50 against model cancer cells) compared to less‐internalized glycoconjugates, suggesting an important role of terminal saccharide in glycan moieties.297 Similarly, Shahbazi et al. observed a significant level of cytotoxicity (approx. 80%) when the HT1080 sarcoma cell line was treated with iron oxide NPs (100 or 200 nm in diameter) coated with glucose, but a similar effect was observed with NPs coated by polyethylene glycol, suggesting the low targeting capability of such conjugates.298

Apparently, AuNPs have not been considered preferential drug carriers, as discussed in a previous section, despite the fact that there are studies reporting the simple decoration of AuNPs with carbohydrate‐based targeting moieties (mannose modified108) and even loaded with therapeutic agents. The latter was achieved by the conjugation of moieties capable of enhanced drug ligation to AuNPs, with cyclodextrins being very sound examples of such approach. Cyclodextrins (and their derivatives299) can host hydrophobic, insoluble, drugs inside their structure294 and can be easily conjugated to AuNPs.300 Alternatively, AuNPs can be conjugated directly with cytotoxic ligands, for example, gold(I) triphenylphosphine.301 On the other side, similar to the above‐mentioned carbon NP‐based nanocarriers, HA derivative coated on gold nanocages was used as a vehicle for the targeted delivery of doxorubicin into CD44 receptor‐expressing cells.302 The intracellular hyaluronase‐1‐induced degradation of the conjugate resulted in drug release and selective cytotoxicity. In contrast to carbon NPs, gold nanocages could also be applied for thermodynamic therapy. This synergy of cancer cell treatment led to the complete elimination of a solid tumor in mice in 9 days by combined photo‐ and chemotherapy.302

Terpen (borneol) stabilized selenium NPs decorated with glucose were also reported to deliver an anticancer drug selectively into Hep2 cells (a hepatocarcinomic cell line).303 In addition to an efficient pH‐sensitive system of drug release from the conjugate, an intracellular, selenium NP‐directed production of reactive oxygen species (ROS) was also observed, making the fabricated glycoconjugate cytotoxic for drug resistant hepatocarcinomic cells.303 Similarly, TiO2 NPs coated with HA and loaded with cisplatin containing ligand were found to carry their payload selectively into an ovarian cell line (A2780) with pH‐induced drug release from these glycoconjugates.304 Nevertheless, only an approximately twofold increased drug‐induced cytotoxicity against model cancer cells was observed upon treatment with conjugated versus unconjugated drug (a decrease to approx. 40 vs. 70% of the original viability, respectively, using 10 μM drug).304

Polysaccharide carboxymethyl dextran was also used as a building block for the synthesis of magnetoliposomes loaded with doxorubicin.305 Drug release was enhanced upon the exposure of the conjugates to a low‐frequency magnetic field in synergy with low pH induced structural changes leading to drug release. In vitro experiments confirmed the low cytotoxicity of the loaded magnetoliposomes to brain cells, while after incubation with 2.5 μg mL−1 of conjugated and free doxorubicin equivalents, the viability decreased to approx. 40 and 70% of original viability, respectively.305

3. Silica‐Based Glycan‐Targeted Drug Carrier Systems

In a rather “traditional” approach, small SiNPs were covalently modified with spacers; each one ended with trivalent glucose as a targeting unit.306 The spacers provided a space for the inclusion of molecules of the anticancer drug paclitaxel. The drug delivery system was the same as described before, that is, whole conjugates were selectively internalized by cancer cell line HepG2, and the drug was released either by intracellular esterases or by low pH. Due to the good pharmacokinetics of the fabricated conjugate, a much higher toxicity (IC50 = 0.7 μM paclitaxel equivalent) was induced than with a treatment by the unconjugated drug upon prolonged incubation (no viability change using 0.7 μM paclitaxel).306

Polysaccharide moieties were also used to increase the biocompatibility of a mesoporous silica doxorubicin carrier.307 Yu et al. adapted an already developed protocol to prepare HA‐coated mesoporous SiNPs transporting doxorubicin selectively into human colon cancer cells.308 A decrease of targeted cell viability by approximately 50 and 20%, respectively, was observed upon incubation with 0.25 μM drug equivalent carried by HA‐coated NPs and uncoated NPs or free drug.308 HA‐targeting mesoporous SiNPs with both a therapeutic agent and HA attached to NP's surface by disulfide bonds were investigated by Zhao et al.309 Disulfide bonds were cleaved by glutathione, causing efficient drug release (Fig. 19). Cytotoxicity assessment showed that after 72 hr of treatment with the drug‐loaded conjugate, a cell line with CD44 receptors retained a viability of 39%, while the viability of a control cell line without CD44 was 49%, suggesting rather strong nonspecific internalization by the NIH 3T3 cell line.309 The same group also prepared mesoporous SiNPs with pores loaded with doxorubicin and capped by HA attached to the surface by disulfide bonds.310 Excess glutathione and hyaluronidases helped to release capping molecules from the conjugate.310 An elegant approach using nonspecific internalization based on differences between the metabolic activity of normal and cancer cells was reported.311 Cancer cells exhibit increased glucose uptake with the enhanced uptake of synthesized glucose‐modified SiNPs. Celastrol used as an anticancer drug negatively affects the mitotic cycle, which is faster in cancer than in normal cells, thus making cancer cells more susceptible to the effect of the drug. Mesoporous SiNPs decorated with glucose via dendritic polymer linkers were found to induce the apoptosis of HeLa cells (50% apoptotic cells after 24 hr of incubation with 5.3 μM drug equivalent). On the other hand, a lower exposure time induced the production of heat shock proteins, suggesting that a subcytotoxic dosage (or exposure time) may even help to protect normal cells.311

Figure 19.

Figure 19

Schematic depiction of glutathione (GSH) induced drug release from hyaluronic acid (HA) capped pores of silica NPs. These pores are filled with disulfide‐bond tethered 6‐mercaptopurine (6‐MP) and, due to HA‐decoration, nanoparticles are captured and internalized via so called CD‐44 receptors—a common surface glycoprotein with significantly higher concentrations on the surface of certain cancer cells. Reprinted with permission from 309. Copyright 2014 American Chemical Society.

Carbohydrate modification can also be used for the selective and triggered drug release from mesoporous magnetic SiNPs.312 Lectin‐like phenylboronic acid (PBA) displayed on their surface anchored dextran, which efficiently gated drug‐loaded pores in the body of magnetic SiNPs. Once glucose is present in sufficiently high concentration, it competitively binds to PBA, and the dextran “gatekeeper” layer is consequently released from the surface. Due to the much smaller size of glucose compared to dextran chains, drug molecules can easily migrate from the pores. This glucose‐dependent release has great potential, for example, in diabetes treatment, even though a selective cytotoxicity against HeLa cells in the presence of glucose was demonstrated in this study (60% decrease of viability compared to a 25% decrease upon treatment of the cells with unloaded and drug‐loaded NPs without dextran, respectively).312 Employing the same gate‐keeping approach, Zhou et al. bound mannose units on the surface of mesoporous SiNPs via disulfide bonds.313 These moieties tethered Con A lectin, a molecule large enough to prevent the migration of doxorubicin from the pores of mesoporous SiNPs. Selective release was triggered by the elevated concentration of glutathione in the cytoplasm of cancer cells, and the conjugate exhibited an IC50 of 25 μg mL−1 against cancer cells, while a negligible viability change was observed when the conjugate was incubated with normal cells having a lower cytoplasmic glutathione concentration.313

Chondroitin sulfate is another natural polysaccharide with the ability to promote the uptake of conjugates by selective interaction with CD44 receptors. Moreover, such a biopolymer has the ability to improve the biocompatibility and stability of NPs. All of these features of chondroitin sulfate were used to fabricate a mesoporous silica‐based vector loaded with a plasmid carrying the gene for the p53 protein.314 A more than twofold increase in translated messenger RNA for p53 was observed in treated cancer cell lines, when the silica‐based vector was coated with chondroitin sulfate compared to bare mesoporous silica–plasmid conjugate.314 Gene therapy induced expression of healthy p53 protein in human cancer cells inhibits tumor growth; thus, the above‐described vector represents another possible way for cancer treatment.

4. Polymer Scaffold Based Drug Carriers

Liposomes prepared from a synthetic building block containing a hydrophobic tail conjugated with galactose as targeting units were capable of transporting doxorubicin easily into HepG2 cells displaying asialoglycoprotein315, 316, 317 and other receptors.44 A very similar system, only with incorporated disulfide bonds in the structure of micelles, was reported.318, 319, 320, 321 Such glycoconjugates were selectively internalized, and a drug was released after the glutathione‐mediated cleavage of S–S bonds.318, 319, 320, 321 Although these studies demonstrated the selective cytotoxicity toward targeted cancer cells in vitro, only Zhao et al. have reported the in vivo inhibition of tumor growth after the localized injection of galactosylated, doxorubicin‐loaded liposomes (tumor weight of approx. 50% compared to animals treated with an unconjugated drug).316 The unfolding of synthetic322 or natural323 micelles triggered by UV irradiation for drug release was also reported, but such an approach was not tested for in vitro or in vivo cytotoxicity. In order to better control the form and chemical properties of nanocarriers, a tri‐block copolymer folded into different types of mannosylated micelles was synthesized.324 Preliminary results suggested that there was some correlation between mannose receptor‐induced internalization and the shape of a micelle, but in vivo or in vitro studies investigating the inhibition of virus binding have yet to be conducted.324

To discuss drug delivery from an application point of view, it is worth mentioning the use of a synthetic copolymer folded into micelles tested for the oral administration of sorafenib—the drug applied mainly for the treatment of kidney and liver cancers.325 In vivo studies have demonstrated that galactosylated, drug‐loaded micelles efficiently and selectively administered sorafenib into the liver and secured its continuous release for several hours.325 To improve the oral administration of darunavir, self‐assembled micelles made from synthetic copolymer poly(ethylene oxide)‐poly(propylene oxide) were glycosylated by microwave‐assisted ring opening reaction and loaded with the drug by a simple incubation of the two components in solution.326 An approximately 500‐fold higher solubility of darunavir was observed upon its integration into micelles. This is a significant step in the development of less expensive anti‐HIV drugs, considering the fact that the low administration efficiency of present darunavir‐based delivery increases its cost.326 Berberine hydrochloride is another drug with a reported anticancer effect with chemical properties not allowing oral administration.327 Drug encapsulation into chitosan‐coated phospholipid micelles significantly improved pharmacokinetics and distribution parameters due to the increased biocompatibility of the conjugate. It should be noted, however, that only the biodistribution and drug release profile were assessed in the study, with results suggesting that chitosan‐coated liposomes are good vehicles for the oral administration of berberin.327 Micelles prepared by the conjugation of α‐tocopherol (recognized as a potential anticancer drug) with pullulan were reported to release the drug 10‐hydroxycamptothecin at the low pH typically present in the cytoplasm of tumor cells.328 In vitro cell assays revealed an approximately 60% decreased viability of targeted cells compared to a control experiment with another cell line.328 A conjugate based on α‐tocopherol derivatives together with HA and cytostatic docetaxel in the micellar form was found to induce cytotoxicity and to decrease multidrug resistance via the α‐tocopherol‐mediated inhibition of the active drug transport from the cell.329 The suppression of drug resistance on a molecular level was also achieved by the delivery of two recently synthesized inhibitors of efflux proteins (P‐glycoprotein and breast cancer resistance protein) loaded in poly‐lactic‐co‐glycolic‐acid.330 A higher inhibition level of cancer cells incubated with conjugated compared to unconjugated inhibitors was demonstrated.330 Interestingly, the same efflux mechanism was also suppressed by hydroxypropyl‐β‐cyclodextrin moieties grafted onto synthetic copolymer NPs, which enhance the effect of low‐soluble immunosuppressor tacrolimus by oral administration.299

Atherosclerosis can be efficiently treated by the internalization of micelles prepared from a reconstituted high‐density lipoprotein (rHDL) loaded with levostatin mediated via Scavenger Receptor class B member 1 (SR‐BI) receptors accessible on the surface of cells present in a macrophage‐infiltrated atherosclerosis lesion.331 Upon coating of the fabricated micelles with HA (Fig. 20), their administration became more efficient and precisely targeted in two steps: (i) because of their lower accumulation in the liver, this is achieved because HA‐decorated particles are not recognized by SR‐BI receptors and “scavenged” (recognition by SR‐BI receptors in liver cells leads to an increased level of phagocytosis). Thus, more particles are delivered into atherosclerotic veins. In the second stage, (ii) HA was readily recognized by CD44 receptors present in atherosclerotic plagues, where HA‐LT‐rHDL was accumulated. Next, due to the presence of hyaluronidases, HA was removed. The formed LT‐rHDL NPs were recognized by SR‐BI receptors of atherosclerosis lesion cells, which delivered them into desired “foam cells” where levostatin was released.331

Figure 20.

Figure 20

Scheme of fabrication and function of dual‐targeted reconstituted liposomes. Upper scheme represents preparation of micelles containing levostatin and coated with HA (HA‐LT‐rHDL). After injection in an atherosclerotic rabbit, HA coating allowed preferential distribution of HA‐LT‐rHDL into veins and their retention in an organism with decreased rate of phagocytosis in liver. Once HA‐LT‐rHDL reached a lesion site, it was recognized by CD44 receptors on the surface of endothelial cells which helped their transportation inside an atherosclerotic plague (the scheme in the lower part of the figure). In the plague, hyaluronidases removed HA from HA‐LT‐rHDL and the resulting LT‐rHDLs were preferentially recognized by SR‐BI receptors on surface of “foam cells” where lovastatin was intended to be released. Reprinted from 331. Copyright 2014, with permission from Elsevier.

The antiseptic drug NK007 was delivered successfully by oral application to regress murine colitis.332 Polysaccharide components of micelles are responsible for efficient target delivery as could be concluded from the in vivo study. Nevertheless, a significant difference between the parameters recorded to evaluate treatment efficacy (i.e., colon length, stool consistency, etc.) was only observed between the control and treated groups but not between groups treated with unconjugated or NP‐conjugated NK007.332

Amphotericin B, an antiparasitic drug effective, for example, against Leishmania donovani, induces several harmful side effects, with nephrotoxicity and hemolytic toxicity being the most severe.333 Moreover, the drug is relatively expensive. Khan et al. conjugated this drug with mannosylated synthetic dendrimer to gain biocompatibility. As a result, no kidney damage or hemolysis was observed with the antiparasitic activity of the drug preserved. In fact, due to the mannose‐driven targeting of conjugates into macrophages, IC50 (39 nM) decreased approximately fivefold compared to the unconjugated drug or its commercial analogue.333

A supramolecular scaffold prepared from a polymer bearing PBA and a “complementary” glycopolymer was degraded under hyperglycaemic conditions.334 The conjugate could be applied for the safe, comfortable, and glucose concentration‐sensitive distribution of insulin.335 Zheng et al. also employed a PBA‐based conjugate with both PBA and lactobionic acid moieties displayed randomly on each copolymer chain.334 Such molecules folded into a scaffold able to encapsulate insulin. PBA enhanced the mucoadhesion of the scaffolds, which could be then used for the nasal administration of insulin. Therapeutic effect was confirmed by in vivo experiments in diabetic mice with glucose levels decreased to approximately 40% 8 hr after the addition of therapeutic NPs, while such a decrease was observed within 0.5 hr when bare insulin was injected.334

The single‐step ligation of HA with doxorubicin seems to be much simpler, forming conjugates that are selectively cytotoxic to cancer cells displaying CD44 receptors336 similar to pullulan‐doxorubicin micelles selectively targeting cells with asialoglycoprotein receptors.337, 338 A similar weight reduction of induced tumor was observed in vivo after treatment with unconjugated and conjugated doxorubicin (approximately 0.4 g of tumor weight compared to 1.8 g developed in a control group), but the life span was longer and the animal weight was larger for NP‐treated mice compared to mice treated with unconjugated doxorubicin, suggesting the significant suppression of a negative side effect of a chemotherapy.338 Plant glucomannan covalently conjugated with an inhibitor (bisphosphonate alendronate) of tumor‐associated macrophage was also prepared as a conjugate inducing selective, mannose receptor‐mediated macrophage apoptosis (a tumor weight of approx. 0.3 g was observed 14 days after the application of therapeutic NPs compared to 1.5 g developed in an untreated group).339 Mannose receptors of macrophages were also targeted with ionic polymer‐based micelles containing the model protein to be delivered (BSA).340 Upon coating of the micelles with β‐glucan from yeast cell walls, NPs were selectively internalized by macrophages.340 So‐called “ivy NPs” are nature‐derived nanocarriers consisting of a heavily glycosylated protein core.341 When loaded with doxorubicin, a targeted delivery and release of a drug into different cancer cell lines was observed.341 The treatment of a solid tumor was equally efficient for the application of both the conjugate and unconjugated doxorubicin, but with a significantly lower weight loss of the animal observed after the application of the conjugate.341

Quite a “minimalistic” approach was reported, relying on short polyethylene glycol chains decorated with several saccharidic units along their length and with a bioactive molecule on the chain end.342 Such conjugates bearing two separated mannosyl units (the optimum distance between these units was found to be 5.6 nm) were internalized by macrophage cells via their mannose‐binding receptors. The authors declared a good biocompatibility of the carriers as demonstrated by the absence of lysosome storage disease‐like effect after their application.342 On the other side, in vivo tests of applicability of such conjugates have yet to be performed. Similarly, Thomas et al. reported micelles prepared from bis‐l‐galactose lysine.343 Galactose displayed on the surface of these NPs was enzymatically oxidized, and the aldehydes formed were used for the covalent crosslinking of more NPs together by di‐ or trivalent amine. The authors tested their delivery system only for the complexation of AuNPs, but selective delivery of drugs is anticipated.343

A selective drug delivery into the central nervous system, passing the blood–brain barrier, is always very difficult. Recently, certain lectins displayed on NPs helped to enhance such crossing.344 For example, polyethylene glycol based micelles decorated with lectin Solanum tuberosum were able to successfully deliver a basic fibroblast growth factor via the nasal route into the brain in order to improve the cognition of those affected by Alzheimer's disease.344 Lactoferrin, an iron‐binding glycoprotein, was found to be helpful in delivering drug‐loaded micelles through the blood–brain barrier345, and the same protein was used to target asialoglycoprotein receptors on HepG2 cancer cells, as well.346

Another way to pass the blood–brain barrier is using activated membrane transporters. Glucose transporter 1 was activated by p‐aminophenyl‐β‐d‐manno‐pyranoside with a subsequent transportation of anticancer drugs into the brain cells.347 Kuo et al. prepared NPs based on solid lipid decorated with p‐aminophenyl‐β‐d‐manno‐pyranoside and folic acid and loaded with etoposide (a drug inhibiting the proliferation of malignant glioblastoma) that were efficiently distributed through the blood–brain barrier with efficient secondary targeting to glioblastoma cells secured by folic acid in in vitro experiments.347

Nonviral gene transport is just another field where the aforementioned techniques of controlled targeted drug delivery have been employed. One of the materials used quite often for the preparation of nonviral vectors is PEI, which can be effectively complexed with the DNA or RNA of interest, but it possesses a certain level of toxicity and its targeting is not selective and thus suitable only for in vitro experiments. In order to apply PEI‐based conjugates for in vivo applications, several ways to improve the performance of such carriers were sought. For example, PEI was complexed with a biocompatible anionic glucose‐based glycopolymer,348 GlcNAc,349 chondroitin sulfate,350 HA,351 or depolymerized guar gum with available mannose units352 with subsequent use in selective targeting. Alternatively, copolymers of the methacrylamide backbone decorated with glucose,353 α‐d‐mannopyranosyl,354 or trehalose355 and cationic moieties could electrostatically complex plasmids with the subsequent selective transport of plasmid DNA into cancer cells353, 354 or siRNA into glioblastoma cells via glucose transporter‐1.355 Furthermore, complexed siRNA was reported to retain its biological activity after freeze drying.355 An electrostatic complexation of DNA with copolymer chains bearing a targeting GlcNAc moiety was also reported.356

Targeted gene delivery was also achieved by DNA incorporation into PEGylated micelles decomposing at low pH and decorated with galactose357 or mannose358 to target asialoglycoprotein or mannose receptors, respectively. Noteworthy, a secondary target ligand was co‐entrapped with DNA to help penetrate through the nuclear membrane.357 Mannose‐decorated cholesteryl‐based synthetic liposomes with virus‐like characteristics were reported to effectively transfect nonactivated dendritic cells by a plasmid‐containing gene for luciferase.359 Mannosylated chitosan was also used for nonviral vector preparation360 as well as mannosylated “bubble lipoplexes,” that is, NPs with ultrasound‐triggered DNA release causing the transfection of M2 macrophages and their switch from tumor growth‐promoting into tumoricidal M1‐like macrophages.361, 362 In vivo experiments confirmed that this treatment could inhibit the growth of various tumors without adverse side effects.361, 362 A triblock copolymer consisting of hydrophobic and pH‐sensitive parts to assure the formation of micelles, polycation complexing oligonucleotides, and a mannose‐modified part was also applied to target M2 macrophages.363 Synthetic vectors based on siRNA‐PEGylated cyclodextrin scaffolds with a peptide ligand as a targeting unit were also investigated.364

In addition to the broadly used electrostatic interactions used for loading nucleotides into delivery NPs, Kim et al. employed hybridization with a specific DNA template with a condensation of the resulted DNA complex by a viral Mu peptide (Fig. 21).365 The formed “DNA nanoballs” coated with HA were effectively internalized by cancer cells. In vivo experiments showed that antisense oligonucleotides were hybridized with their complementary mRNA in the cytoplasm, leading to a significant sensitization of the cells to doxorubicin treatment and to a significant decrease of tumor growth in mice.365

Figure 21.

Figure 21

RCA template and hybridization efficiency. (A) Secondary structure of scrambled rolling circle amplification (RCA) template. (B) Secondary structure of a dual antisense oligonucleotide (ASO) hybridizing RCA template for Dz‐13 and OGX‐427. (C) RCA products with poly ASO‐binding sequences were hybridized with two therapeutic ASOs, Dz‐13 and OGX‐427, to produce dual ASO‐hybridizing RCA products. (D) The hybridization efficiencies of the ASOs were tested for products of scrambled RCA templates and dual ASO‐hybridizing RCA templates using fluorescently labeled ASOs. Reprinted from 365. Copyright 2015, with permission from Elsevier.

A very simple approach relying only on the application of bare therapeutic oligonucleotides conjugated with a targeting ligand (e.g., a triantennary GalNAc366, 367, 368 or glucose369) was also tested. These agents were capable of blocking the adverse immunostimulation of an anti‐HIV oligonucleotide. This may be helpful in the fabrication of anti‐HIV drugs without adverse side effects. The conjugate can be easily prepared, but there is a concern regarding the stability of the carrier when exposed to endo‐ and exonucleases.

B. Photothermal and Photodynamic Therapy

Photothermal and photodynamic therapeutic methods rely on the targeted delivery of entities capable of strong energy absorption in the NIR spectrum. As a result, the NIR‐triggered increase of local temperature damages targeted (cancer) cells. Traditionally, metallic NPs have been used as photothermal agents, with AuNPs being the first choice. For example, HA‐covered gold nanostars very efficiently inhibit HeLa tumor growth in mice with almost complete tumor disappearance within 7 days after injection of the conjugate and laser irradiation.370 The recent trend, however, is the use of a combination of simple photothermal therapy with other treatments, for example, chemotherapy. AuNRs wrapped in GO sheets conjugated with doxorubicin were reported to be fourfold‐stronger inducers of HeLa cell death compared to the same conjugates without doxorubicin used for sole photothermal treatment.290

In addition to AuNPs, carbon mesoporous NPs were also employed simultaneously as carriers and photodynamic agents.296 A synergic chemotherapeutic and photothermal effect was observed after loading their pores with doxorubicin and final coating with HA. The observed IC50 against the MDA‐MB‐231 cell line decreased from 8.7 to 2.3 μM doxorubicin after simultaneous treatment with the drug‐loaded NPs and NIR laser.296

A very simple but effective system was reported based on the electrostatic integration of HA and polyaniline applied as a targeting and photosensitizing component, respectively.371 The use of these NPs with subsequent NIR laser treatment led to the complete degradation of induced tumors in mice approximately 8 days after treatment without any observable body weight loss.371 However, the ternary design of multimodal therapeutic NPs was presented, containing poly(lactic acid) NPs coated with derivatized chitosan to increase the biocompatibility of the conjugate and IR 820 (a photosensitive dye).372 Interestingly, two absorption peaks were found for IR 820 encapsulated in the polymer; thus, irradiation with two different wavelengths increased the photothermal effect with the decreased viability of the targeted breast cancer cell line by 70%.372

In another treatment design called photodynamic therapy, photosensitizers were used to generate cytotoxic ROS upon the absorption of irradiation with a specific wavelength. Recently, AuNPs coated with HA (a targeting component) and a porphyrin‐based photosensitizer were reported to decrease the viability of cancer cells with CD44 receptors down to approximately 15% upon irradiation with UV light.373

AuNPs can also exhibit a photosensitizing effect, but for the generation of cytotoxic radicals, X‐ray irradiation is required. In this sense, glucose‐decorated AuNPs were tested in vitro as selective sensitizers for radiotherapy, leading to increased cancer cell death by 20% compared to radiotherapy with unconjugated AuNPs.374

Organic carriers for ROS‐generating photosensitizers were also reported. For example, porphyrin‐derived photosensitizer conjugated to glucose‐decorated poly(methacrylamide) polymer chains375 or encapsulated into poly(lactide‐co‐glycolide)‐based NPs coated with HA.376 In addition to porphyrin‐based photosensitizer, docetaxel was also co‐entrapped to induce a synergistic photochemotherapeutic effect with IC50 of 8 ng mL−1, while an IC50 of 160 ng mL−1 was observed upon treatment with an unconjugated drug under the same conditions.376

Fu et al. used chitosan‐coated SiNPs loaded with benzoyl peroxide as photosensitizers.377 A cytotoxic test against human breast carcinoma cell line ZR75‐30 revealed that chitosan coating did not substantially affect cell viability (70 and 74% of retained viability after incubation with uncoated and coated NPs, respectively), even though the conjugation of benzoyl peroxide increased cytotoxicity (90 and 74% of viability retained after treatment with unconjugated vs. conjugated benzoyl peroxide, respectively).377

GO was successfully applied as a carrier for the loading of photosensitizers, as reviewed recently.378 Recently, HA was conjugated to GO nanosheets with the subsequent physisorption of a photosensitizer.379 The efficient uptake of such modified GO NPs, with a size of 100 nm, was observed. The photosensitizer desorption led to enhanced NIR absorption and the generation of ROS in the cells. The authors reported IC50 values of 1 and 0.1 μg mL−1 of photosensitizer equivalent, respectively, when targeted cells were treated with either free or NP‐conjugated photosensitizer.379

A system combining both photodynamic and photothermal effects has also been developed. While an rGO/ZnO hybrid is responsible for ROS generation upon light irradiation, NIR laser irradiation induced local hyperthermia322 because rGO effectively transferred heat to cells, with a local temperature increase upon exposure to NIR irradiation.380 To secure targeted treatment, HA was conjugated with the rGO/ZnO complex. The function and structure of rGO/ZnO‐HA NPs are depicted in Figure 22, where the viability of targeted cells is also depicted. From these plots, it is obvious that combined photodynamic and photothermal therapy decreased cell viability down to approximately 20%, much more than the application of only one type of treatment.322

Figure 22.

Figure 22

(A) Schematic illustration of sequential irradiation‐activated high‐performance apoptosis. (B) In vitro cell viability of MDA‐MB‐231 cells treated with rGO‐ZnO‐HA following PDT, PTT and combined PDT/PTT treatments. Reproduced from 322, with permission by John Wiley & Sons.

Targeted irradiation by neutron beam is yet another way to induce the cytotoxic effect of certain agents, such as 10B ions using “boron neutron capture therapy.” Radionuclide 10B, after accumulating in the cells, captured supplied protons and underwent fission, generating heavily cytotoxic 7Li and 4He particles.381 To achieve a sufficient amount of boron in cells (on average 1011 10B ions per cell), mesoporous SiNPs were used to carry 10B coordinated to an organic ligand with high selectivity and an accumulation rate achieved by the decoration of the NPs with multivalent galactose units. The delivery efficiency was illustrated by having approximately 3 × 109 atoms in cells when treated with unconjugated boron ligand compared to 1011 atoms when delivered by NPs. Preliminary results suggest that the NP‐delivered amount of 10B atoms is high enough to efficiently perform boron neutron capture therapy.381

C. Cell Imaging

The principles applied to selective delivery can also be employed in cell imaging with appropriate carbohydrate‐binding receptors. Many studies have been published regarding the conjugation of glycan‐displaying NPs with dye molecules to facilitate detection in the UV‐VIS range, contrast enhancers for NMRI or computed tomography imaging of tissues or single cells accumulating nanocarriers.382

1. UV‐VIS Probes

The recent trend is to combine the therapeutic and imaging effects in so‐called theranostic (i.e., therapeutic + diagnostic) NPs loaded with both an imaging probe and a drug as discussed above.44, 381, 383 The imaging function of the conjugate can also be combined with antiadhesive properties.239 Noteworthy, NIR‐absorbing GO/doxorubicin/HA NPs for combined photochemotherapy could be applied to imaging even without any additional dye or label incorporated due to the fluorescent signal obtained from a carrier drug (e.g., doxorubicin). Such an approach was applied for the visualization of cells that internalized nanocarriers.281, 384

Dye‐loaded NPs releasing their cargo after internalization promoted by surface‐displayed carbohydrate moieties were reported.385 The encapsulation of dyes into polymer NPs significantly increased the biocompatibility of imaging probes with the selective visualization of intracellular membranes of targeted cells (Fig. 23).385 Self‐assembled NPs prepared from a natural polysaccharide levan were able to encapsulate indocyanine green.386 The selective accumulation of the conjugate in tumor cells was mediated via overexpressed glucose receptors.386 NPs formed from a copolymer containing fluorescent rhodamine and glucose were successfully internalized by cells with asialoglycoprotein receptors enabling their fluorescent imaging.387 The chemical and enzymatic stability of the imaging NPs were very good, with a maximal release of only 2.5% of the loaded dye within 4 days in the presence of lipase and esterase.387

Figure 23.

Figure 23

Effective intracellular delivery of rhodamine B octadecyl ester in HDF cells mediated by (1:9 PGalSMA34 + PGMA51) PHPMA270 vesicles (prepared via thin film rehydration to ensure sterility and enable loading with a fluorescent dye). Cells were incubated with 1.0 mg/mL rhodamine B octadecyl ester loaded vesicles for 16 hr. (A) Confocal microscopy image of live HDF cells: note the intracellular staining of membranes (red) after exposure to the rhodamine‐loaded vesicles, cell nuclei are counter‐stained blue using Hoechst 33342. (B) HDF cells treated with the same vesicles containing no rhodamine dye (negative control). (C) Higher magnification image obtained for (A): effective intracellular delivery of rhodamine dye allows selective staining of the nuclear membrane (white arrows). Scale bar: 50 μm. Reprinted with permission from 385. Copyright 2013 American Chemical Society.

In addition to diagnosis, the dye labeling of NPs has also been used to evaluate the cell uptake rate. For example, the preparation of mannosylated micelles was optimized by the visualization of their uptake in the cells.388 Further in vivo experiments confirmed their selective imaging capability.388 Perylene bis(imide) derivative decorated with mannose was found to be fluorescent only after the degradation of the formed scaffold triggered by its ligation to a mannose‐specific lectin.389 The fluorescent imaging of macrophage cells overexpressing such receptors has been reported (Fig. 24).389 A novel NIR fluorophore activated upon isomerization at a low pH in lysosomes was used by Wu et al.390 Biocompatible poly(styrene‐co‐maleic acid) NPs loaded with this probe specifically targeting surface‐displayed sialic acid were able to selectively tag and mark tumors in vivo.390 Cell imaging using illumination outside the range of UV‐VIS and NIR has also been tested, for example, by Mäkilä et al., who radiolabeled (68Ga) therapeutic siRNA oligonucleotides conjugated with multivalent galactose units to evaluate their in vivo distribution.391 They observed that the valency of the displayed galactose was crucial to selective and efficient accumulation in liver, and the conjugate with seven glycan units exhibited the best performance, making them suitable for the further development of targeted genotherapy.391

Figure 24.

Figure 24

Confocal microscopic images of murine macrophage cells after incubation with water‐soluble glycocluster based on perylene bisimides PBI‐12‐Man (10 μg/mL, Man = mannose) without (a, excited at 559 nm; b, bright field; c, merging of photos a and b) or with mannose (18 mg/mL) inhibition (d, excited at 559 nm; e, bright field; f, merging of photos a and b) in PBS buffer at 37°C for 1 hr. As shown in a–c, the red fluorescence of PBI‐12‐Man was predominantly intracellular with punctate appearance, suggesting cell surface binding and endocytosis being the cell entry mechanism that results in vesicular (endosomal) localization. For the inhibition experiment, in the presence of α‐d‐mannopyranoside (d–f), the remarkable decrease of the red fluorescence of PBI‐12‐Man indicated the selectively binding interactions of PBI‐12‐Man with the surface mannose receptor of the macrophage cells. Reprinted from 389. Copyright 2014, with permission from Elsevier.

Figure 25.

Figure 25

Photoacoustic tumor imaging in mice with sialic acid‐decorated polymer nanoparticles (pNIR@P@SA). Nude mice bearing H22 subcutaneous tumors were intravenously injected with phosphate buffer saline (PBS; 100 mL) or pNIR@P@SA (40 mg kg−1). The mice were imaged 24 hr after vesicle injection. Control images were obtained from mice before intravenous injection of pNIR@P@SA or PBS. A significantly higher photoacoustic signal obviously resulted from tumor issue after incubation with pNIR@P@SA (lower right panel). Reproduced from 390 with permission of the Royal Society of Chemistry.

Figure 26.

Figure 26

CT number for tumor versus time. The blue line is the CT number of the control group, whereas the red line represents for the PEG Glc‐GNP injection group. Reprinted from 401, with permission from Elsevier.

Other recent studies reported the preparation of simple nanocarriers based on synthetic392, 393 or natural394, 395 polymer NPs conjugated with glycans and imaging probes with selective adhesion to specific cell surface receptors, enabling the visualization of the surfaces of these cells. A complex study was carried out to visualize the binding of radiolabeled mannose‐containing polymer (γ‐Tilmanocept, approved by the FDA as a lymphatic node imaging probe) to targeted cells.396 The authors used a cyanine dye conjugated with Tilmanocept to specifically bind mannose receptors of macrophages, facilitating the delivery of a radiopharmaceutic drug.396 Multivalent clusters of iminosugars conjugated with pyrene or boron‐dipyrromethene cores exhibited fluorescence spectra applicable in cell imaging.397 As discussed earlier, multivalent iminosugars have been intensively tested as promising pharmacological chaperones.

The conjugation of nanocarriers with photosensitizers applied in photodynamic therapy has also often been used for simultaneous therapy and imaging since the majority of molecules applied as photosensitizers exhibit fluorescence. For example, a porphyrin derivative conjugated with glycopolymer exhibited an emission peak at 633 nm, allowing the real‐time visualization of the NP uptake with confirmed targeted cytotoxic effect.375 A similar effect was also observed with functionalized GO integrated into a pH‐sensitive HA nanogel serving as selective carrier for doxorubicin.288 The conjugate based on GO allowed both photodynamic therapy and fluorescence imaging,288 underlining the amazing versatility of graphene‐based nanomaterials.

Deeper tissue penetration and better resolution are the main advantages of photoacoustic imaging. In this method, a probe with an absorption maximum at longer wavelengths is used. The absorption resulted in changes in the probe's properties (thermoelastic expansion); hence, after the activation by a deep‐penetrating laser pulse, the probe was transformed into a detectable ultrasound signal.398 This imaging method was employed using sialic acid‐decorated polymer NPs loaded with a profluorophore, turning it into a photoacoustic probe by isomerization at a low lysosomal pH.390 In the end, it became evident that a significantly higher photoacoustic signal was achieved in tumor vein imaging using this method—see Figure 25.390

2. Metallic NPs in Selective Cell Imaging

An inherent NIR‐induced fluorescence of small Au nanoclusters with the size of 2 nm was used in the preparation of selective imaging probes. Selectivity, stability, and biocompatibility were achieved by the conjugation of the nanoclusters with zwitterions and trivalent mannose ligands.399 The integration of the latter component into the conjugate increased the internalization rate by 62 and 256% when targeted dendritic cells were incubated with 1 and 25 μg mL−1 of the NPs, respectively.399

The absorption of energy by AuNPs from high‐frequency radiation has been employed to enhance the effectivity of radiotherapy (see Section 6.A.5) and as a contrast enhancer during computational tomography (CT) scans, as well. For example, in situ generated small AuNPs modified by dendrimers containing polyvalent lactobionic acid were reported to enter selectively hepatocarcinomic cells via their asialoglycoprotein receptors, allowing the high‐resolution computational tomography imaging of tumors.400 The same method for selective tumor visualization was also enabled by glucose‐modified AuNPs mediated via glucose transporters overexpressed on the surface of cancer cells.401 Tumors could be monitored for a week, as shown in Figure 26.401 Glucose‐conjugated AuNPs bearing a ligand with 68Ga as a tracer were biocompatible and excellent for in vivo imaging using positron emission spectroscopy.402 Moreover, neuropeptides loaded on glucose‐68Ga‐AuNPs enabled penetration through the blood–brain barrier.402

Magnetic resonance is a broadly used imaging method in which the application of contrast agents significantly improves image quality, especially when these are in the form of NPs. In most experiments, iron oxide NPs decorated with stabilizing, targeting, or biocompatible materials have been tested.403 As an example, versatile glycopeptide grafting to magnetic iron oxide NPs was reported but without in vivo testing.404 A step further using sialic acid modified Fe3O4 NPs for the selective in vivo MR imaging of β‐amyloids applicable for the early diagnosis of Alzheimer's disease was reported.405 Mannose‐containing diblock copolymer grafted onto Fe3O4 NPs enhanced the carbohydrate receptor‐driven uptake into lung cancer cells with potential application in the diagnosis and localization of this type of cancer.406 HA‐grafted Fe3O4 NPs employed in the selective MR imaging of tissues with CD44 receptor‐overexpressing cells, that is, tumors, or local inflammations were also described.407, 408 A similar system with core Fe3O4 NPs having a thin golden shell covered with an HA layer enabling simultaneous MR imaging and photothermal therapy targeted toward cells with CD44 receptors has been reported.370 In order to increase the in vivo stability of the Fe3O4 core, its coating with a silica shell was described in several studies.384, 409 An enhanced imaging resolution of brain lesions in mice after simulated stroke can be observed in Figure 27, showing that NPs with different glycosylation exhibited different biodistribution.409 Sialic Lex present on NPs allowed their accumulation in ischemic, that is, damaged, brain tissue due to selectin overexpression; NPs decorated with Lex (without sialic acid present) could visualize such tissue less effectively, which was also confirmed by the software evaluation of dark and bright voxels in the images.409 Nevertheless, good results were also obtained with NPs bearing hydroxyls groups on the NP surface instead of glycans.409 In addition to the protective function of a silica shell, such a layer could provide a better environment for the covalent grafting of targeting ligands. The application of silica‐based nanocarriers for MR imaging has recently been reviewed by Caltagirone et al.410

Figure 27.

Figure 27

T2 maps and T2‐weighted images at 5 and 24 hr after MCAO in a representative animal tissue that received iron oxid‐silia nanoparticles decorated with (A) hydroxyl groups (HO@MNPs), (B) Lewis X without sialic acid (LX@MNPs), or (C) sialyl LewisX (SX@MNPs). Note: the color scale bar corresponds to the T2 value (msec). Reprinted with permission from 409. Copyright 2014 American Chemical Society.

In addition to Fe3O4 NPs, AuNPs were also applied in cell imaging. Small AuNPs of 1.8 nm in size grafted with lactobionic acid via PEG spacers were found to penetrate human hepatocellular carcinoma cells selectively via their overexpressed asialoglycoprotein receptors.400 While T2‐weighted MRI was used for contrast enhancement applying iron oxide NPs, T1‐weighing was used for the same purpose using AuNPs loaded with a Gd3+ complex.411 The modification of AuNPs by a combination of different carbohydrates helped to achieve a high imaging selectivity of tumor cells in mice models.412 AgNPs prepared by the reduction of Ag ions using saccharides present in sugar cane juice have ferromagnetic properties and could be applied for MRI.411

3. Quantum Dots as Imaging Probes

QDs as NPs composed of single nanocrystals of metal sulfides or other semiconductors have distinct optical properties resulting from their nano‐size. One of the most important features is their stable and adjustable fluorescence together with the overall stability inherent to all inorganic materials. Recent studies have reported that, after the encapsulation of QDs into a polymer shell with a final modification by carbohydrate moieties (for specific cell targeting), the resulted NPs still retain their fluorescence. The surface of QD‐modified NPs could be modified by a diverse range of functional groups with adjusted properties of NPs as reported by Schmidtke et al.413 This study suggested applicability of such NPs in in vivo imaging, even though this has not been tested.413 On the other side, the uptake and intracellular distribution of core‐shell CdSe‐ZnS QDs covalently grafted with different carbohydrates were assessed.414 In addition to lactose, which enhanced the uptake of the QD‐glycan NPs into cancer cells, the composition of a mixed carbohydrate shell (i.e., lactose and mannose vs. lactose and maltotriose) significantly altered the internalization of NPs.414 In another study, a secondary radiotracer (125I) was used as the probe conjugated with CdSe/CdS QDs decorated with a sialic acid‐binding lectin.415 These NPs were able to image breast cancer cells, as revealed by in vitro experiments.415 Enhanced selectivity in the targeted imaging of muscle cells was observed for glucose‐decorated QDs with insulin‐induced uptake mediated via glucose receptors, as illustrated in Figure 28, and such an approach could be applied for selective drug delivery as well.416 Since the vast majority of inorganic QD particles exhibit cytotoxicity, Shinchi et al. focused on the development of cadmium‐free ZnS‐AgInS2 NPs with lower cytotoxicity but still exhibiting good fluorescence properties and applicability in selective cell imaging after decoration with short targeting carbohydrates.417 From the graphs shown in Figure 29, it is obvious that all carbohydrate‐coated ZnS‐AgInS2 QDs exhibited minimum cytotoxicity against HepG2 cells (panel A), unlike Cd‐based QDs (panel B).417

Figure 28.

Figure 28

(A) A molecular structure of glucose‐functionalized quantum dots (Glc‐QDs). (B) A schematic illustration of the cellular uptake of Glc‐QDs regulated by insulin and 2‐deoxyglucose (2‐DG) in C2C12 muscle cells. Reproduced from 416 with permission of the Royal Society of Chemistry.

Figure 29.

Figure 29

MTT assay for SFNPs. HepG2 cells were incubated with ZAIS/ZnS NPs (A) or CdTe/CdS QDs (B). The NP concentration was in the range of 5 to 50 μg mL−1 (left to right). Reprinted with permission from 417. Copyright 2014 American Chemical Society.

QD‐like fluorescence was assigned also to GO‐based NPs,378 which were used, for example, for combined imaging and chemotherapy with an HA grafted as a targeting agent.288 It is worth mentioning that the replacement of semiconductor‐based mostly cytotoxic QDs with less harmful graphene‐based NPs would be another step to develop novel, more efficient theranostic particles with low cytotoxicity. Silica QDs possessing inner fluorescence exhibited low cytotoxicity, having a surface that could be easily modified with glycans.418, 419 Furthermore, fluoride nanocrystals doped with rare earth element ions were also suggested as possible substitutes for “classical” Cd‐containing QDs—see, for example, 420 and references therein.

4. Toxicity of Nanomaterials

It is beyond any doubt that the massive application and employment of nanomaterials have brought and should bring in the near future amazing achievements and technical possibilities—in fact, many authors are talking about the nanoage or nano‐revolution. Nevertheless, the other side of this “nano‐enthusiasm” is the persistent uncertainty about the possible toxicity of NPs. This issue is particularly delicate in medical applications, where NPs are supposed to be delivered directly into the human body and interact with cells at a molecular level. It should be noted that these concerns have been raised simultaneously with nanomaterial applications—see, for example, a 1982 study on the toxicity of a potential drug carrier.421 In this study, one example of possible cytotoxicity mechanism of NPs was outlined, that is, the toxicity of monomers released from the intracellular degradation of NPs. Other known mechanisms, including unwanted aggregation of proteins, delivery of toxic molecules conjugated with NPs (including NPs from transportation and industrial emissions) and generation of highly cytotoxic ROS (the most toxic effect), were comprehensively reviewed.422, 423, 424, 425 The NPs’ behavior in living organisms is prevalently determined by their physical and chemical properties. For example, decreased NP size increases their active surface and, consequently, the rate constant of any catalytic reaction taking place on the NP surface. Moreover, the size also determines the biodistribution mode in an organism—see, for example, different modes of interactions of small and large graphene sheets with cells (while the former tend to disrupt cell wall,426 the latter more likely wrap it without any damage427). Another crucial aspect is the nature of NP surface modification, including (i) surface charge, the adjustment of which can turn otherwise harmless NPs, for example, into cell disruptors (see references in 423) or other biological functions,428 and (ii) the modification of NPs by biologically active moieties with examples, which can be found in sections of this review dealing with drug delivery, vaccine and other therapeutic effects, and cell imaging.

Some toxic impacts can be estimated from the physical or chemical properties of the NPs acquired from a precise and accurate characterization of the NPs. This is usually accomplished since physical and chemical characterization and at least in vitro cytotoxicity tests are included in practically any study concerning the administration of NPs into the human body (drug carriers, imaging NPs, etc.). Nevertheless, the correlation between in vitro and model animal in vivo studies may significantly differ from the real impact on humans, nota bene when the subacute effect is considered.429 Therefore, unless any negative health impacts are ruled out, appropriate precautions should be taken, and precise toxicity assessment must be performed in parallel with nanomedicine progress.

7. GLYCAN ENRICHMENT AND SEPARATION

NPs by definition are any objects with at least one dimension below 100 nm exhibiting unique physicochemical properties, which can be effectively applied to enhance the performance of glycan analysis by MS or to increase the efficiency of glycan enrichment. This is especially true due to the high surface‐to‐volume ratio, which can help to address problems with mass transfer; high surface area also means that the high density of active functional groups could be attached to NPs to increase separation efficiency or aid in MS analysis.430 NPs can be synthesized with controlled size and morphology, and it is also possible to prepare hybrid NPs with unique characteristics (e.g., MNPs covered by a gold film suitable for the formation of a SAM on their surface, etc.).63

SiNPs are chemically stable over a wide pH, a feature that is important for column packing material. Nanoporous silica materials, with a pore size spanning range from 2 to 150 nm with various modifications, are quite often applied as packing material for the separation of glycans. Other NPs, including metal oxides, CNTs, fullerene, and graphene, or GO can be used as packing/enrichment material either in their pristine or modified state. Recently, imprinted polymers have become popular because they are regarded as affinity matrices with tailored properties for the separation of a particular analyte with lectin‐like properties.430

A. Glycan Release

Glycans attached to the protein backbone can be analyzed either in their intact form (i.e., glycoproteins), after protein digestion by endopeptidases or endoproteinases (i.e., glycopeptides) or as pure glycans released from the protein or peptide backbone using the enzyme PNGase F or PNGase A (Fig. 30). The release of glycans from O‐glycans can be done not using enzymes but rather chemical reaction, that is, β‐elimination or the use of hydrazine is needed. When glycopeptides are produced from glycoproteins by a tryptic digest, glycopeptides are only a minor component of the tryptic digest, and their enrichment is important for high‐performance MS analysis. Peptides isolated from glycopeptides can be further applied for protein fingerprinting.431, 432

Figure 30.

Figure 30

A graphical summary of different approaches, which can be applied for glycoprotein analysis including glycomics (analysis of released glycans), proteomics (identification of peptides after removal of glycans) and glycoproteomics (characterization of intact glycoproteins in order to indentify a site‐specific connectivity between glycans and proteins).

B. Mass Spectrometry

MALDI‐time‐of‐flight‐MS (MALDI‐TOF‐MS) is a gentle technique allowing the analysis of large biomolecules in both positive and negative ionization modes. This is why this technique is the most commonly applied in glycan, glycopeptide, or glycoprotein analysis, even though the MALDI‐TOF process itself is not yet fully understood.433 On the other hand MALDI‐TOF and electrospray ionization (ESI) might not distinguish glycan isomers when operated in a conventional mode. Various on‐line separation techniques (i.e., using porous graphitized carbon packed columns), which can be coupled to ESI MS, can effectively resolve this problem.434 Alternatively, tandem MS, that is, MS/MS or MSn, can resolve this issue as well.435 MALDI‐TOF compared to ESI exhibits higher sensitivity for the determination of glycans and efficiently ionizes molecules with a higher molecular weight. At the same time, MALDI‐TOF is more tolerant to contaminants.435 MALDI‐TOF when compared to ESI introduces higher energy to the sample, resulting in the fragmentation of labile functional groups, including sulfates, phosphates, and sialic acids.435 Since sialic acids are quite labile molecules with significant involvement in many biological processes, an analysis of sialic acids requires the development of special analytical strategies.436, 437, 438, 439 Moreover, a proper matrix must be chosen to effectively generate ions of large molecules for MALDI‐TOF analysis, and as for ESI, the sensitivity of detection decreases with the increasing molecular weight of glycans.435

C. Glycan Enrichment

There are few main reasons why glycans have to be enriched prior to MS analysis: (i) the glycan level in the studies sample can be well below detection limit of an MS instrument; (ii) glycopeptides or glycans must be removed from peptides due to their lower abundance compared to peptides; and (iii) the ionization of glycans or glycopeptides in the presence of peptides is frequently less efficient.63 Glycans, glycopeptides, or glycoproteins can be enriched in numerous ways, including boronate affinity, hydrazide chemistry, lectin affinity, hydrophilic interactions, and other approaches (Fig. 31).440

Figure 31.

Figure 31

Various ways glycans can be enriched using hydrophobic, hydrophilic, or ionic interactions (upper left part) or biorecognition interactions involving glycan binding proteins (lectins, lower left part). Alternatively for glycan capture/release particles modified by boronate functional groups or hydrazine can be applied, as well.

1. Boronate‐Based Enrichment

Boronate‐modified materials are applied for glycan enrichment due to the strong interactions between boronate functional groups and cis‐diols present in glycans under basic conditions, that is, at pH 8–9.441 The main prerequisite for glycan binding to boronate‐modified material is the choice of a proper pH, which should be above the pK a of the boronate moiety of a boronate‐terminated molecule (e.g., pK a = 8.9 for frequently applied PBA). Sialic acids are exceptions to this rule since the effective binding of SA to boronate‐modified material can occur at a pH lower than the pK a of boronate functional group. Recent studies however suggest that besides proper choice of pH, other factors come into play during the interaction of glycans with boronate‐modified material, such as steric factors, and the nature of buffer components.442 Decreased pH can be effectively applied to release captured glycans for further analysis. Relatively high pH needed for effective glycan enrichment based on boronate affinity can be a problem for quite complex biomolecules. Such glycopeptides or glycoproteins can become unstable at a high pH. To counter this, various strategies have been applied to lower the pH needed for such binding, including the proper choice of substituents (electron withdrawing groups) in proximity to boronate functional groups.443 Alternatively, benzoboroxozole derivatives can be applied to lower the pH required for glycan binding via boronate affinity.444 Such approaches are also useful due to the widening of the applicable pH window for glycan enrichment.

2. Hydrazide‐Based Enrichment

Hydrazide‐modified materials can be efficiently applied for glycan enrichment, but glycans must be oxidized first to form aldehydes from cis‐diol groups. Such aldehydes react with hydrazide‐forming hydrazone bonds, which are stable under basic conditions, and glycan can be released from enrichment material by the application of acidic pH, similar to glycan release from boronate affinity materials. Alternatively, PNGase F could be applied for the release of glycopeptides.445, 446

3. Oxime‐Based Enrichment

Oxime‐modified surfaces can be a good alternative to the hydrazide‐based enrichment of glycans since the process of enrichment can be considerably shorter (1 hr) compared to hydrazide‐based enrichment (12–16 hr), with high enrichment sensitivity with LOD in the low femtomole range and with the selectivity of glycopeptide enrichment even in the presence of a 100‐fold excess of nonglycopeptides. Glycopeptides must be oxidized in order to interact with oxime functionalities, and overnight incubation with PNGase F was required for glycan release for subsequent MALDI‐TOF‐MS analysis.447

4. Hydrophilic Interactions

A hydrophilic interaction‐based method for glycan enrichment involves the application of a polar stationary phase and a nonpolar mobile phase for separation. Analytes partition between a water‐rich layer on the surface of the stationary phase and the mobile phase. Glycans as hydrophilic molecules will be attached to the column/material, while other more hydrophobic molecules (including peptides) will be dissolved in the mobile phase and washed away. Hydrophilic interaction based on zwitterionic functional groups has become popular in recent years due to the ability of zwitterions to form a stable water layer on the surface of the separation phase, which is effective for glycan partitioning.430

5. Lectin‐Based Enrichment

A lectin‐based approach for glycan enrichment is based on the natural bioaffinity interaction between glycans and glycan‐binding proteins (lectins) triggered by the interaction of glycans, especially with aromatic stacking amino acids and amino acids providing hydrogen bonds.448 The application of lectins for glycan enrichment is advantageous compared to boronate, hydrophilic interaction or hydrazide‐modified materials due to the higher degree of specificity for some glycan structures, but selectivity and binding affinity are weaker compared to antibody‐based biorecognition. Moreover, lectins can distinguish minor changes in glycan structures. A good example is SNA, recognizing sialic acid bound to galactose via an α‐2,6 bond, while Maackia amurensis agglutinin binds to α‐2,3‐linked sialic acid. Another example is the arm‐specific recognition of bisecting glycans (i.e., glycans with two arms).449 Thus, not all glycans present in the sample will be enriched using lectins, and a lectin‐affinity enrichment strategy can be applied to fractionate glycans into several groups. Finally, glycans can be released from lectins by the application of free carbohydrates or by exposure to an acidic eluting buffer.

6. Other Ways for Enrichment

There are other options for glycan enrichment, such as reverse‐phase mode, electrostatic mode (for glycans containing negatively charged sialic acids), electrostatic repulsion hydrophilic interactions, and affinity capture based on protein A, which is applicable for the selective enrichment of antibodies with the subsequent glycoprofiling of glycans present especially in the Fc fragment of IgGs.21, 430

D. Nanoporous Materials

Porous materials are, according to IUPAC definition, considered nanoporous only if the pore size is below 1 μm, but earlier terminology defining materials as macroporous (above 50 nm), mesoporous (2–50 nm), and microporous (below 2 nm) is frequently used in the literature.450 In the forthcoming paragraphs we will stick to the latter division of nanoporous materials into three categories. The other important parameters of porous materials are distribution of pore size, pore shape (cylindrical, slit shaped, funnel shaped, etc.), and degree of pore interconnections. The porosity of the given material can be characterized by the total pore volume and a specific surface area. Such porous materials are quite frequently applied as packing material for the separation columns for the enrichment/separation of glycoproteins, glycopeptides, or glycans and have been reviewed in the past.430, 446, 451, 452 The size and modification of pores play a prominent role in interactions with ligands due to the confinement effect.453 For example, when glycoprotein (ribonuclease B) interacted with a mesoporous material, the enhancement factor (i.e., K D of the interaction with mesoporous silica compared to non‐porous silica) increased from 45 to 900, when, in addition boronate affinity, electrostatic interactions were also involved. Upon the decreased pore size of mesoporous silica from 2.6 to 2.1 nm, a further increase in the enhancement factor to 2100 was observed.453 This indicates that for effective ligand capture, the careful design of surface chemistry and the morphology of porous materials are important.454 An interesting approach for how to increase the surface area of composites (i.e., from 69 to 93 m2 g−1) while decreasing the pore size (from 7.6 to 5.0 nm) by mixing GO sheets into composites was demonstrated by He et al.455

1. Silica‐Based Nanoporous Materials

Porous silica material with an ordered/controlled size and shape of large pores (1 μm) was prepared by Yan et al.456 using polystyrene colloidal crystals as a hard template, with mesopores of 4.6 nm using a surfactant as a soft template and applying tetraethylorthosilicate (TEOS) as a silica source. Moreover, macropores were interconnected via pores of 50 nm in diameter (Fig. 32). The specific surface area of the material was 255 m2 g−1 with a pore volume of 0.46 cm3 g−1. Such hierarchically ordered material was then modified with 4‐vinylphenylboronic acid to form polyboronic acid‐modified material, which was successfully applied for the effective enrichment of glycopeptides prepared by the tryptic digest of a model glycoprotein ‐ HRP. The method using glycan enrichment (10 min) revealed the presence of 12 glycans by MALDI‐TOF MS, while only four glycans were obtained without any glycan enrichment. The glycan of HRP could be detected with an LOD of 1 ng μL−1 (1 fmol) even in the presence of BSA, which was in 50:1 excess compared to HRP.456

Figure 32.

Figure 32

SEM image of hierarchically ordered macro/mesoporous silica material before (left) and after (right) boronate modification. Reproduced from 456 with permission by John Wiley & Sons.

Mechanically stable silica microparticles of 1.6 μm in diameter with macropores ranging in size from 50 to 150 nm were applied to immobilize two lectins, Con A and Aleuria aurantia lectin, by Mann et al.457 Such particles with interconnected pores and with a high surface area of 200 m2 g−1 accommodated a high density of immobilized lectins (16 mg g−1). When lectin‐modified particles were applied as a support for loading a chromatography column, up to 75 μg of glycoproteins could be bound to the column (50 × 1 mm) with immobilized Con A. Finally, the columns were used to enrich glycoproteins from just 1 μL of blood serum after removing IgG and albumin. Subsequently, the glycomic and glycoproteomic profiling of bound glycoproteins was performed using MALDI TOF/TOF MS.457

A capillary with boronate‐modified mesoporous walls was used for the selective enrichment of neutral or acidic glycans via pH manipulation by Lu et al.458 When the binding solution had a pH lower than the pK a of boronate by one pH unit or more, the boronate‐modified capillary column captured sialylated glycoproteins. In contrast, when the pH of the binding buffer was higher than the pK a value of boronate by one pH unit or more, glycoproteins containing SA were electrostatically repelled from interaction with the monolith, and glycoproteins with neutral glycans were preferentially captured. Furthermore, the ionic strength of the binding buffer played an important role in the capture of sialylated glycoproteins.458

A boronate‐modified affinity column was also helpful in the identification of DNA aptamers binding to glycoproteins using the systematic evolution of ligands by exponential enrichment as proposed by Nie et al.459 The boronate column served as a matrix for binding glycoprotein (HRP), with the complete process performed on the column; the authors identified seven DNA aptamers binding HRP with an affinity constant down to 10 nM.459 DNA aptamers selected specifically against glycoproteins can be applied for the selective capture of some glycoproteins in the future since their K D (10−8 M) can be lower than that of lectins.459

2. Carbon‐Based Nanoporous Materials

TEOS with a surfactant as a structure‐directing agent was applied by Qin et al.460 to prepare SiNPs with a uniform size of 70 nm. The particles with a surface area of 901 m2 g−1 with a pore size of 2.8 nm were treated with sulfuric acid and subsequently carbonized with the appearance of sp2‐hybridized aromatic carbon structures, which were effective in glycan enrichment. Thirteen N‐glycans released from just 5 ng of ovalbumin (i.e., LOD of 100 fmol) by PNGase F could be detected. Finally, the particles were applied for the enrichment of N‐glycans from 50 nL of human serum and analyzed by MALDI‐TOF‐MS. Eight new N‐glycans that were not observed in the MS spectrum when standard carbon adsorbent was applied were observed, including low‐abundant fucose and high‐mannose glycans.460

Mesoporous silica composites were prepared by Sun et al.461 using a graphene layer as a support. In this case, graphene was oxidized by nitric acid to deposit oxygen‐rich functionalities, which were used in the subsequent step for the formation of a mesoporous silica layer by the deposition of TEOS in the presence of a surfactant as a structure‐directing agent. Finally, the whole nanocomposite was carbonized to transform the surfactant into a carbon layer. The resulting material exhibited a uniform pore size of 2.8 nm with protein‐excluding properties with a surface area of 372 m2 g−1. MALDI‐TOF‐MS showed the presence of 25 N‐linked glycans released from ovalbumin when glycan enrichment with graphene‐based nanocomposite was applied, while enrichment with active carbon material was less effective in terms of the number of glycans detected and the signal intensity obtained. MALDI‐TOF‐MS analysis without any enrichment did not show any sign of glycans.461

Commercially available mesoporous graphitic carbon with a pore size of 25 or 30 nm was applied by Zhao et al. as a packing material for fully automatable two‐dimensional liquid chromatography for high‐throughput proteomic and glycomic analysis of various lysates/samples.462 With this fully automated approach, it was possible to identify up to 2678 proteins, 11,984 unique peptides in neurons or up to 130 N‐glycoproteins, 705 N‐glycans, and 254 glycosylation sites in macaques plasma (Macaca fascicularis) with a total analysis time of 19 hr using ESI‐MS/MS. According to authors, the technology offered unattended, robust, and scalable analyses of samples on a submicrogram scale when sample injection was performed once a day, and the system was able to operate continuously for up to 14 days without experiencing any major problems.462

A porous silica column was applied for the covalent immobilization of PNGase F by Jmeian et al., and such a column was used for the continuous (online) release of neutral and acidic glycans from glycoproteins with subsequent continuous glycan enrichment in a column loaded with porous graphitic carbon and with a subsequent analysis of glycans.463 The capillary was coupled to a C8 trap and a porous graphitic carbon HPLC‐chip and finally interfaced to perform liquid chromatography‐MS and liquid chromatography‐MS/MS analyses. The main advantage of the system is the short time (6 min) needed to release glycans compared to the usual overnight incubation at 37°C. Moreover, glycans could be effectively analyzed from just 100 fmol of protein or 0.1 μL of human blood serum.463 The time needed for online glycan removal is shorter compared to that needed for the microwave‐assisted release of glycans in the presence of PNGase F (30 min at 37°C).464

GO was due to the large surface area (theoretical relative surface area of 2630 m2 g−1) effectively applied by Ren et al. as a support for the covalent immobilization of a high amount of PNGase F (688 μg g−1 of GO, which is threefold higher compared to SiNPs). Highly efficient N‐glycan release from a protein backbone of two model glycoproteins (ribonuclease B and asialofetuin) can be completed within 2 min, and the enzyme can be reused. The stability of the enzyme complex is remarkable, that is, up to 8 weeks, when stored at 4°C, and as low as 2 μg μL−1 of the enzyme complex was needed to analyze the plasma extracts.465

3. Other Nanoporous Materials

Hydrophilic mesoporous phenol‐based material with added PEI, prepared by Jin et al. with a template‐free method, exhibited a large surface area (548 m2 g−1) with 13 nm466 mesopores. When the amount of PEI changed, it was possible to change both the porosities and surface area of the material. Glycopeptides could be detected with an enrichment factor (MS intensity ratio after and before enrichment) of 62 with a recovery index of 80.4%. A tryptic digest of IgG could be detected down to 5 fmol with only a moderate improvement compared to commercial hydrophilic interaction chromatography beads (40 fmol).466

A capillary modified with a polymeric material with an introduced –SH group having a surface area of 30.3 m2 g−1 was applied for the further selective modification of the surface with AuNPs (13 nm) by Wu et al.467 The gold surface was further modified by two thiols terminated in boronate and amine functional groups making an intramolecular B‐N coordination for the enhanced specificity of glycoprotein capture with a binding capacity of 0.39 mg g−1. The capillary was applied for the selective enrichment of a glycoprotein over a protein (1:1000 ratio) with a recovery of 85% and finally applied for the glycoproteomic profiling of just 9 μg of human plasma with 160 glycoproteins identified by MS.467

A boronate‐modified affinity monolithic column with a surface area of 13.7 m2 g−1 and with bimodal pores containing mesopores (3.9 nm) and macropores (1.4 μm) was prepared by Liu et al. using ring‐opening polymerization to mimic the function of protein A to bind antibodies.468 In this case, mesopores could be accommodated by the glycan of IgG via the interaction of glycans with boronate, while the protein backbone of IgG could not enter the mesopores (Fig. 33). The binding capacity of such material for IgG binding was comparable (23.7 mg g−1) to a number of protein A mimics. The monolith was a quite stable and cost‐effective alternative to using protein A with the price of 40 USD per 1 g. Moreover, the IgG attached to the monolith still exhibited its binding affinity toward antigens.468

Figure 33.

Figure 33

A scheme showing a specific recognition of IgG by the monolith exhibiting protein A‐like binding with presence of bimodal pores (macropores and mesopores) modified by boronate functional groups. Reproduced from 468 with permission of the Royal Society of Chemistry.

E. Imprinted Polymers

MIP can be effectively applied for the selective capture and release of analytes because the analyte molecule is imprinted, and after the formation of a thin layer of polymer around the template (analyte), the analyte is removed from the MIP. Thus, such MIP is then able to selectively recognize the analyte over other molecules.

Such an approach was applied to imprint HRP as a model glycoprotein on the inner wall of the capillary tube modified by boronate functionality as described by Lin et al. (Fig. 34).469 Then, a polydopamine film was formed around HRP with the final removal of HRP. Such an MIP was able to recognize HRP with a bound amount of 4.6 mg g−1 over other glycoproteins, while the boronate‐modified capillary also effectively captured other glycoproteins.469

Figure 34.

Figure 34

(A) Preparation of vinylphenylboronic acid‐based molecularly imprinted monolith with polydopamine coating and (B) its recognition mechanism toward glycoproteins. In the figure the following four major steps are shown: (1) preparation of the VPBA‐based polymeric skeletons; (2) reversible immobilization of glycoprotein via boronate affinity interaction; (3) self‐polymerization of DA on the surface of the glycoprotein‐immobilized boronate affinity monolithic skeletons; (4) the formation of glycoprotein‐imprinted monolith after removal of template that is complementary in shape, size, and functionality with respect to the template. Reprinted from 469. Copyright (2013), with permission from Elsevier.

An interesting imprinting approach for the selective binding of a glycoprotein was recently applied by Mendes et al. (Fig. 35).470 Gold surface was modified by an acrylamide‐alkyne cysteine derivative to make a thin film terminated in alkyne and acrylamide functionalities. Then, a glycoprotein was incubated with (3‐acryl‐amidophenyl)boronic acid when boronate functional groups interacted with a glycan part of the glycoprotein (PSA), and the other functional groups were applied for the attachment of PSA on the surface via acrylamide copolymerization. Finally, the surface was blocked by the addition of OEG‐N3 molecules via click chemistry. Because the boronate–glycan interaction can be disrupted by low pH, a simple pH lowering was applied to remove the PSA template from the surface. Such an approach exhibited a 30‐fold higher affinity for its target compared to that of other (glyco)proteins.470 Even though this imprinting strategy was applied for SPR sensing, there is a possibility of using this approach for selective PSA enrichment from a complex sample.

Figure 35.

Figure 35

Experimental design for the formation of surface‐restricted click‐imprinted binding sites for glycoproteins. Disulfide dimer (DFC) SAMs were prepared by immersing clean gold substrates in 0.1 mM methanolic solutions of DFC for 24 h (step 1). In step 2, BA receptor units are introduced via (3‐acrylamidophenyl)boronic acid (AM‐BA) that is incubated for 30 min at an optimized pH (8.5) with a template target glycoprotein. Multiple boronate esters are formed reversibly between the AM‐BAs and the carbohydrate structures of the glycoprotein template. The pre‐assembled glycoprotein–AM‐BA complex is then grafted on the DFC SAM via acrylamide co‐polymerization, affording the creation of spatially arranged sets of BAs on the surface that are specific for the target glycoprotein (step 3). In order to provide complimentary allosteric specificity, a mould or imprint is created around the glycoprotein template at the surface by so‐called click chemistry functionalization of the alkynes of the DFC on the SAM by reacting azide‐terminated heptaethylene glycol (Az‐OEG) moieties with the terminal alkynes on the DFC SAM via a copper‐catalysed alkyne–azide cycloaddition (CuCAAC) reaction (step 4). The glycoprotein targets are removed by washing under acidic conditions (step 5). Reproduced from 470 with permission of the Royal Society of Chemistry.

In their study, Liu et al. focused on finding the relationship between the thickness of the imprinted polymer and the size of the imprinted glycoprotein regarding the binding efficiency.471 Three glycoproteins (ribonuclease B, HRP, and GOx) were imprinted within a polydopamine film deposited over magnetic particles modified by boronate functional groups. The thickness of the polydopamine‐deposited film (5.7, 10.2, 16.3, and 25.3 nm) was controlled by polymerization time (1, 3, 6, and 15 hr). The higher the size of the glycoprotein (15–80 kDa), the thicker the film (5.7–16.3 nm) needed to be to achieve maximal binding capacity (16.7–19.5 mg g−1).471

Polymers with imprinted glycans isolated from two model glycoproteins—ribonuclease B and transferrin—were prepared by Bie et al. on 100 nm boronate‐modified MNPs.472 Glycans released from a glycoprotein were attached to boronate‐modified MNPs, and glycans were imprinted by forming a thin (2.5 nm) silane layer. Finally, the glycan template was removed, and such NPs were applied for the enrichment of glycoproteins. The imprinting ratio (i.e., the ratio of glycoprotein attached to imprinted vs. non‐imprinted NPs) was 8.4 for ribonuclease B and 21.8 for transferrin, with a maximal sorption capacity of 1.4 mg g−1 and a K D of 25 μM, suggesting only moderate glycan enrichment. The transferrin glycan‐imprinted polymer was applied for the enrichment of transferrin from a human serum sample.472

F. Magnetic NPs (MNPs)

Glycan enrichment can be effectively performed using MNPs with different glycan‐recognizing functional groups present on the surface of such NPs. Core‐shell NPs with an MNP (Fe3O4‐based) core and silica shell having uniform 2.2 nm mesopores (formed by the removal of a surfactant from the shell layer) were prepared by Zheng et al.473 Such NPs were further activated, and glucose was covalently linked to it by click chemistry (Fig. 36) to provide hydrophilic interactions. Such particles exhibited a large surface area (324 m2 g−1), high ability to enrich glycopeptides (250 mg g−1), high sensitivity (50 fmol), short incubation time (5 min), and high recovery (94.6%) using ESI MS analysis. When 0.25 μL of human serum without enrichment was analyzed, only 12 N‐glycans were found, while 42 N‐glycans were identified after the application of the MNP‐based enrichment step in the ESI MS spectra.473

Figure 36.

Figure 36

(A) Schematic representation of the synthesis of hydrophilic MMNs and (B) the selective enrichment process for glycopeptides using hydrophilic MMNs. Reprinted from 473. Copyright 2014, with permission from Elsevier.

MNPs were modified by Cao et al. using a polymer to which hydrazide was attached, forming a 3D matrix for glycan enrichment with a threefold higher loading of hydrazide compared to single‐layer NPs.474 The enrichment of glycopeptides was effective even in the presence of a 100‐fold excess of peptides with a recovery index of 78% and with a binding capacity for glycopeptides of 25 μg mg−1. Glycopeptides enriched from mouse liver tissue were analyzed by MALDI‐TOF‐MS.474

In order to enhance the hydrophilicity of the MNPs, Chen et al. covered such particles by a thin layer of SiO2 to which zwitterionic molecules were attached by precipitative polymerization.475 Such particles possessing a highly hydrophilic surface were effective in glycan capture, when by MALDI‐TOF‐MS, glycans from just 0.1 fmol of IgG could be detected with a high binding capacity of 100 mg g−1 and high enrichment recovery of 74% with a rapid magnetic separation. Finally, the particles were applied for the glycoprofiling of 65 μg of proteins extracted from mouse liver.475

MNPs with co‐precipitated ethylenediaminetetraacetic acid having a size of 15 nm were modified by Dong et al. using Cu(II) with the subsequent high loading of Con A lectin (up to 28 wt%).476 Such particles were applied for the enrichment of a model glycoprotein, namely ovalbumin, with a binding capacity of 72 mg g−1, while a high affinity with K D of 38 nM was observed. Glycoproteins were successfully enriched, even in the presence of a non‐glycoprotein in molar excess of 600:1 with a fast magnetic separation within 15 sec.476

MNPs with a size of 15–20 nm during synthesis formed larger aggregates with a size of 140 nm and finally were modified by chitosan using the one‐pot method as described by Fang et al.477 Such particles were able to detect glycans from as low as 8 fmol of a tryptic digest of IgG using MALDI‐TOF‐MS with a binding capacity of 17.5 mg g−1. Finally, 45 μL of tryptic digest from HeLa cells was successfully glycoprofiled.477

Magnetic mesoporous (pores with 3.8 nm) particles with a surface area of 211 m2 g−1 and with a total pore volume of 0.38 cm3 g−1 were applied by Deng et al. for the enrichment of as low as 10 fmol of a model glycoprotein in 300‐fold excess of protein (BSA), and finally, glycans enriched from human serum were determined by MALDI‐TOF‐MS.478

Liu et al. applied MNPs (d = 100 nm) patterned by a PAMAM dendrimer further modified by boronate functional groups for model glycoprotein (HRP) enrichment.479 Boronate present on a dendrimer modified MNPs had a 3–4 orders of magnitude higher affinity constant for glycoproteins compared to single boronate, while glycoprotein enrichment was possible even in a 1 million‐fold excess of competing monosaccharide with an efficiency of 42–88%. HRP could be adsorbed with density of 21 mg g−1 of support with LOD of 180 amol with extraction equilibria reached within 1 min (with desorption equilibria of 5 min). The reusability of glycoprotein enrichment was highly reproducible, with an RSD of 7.5% for five consecutive enrichment steps. Finally, the approach was also applied for the analysis of glycoproteins in human saliva.479

Deng et al. applied MNPs (100 nm) modified by poly(styrene‐co‐vinylbenzene‐boronic acid) for glycopeptide enrichment.480 Such particles could detect glycopeptides down to 125 fmol from a tryptic digest of HRP, even in 120‐fold excess of peptides. Glycopeptides enriched from human serum were analyzed using MALDI‐TOF‐MS.480

Lu et al. developed an interesting strategy to increase the selectivity of glycan enrichment using two types of nanomaterials.481 The first nanomaterials were MNPs (70 nm) modified by boronate functionalities for glycopeptide capture, and the second were poly(methyl methacrylate) beads (200 nm) for selective peptide capture. Model glycoprotein (HRP) was detected down to 220 fmol, and enrichment could be performed in 100‐fold excess of a nonglycoprotein with a maximal binding capacity for glycopeptides of 150 mg g−1. MALDI‐TOF‐MS revealed 90% recovery using this synergetic enrichment, and as little as 1 μL of human serum was sufficient for analysis.481

MNPs could also be successfully used for the prefractionation of glycoconjugates (mainly glycopeptides and glycoproteins). Although the traditional method is hydrazide chemistry‐based solid‐phase extraction, solid‐phase extraction through reductive amination by amine‐functionalized MNPs had also been developed,482 shortening the extraction time to 4 hr and improving the LOD by 2 orders of magnitude. Magnetic Fe3O4 NPs were functionalized by 3‐aminopropyltriethoxysilane and subsequently incubated with glycoconjugate sample, which was converted into aldehydes by sodium periodate oxidation prior to incubation. While nonspecifically adsorbed proteins could be easily washed away, glycopeptides/glycoproteins remained immobilized on the surface. Using a specific PNGase F enzyme, an excellent isolation performance and identification of glycosylation sites using nano‐LC‐MS/MS analysis were achieved.482

The highest binding capacity toward glycoproteins was achieved by boronate‐modified magnetic particles (265 nm) using ovalbumin as a model glycoprotein of 778483 or 882 mg g−1 using magnetic particles with size of 500 nm.484

An elegant method to increase the low affinity of glycan binding by three different lectins was addressed by the modification of lectins with boronate linkers—called boronic acid decorated lectins (Fig. 37)—was suggested by Lu et al.485 When such hybrid biomaterial was immobilized on MNPs, a 2‐ to 60‐fold increase in the detection sensitivity for glycoproteins was observed due to the increased affinity from 2.2‐fold (Aleuria aurantia lectin) to 5.6‐fold (Con A) for particular glycans. Glycoproteins could be detected with an LOD of 33 fmol using MALDI‐TOF‐MS. Finally, the enrichment step was utilized for the glycoproteomic analysis of a tryptic digest of HeLa cells.485

Figure 37.

Figure 37

A schematic illustration of dual binding of a BAD‐lectin (BAD = boronic acid decorated) to a glycoprotein. (i) A BAD‐lectin. (ii) A glycoprotein captured by the lectin via noncovalent glycan‐specific recognition. (iii) A glycoprotein captured by both lectin and BA; the latter mediates the formation of a boronate ester generating a stable covalent lectin‐glycoprotein complex. (iv) A glycoprotein captured by a BA ligand alone. Reprinted with permission from 485. Copyright 2013 American Chemical Society.

G. Gold NPs (AuNPs)

An interesting approach to simplify glycan enrichment based on the formation of a polymeric monolith within a pipette tip was presented by Alwael et al.486 In order to enhance the overall surface area of the monolith, 20 nm AuNPs were attached to the polymer, and the gold surface was further modified by thiols for the covalent immobilization of Erythrina cristagalli lectin (Fig. 38). Such a lectin‐modified monolith could selectively enrich galactosylated glycans based on the lectin´s preferential affinity with a high recovery of 95%. Finally, the device was applied in combination with reversed‐phase capillary HPLC for the analysis of E. coli lysate.486

Figure 38.

Figure 38

SEM images of a porous polymer monolith formed within a polypropylene pipette tip with different magnification (on left and in the middle). Field emission scanning electron microscopy images of a porous polymer monolith agglomerated with covalently attached 20 nm AuNPs with 60,000× magnification. Reproduced from 486 with permission of the Royal Society of Chemistry.

A quite interesting approach to increase the sensitivity of glycopeptide/glycoprotein detection using LDI‐TOF (MALDI‐TOF‐MS, but without a need to use a matrix) was proposed by Liu et al.487 Boronate‐modified magnetic particles with a size of 412 nm were applied to capture glycopeptides from a tryptic digestion of a model protein (HRP) or intact HRP. In the subsequent step, magnetic particles with captured glycopeptides/glycoprotein were incubated with activated AuNPs (13 nm) to covalently capture glycopeptides/glycoprotein. Unbound AuNPs were removed from the system, and glycopeptides/glycoproteins were released from boronate magnetic particles by exposure to acidic pH. Finally, AuNPs with captured glycopeptides/glycoproteins were measured using MS. AuNPs containing 64,000 Au atoms each could enhance the MS analysis of glycopeptides when applied as MS tags even without the need to use a matrix since MS could detect AuNPs with an LOD of 0.03 amol and HRP with an LOD of 45 fM. Since detection is based on the analysis of the Au2 + ion rather than the analysis of glycopeptides/glycoproteins, the method can be applied not for the identification of glycoproteins but rather for obtaining information with high sensitivity when glycoproteins are present in a particular sample.487 Another interesting approach for the matrix‐free analysis of various low‐molecular‐weight compounds (but not glycans) was proposed by Razunguzwa et al. using an array of silicon pillars with a diameter of 150 nm, a spacing of 337 nm, and a length of 1.2 μm, which can detect analytes down to femtomole without any enrichment.488

Hydrazide‐functionalized ultrasmall AuNPs with a size of 1.2 nm were applied by Tran et al. for the very selective capture of periodate‐oxidized glycopeptides, when as much as 97% of all of the peptides captured from rat kidney tissue were glycopeptides.489 This highly selective capture of glycopeptides was possible due to the extremely high density of hydrazide on AuNPs, that is, 630 nmol mg−1, which is a 79‐fold higher density compared to hydrazide density on magnetic particles of 200–500 nm.489

H. Silica NPs (SiNPs)

Three different strategies to deposit zwitterionic brushes with a thickness of 5 nm on the surface of SiNPs (90 nm) were compared by Huang et al. using the tryptic digest of IgG as a model glycoprotein.490 The results showed that the most efficient strategy for glycan enrichment was the application of NPs with the polymer grafted using reversible addition–fragmentation chain transfer with a low LOD of 10 fmol and a high recovery index of 88%. The approach was also successfully applied to analyze the tryptic digest of mouse liver with 303 unique glycosylation sites and with an enrichment efficiency of 70% using MALDI‐TOF‐MS, which was much higher compared to the other two approaches tested in the paper and other commercially available approaches.490

I. Carbon NPs

1. Graphene and Graphene Oxide (GO)

Graphene as a 2D crystalline material consisting of a single layer of carbon atoms with unique properties has attracted considerable attraction since its discovery in 2004.6 Graphene, having a high surface area, could be quite effectively applied for the enrichment of glycans. Zhang et al. recently published an approach with the application of GO noncovalently modified by pyrenebutyric acid via π–π stacking interaction between graphene and a pyrene moiety.491 In the subsequent step, the –COOH group was activated by SOCl2 to prepare pyrenebutyryl chloride‐derivatized GO, which was applied for selective glycan binding (Fig. 39). A simple visual monitoring of glycan enrichment could be conducted due to GO crosslinking by attached glycans, leading to aggregation. Finally, glycans were released from the GO surface in an acidic environment by sonication at 60°C, supporting the hydrolysis of an ester bond. The enrichment protocol allowed the detection of the main glycan from just 10 ng (i.e., 0.2 pmol) of fetuin using MALDI‐TOF‐MS, and the method was applied to analyze glycans in cancer cells. Interestingly, glycoprofiling using graphene‐based enrichment method was successfully applied even when glycoprotein was highly diluted in a protein sample not having glycans at ratio of 1:100.491

Figure 39.

Figure 39

Graphene oxide modified by 1‐pyrenebutyric acid with subsequent activation of –COOH group by SOCl2 for effective glycan enrichment. Reprinted with permission from 491. Copyright 2013 American Chemical Society.

GO chemically modified with pyrenebutyric acid hydrazide was applied by Bai et al. for glycan enrichment.492 In addition to the model protein fetuin, human plasma was applied in the study with a final MALDI‐TOF‐MS analysis of the captured glycans. Glycan (maltoheptaose) recovery in a model sample spiked with BSA was 100%, but human serum spiked with maltoheptaose showed a recovery index of 73%.492

2. Nanodiamonds

Boronate‐modified nanodiamonds could also be applied for glycan enrichment, as shown by Xu et al.493 In this particular case a tryptic digest of HRP as a model glycoprotein was performed, and 50‐fold enhanced MALDI‐MS spectra were obtained after glycan enrichment compared to a tryptic HRP digest without any enrichment, with HRP being detectable at an LOD of 0.5 nM in 100 μL (i.e., 0.5 fmol). The recovery index for glycopeptide analysis was 72%, and the purification efficiency for an analysis of glycopeptides in the mouse liver fraction was 69% with 24 newly identified glycosylation sites compared to databases.493 Loh et al. clearly showed that the modification of nanodiamonds by boronate functionalities must be performed to have a linker between the surface of nanodiamonds and boronate functional groups in order to prevent the nonspecific binding of proteins to the hydrophobic nanodiamond surface, which would negatively influence enrichment specificity.494

Nanodiamond particles (DNPs) were effectively applied by Wu et al. to enhance the sensitivity of glycan analysis by MALDI‐TOF‐MS.495 In this case DNPs were used to transfer energy from matrix to glycans within a trilayer (i.e., by making a sandwich: matrix‐DNPs‐sample). The most important functions of DNPs were to mediate heat transfer between matrix‐ and glycan‐containing samples, avoiding direct heat exchange between these two components, and to prepare the highly homogeneous morphology of the spot on the MALDI target (Fig. 40) compared to two other methods not involving DNPs. Such particles have a low extinction coefficient not absorbing laser energy in the near‐UV region, and since DNPs are inert, they do not compete for charges with the analyte. When a model analyte dextran was analyzed by MALDI‐TOF, a 79‐ or 7‐fold increase in the detection sensitivity was achieved compared to dried‐droplet (a mixture of a matrix and a sample) or thin‐layer (layer of a sample deposited over a matrix layer) methods, respectively. The size of such particles (50–500 nm) did not influence sensitivity enhancement.495

Figure 40.

Figure 40

Morphology of trilayer and other samples. (A) Schematic of the configuration of matrix, DNP, and analyte in trilayer samples, (B) image of a dried‐droplet sample, (C) image of a thin‐layer sample, and (D) image of a trilayer sample containing 3 μg DNPs. The scale bars represent 1 mm. Reprinted with permission from 495. Copyright 2013 American Chemical Society.

3. Single‐Walled CNTs

Strano´s group modified SWCNTs with derivatives of PBAs containing –COOH, ‐NO2, and –NH2 functional groups with ortho‐, meta‐, and para‐ substitutions generating 144 distinct corona phases on the surface of SWCNTs and some of them exhibited remarkable binding affinity to certain monosaccharides, while others were not bound.496, 497 Even though the method was applied for sensing purposes (i.e., monitoring of quenching of intrinsic fluorescence of SWCNTs496, 497), this can be applied for the enrichment of glycans.498

J. Hybrid NPs

A polydopamine film was deposited by Bi et al. using self‐polymerization on an rGO‐Fe3O4‐modified surface and applied for the subsequent deposition of AuNPs.499 Thiolated mannose finally formed SAM on AuNPs, and such a nanocomposite was employed for glycan enrichment. HRP as a model glycoprotein could be detected by MALDI‐TOF from a tryptic digest of the protein down to a concentration of 0.1 ng uL−1 (i.e., 40 ng or 1 pmol).499

Hu et al. modified silica bubbles (30 um) with AuNPs (20 nm), which were further functionalized with boronate‐terminated thiol.500 Glycopeptides prepared by a tryptic digest from two glycoproteins (HRP and IgG) could be enriched with a binding capacity of 60 mg g−1, and as much as 10 ng (∼200 fmol) of protein was needed for glycoprofiling with a rather low enhancement (approximately tenfold) of MALDI‐TOF signal compared to the signal obtained without enrichment.500

Ju et al. applied hybrid NPs (magnetic CNTs) prepared on CNTs with d = 40–60 nm as a scaffold by the in situ formation of MNPs (d = 10–15 nm) from Fe3+ ions.501 Finally, hybrid NPs were patterned by the boronate functional group. Model glycoprotein HRP could be enriched with a sorption capacity of 346 mg g−1, while the sorption of nonglycoprotein HSA was quite low (52 mg g−1). The LOD for the detection of HRP by MALDI‐TOF‐MS using an enrichment step was 1 pmol, while with commercially available boronate‐modified agarose gel, it was not possible to detect 10 pmol of the glycoprotein, and hybrid NPs could enrich glycopeptides in the presence of nonglycosylated peptides, while the latter being in 50‐fold excess.501

Zou et al. applied a quite sophisticated strategy for glycan enrichment.502 GO with deposited MNPs were covered by a silica shell of a final thickness of 50–60 nm. In the next step, the PAMAM dendrimer was grafted to the surface with subsequent modification by AuNPs on which thiolated maltose was anchored. Such a maltose‐modified hydrophilic composite with a surface area of 57.8 m2 g−1 and with a maltose density of 2.4 μmol m−2 could enrich glycopeptides with an LOD of 0.5 fmol. This approach was finally applied for the analysis of as low as 50 μg of mouse liver tryptic digest.502 For comparison, a commercially available meta‐aminophenylboronic acid modified agarose could enrich glycopeptides with an LOD of 30 nmol.503

Yang et al. prepared a nanocomposite with graphene as a support to accommodate MNPs (100 nm) and a phenolic‐formaldehyde resin (condensation of formaldehyde and hydroquinone) with a final modification by aminophenylboronic acid for glycopeptide enrichment.504 The graphene‐based composite with a thickness of 10 nm and a surface area of 76.3 m2 g−1 could detect glycopeptides down to 1 fmol using MALDI‐TOF‐MS, even when the concentration of peptides was in excess of 100:1 compared to glycopeptides. The composite was applied to analyze human serum, when as little as 1 μL of a sample was sufficient.504

K. Other Interesting Approaches

Herein are described interesting strategies of effective glycan enrichment not necessarily based on the application of NPs. The approach developed by Jiao et al. is based on the use of hydrazinonicotinic acid as a matrix for the MALDI‐TOF‐MS analysis of glycans, where the matrix, besides adsorbing laser energy, also contains a hydrazine moiety for selective interaction with glycans.505 Thus, no glycan enrichment is needed since laser energy is mainly adsorbed by glycans even in the presence of proteins/peptides. The detection limit for a glycan is down to 1 amol, which is 5 orders of magnitude lower amount compared to 2,5‐dihydroxybenzoic acid used as a matrix. The other advantages of using this novel matrix are the higher homogeneity of glycan spots and better salt tolerance compared to the traditional matrix. The approach was finally applied for the analysis of a human serum.505

The online enzyme digestion of glycoproteins within a microbore hollow fiber reactor (ID = 200 um) was suggested by Kim et al. using trypsin to digest glycoproteins into peptides and glycopeptides within 30 min, which were then isolated from peptides using lectins.506 Finally, glycans were released from glycopeptides by the application of PNGase F, and the method was applied for the analysis of human urinary samples (PC patients).506 An improved assay protocol from the same group was applied for the analysis of sera from patients with liver cancer.507 Time needed for tryptic digestion was comparable to that needed for the microwave‐assisted release of glycans in the presence of trypsin (10 min at 50°C).464

Direct selective glycan enrichment was performed by Li et al. using a hydrophobic fluorinated carbon tag with an –NH2 terminal group for specific coupling to the reducing end of glycans.508 Such modified glycans could be ionized more efficiently by one order of magnitude compared to unmodified glycans using MALDI‐TOF‐MS. Alternatively, hydrophobized glycans could be selectively isolated from a mixture with other biomolecules using fluorous solid extraction.508

Liu et al. developed a matrix‐free strategy for MS using a lithium‐rich metal oxide composite with a particle size of 200–300 nm applied to analyze low‐molecular‐weight analytes, including several oligosaccharides (not glycans).509 Ruman et al. applied AgNPs with a size of 100 nm for the matrix‐free MS of various low‐molecular‐weight analytes, but not glycans, with a remarkable sensitivity of detection down to 33 amol for ribose.510 Moreover, the application of AgNPs as a matrix in the MS analysis of low‐molecular‐weight molecules was recently reviewed by Sekula et al.511

Yang et al. developed an on‐plate glycopeptide enrichment procedure using gold‐coated silicon wafer modified by SAM with a final modification by boronate functional groups taking 24 hr to complete.512 This approach could effectively pre‐concentrate glycopeptides released from three model glycoproteins with an LOD of 1 fmol, which increased 93‐ to 248‐fold compared to a procedure without enrichment. The plate could, however, be reused only three times because its capability to enrich glycopeptides then decreased sharply.512 Lu et al. deposited 900 μm gold spots on a hydrophobic silica wafer and the gold layer was patterned by 4‐mercaptophenylboronic acid for specific glycoproteins/glycopeptides enrichment.513 The LOD for glycopeptides released from a model glycoprotein HRP was 230 fmol, which is 1 order of magnitude lower compared to MALDI‐TOF‐MS using a standard stainless steel plate.513

Magnetic particles with d = 220 nm were used in the study performed by Xiong et al.514 The particles were covered by silane terminated in the –NH2 group, thus forming a positively charged surface. A layer‐by‐layer method was then applied to cover modified particles by the alternate deposition of negatively charged HA and positively charged chitosan. The best glycan enrichment strategy was obtained with particles having ten layers of both polysaccharides. Glycan enrichment with a binding capacity of 200 mg g−1 was achieved by hydrophilic interaction with glycans and polysaccharide‐modified MNPs. Three glycopeptides from a tryptic digest of IgG could be detected from just 0.2 fmol of IgG with a recovery as high as 69%. The most abundant peak in MALDI‐TOF‐MS was enhanced 111‐fold compared to the procedure without any glycan enrichment. Finally, the approach was applied for analysis of the glycoproteome from just 20 μg of a mouse liver protein sample with the identification of 605 unique N‐glycosylation sites in 616 distinct glycopeptides.514

Another approach using particles larger than 100 nm described by Ma et al. is worth mentioning.515 This ligand‐free approach is based on the application of hybrid particles having a magnetic core with 22 nm AgNPs deposited on the surface. Selective glycan enrichment by such hybrid particles was achieved by the reversible interaction between glycans and the Ag surface, and glycopeptides could be effectively separated from a mixture having a molar ratio of glycopeptides to nonglycopeptides of 1:100 within 1 min. Finally, the method was applied for MALDI‐TOF‐MS glycan analysis from just 1 μL of rat serum.515

A homogeneous system for glycan enrichment based on the pH‐responsive polymer poly‐(acrylic acid‐co‐methyl acrylate) was proven by Bai et al. to be much more effective (96.2% of glycoproteins captured within 1 hr) compared to a solid‐phase glycan enrichment (90% captured in 8 hr).516 The polymer with a hydrodynamic size of 30 nm was soluble at pH 6.0 but became insoluble at pH 2.0. When the hydrazide‐modified polymer was incubated with oxidized glycopeptides/glycoproteins, their separation could be performed by switching the pH to 2.0 with subsequent centrifugation. From a mixture of glycoproteins with proteins at a ratio of 1:100, low levels of glycoproteins (1 fmol) can be effectively captured. Using polymer‐based glycan enrichment MALDI‐TOF‐MS, the signal intensity increased 29‐fold and the S/N ratio increased 325‐fold. The glycan enrichment strategy was finally applied for the analysis of mouse brain samples.516

Zhang et al. applied a hydrophilic support‐based amino‐functionalized metal‐organic framework containing 25 nm NPs with a specific surface are of 2187 m2 g−1 for glycopeptide enrichment.517 A tryptic digest of IgG as a model glycoprotein could be detected after enrichment using MALDI‐TOF‐MS with an LOD of 20 fmol, and an analysis of human serum was performed from a volume as small as 10 μL.517

8. ON‐PLATE ANALYSIS OF GLYCOSYLTRANSFERASE ACTIVITIES

The identification of novel glycosyltransferases is important for the effective production of glycans since enzymatic production does not require tedious protection/deprotection steps, and even complex glycans can be effectively produced either enzymatically or by using a chemoenzymatic approach.151 Thus, new ways for effective and label‐free screening approaches are vital in this field. One of the most promising approaches besides offering the label‐free characterization of enzymatic activities also providing a high‐throughput analysis is to perform enzymatic reactions directly on the MALDI targets as pioneered by Mrksich´s group518, 519 and later extended also by Flitsch´s520, 521 and Reichardt´s522 groups. The most promising material for such targets is gold because SAMs can form on gold through a modification of thiols. When two thiols are mixed during the formation of SAM, a mixed SAM can be produced with an adjusted density of functional groups on the surface.151, 523 Mrksich´s group applied this strategy to screen 57,120 reactions (14,280 combinations of enzymes, immobilized acceptor substrates, and donor substrates in four different buffer systems) on a plate having 384 spots with 24 oligosaccharide acceptors.524 In the assays, 85 glycosyltransferases (including 76 bacterial enzymes that had not been previously characterized) in their crude form produced using an in vitro expression system were tested. The results using SAMs for MALDI‐MS showed 44 new glycosylation products, the enzymatic activities of four previously uncharacterized enzymes and the unknown donor preference for two known galactosyltransferases. These assays are quick, with the screening of 24 disaccharides taking 4 hr. Although various reaction conditions were tested (pH, type of a buffer, concentration of donors, time of analysis, presence of various divalent metal ions), the density of functional thiol (thiolated glycan, maleimide terminated thiols or azide terminated thiols) within a mixed SAM did not vary, with a ratio between functional and diluting thiols (OEG thiol) fixed at 1:4. The only drawback of this approach was a need to use NMR to identify the type of glycosidic linkage formed.524

This drawback was recently addressed by Both et al. using travelling wave ion mobility spectrometry MS to identify diastereomeric glycoconjugates (Fig. 41) with several asymmetric centers differing only in their configuration at a single position.525 Moreover, GlcNAc and GalNAc oxonium ions generated by collision‐induced dissociation could be identified by ion mobility with an application for screening native glycopeptides built from different epimeric carbohydrates.525 The most recent study from Seeberger´s group showed that IM‐MS can unambiguously identify carbohydrate stereoisomers and linkage‐isomers even in a mixture and that the minor isomer could be detected in 1000‐fold excess of the other isomer.526 Kolarich´s group recently focused on the optimization of collision‐induced dissociation energy parameters for improved fragmentation of both glycans and peptides.527

Figure 41.

Figure 41

Examples of common epimeric glycoconjugates and families of enzymes involved in their biosynthesis. (a) The pp‐α‐GnT family of enzymes mediate the transfer of an α ‐linked GalNAc residue to the hydroxyl groups of serine and threonine residues in proteins. This modification is common in higher eukaryotes (including humans) and represents the first step in the biosynthesis of mucin‐type O‐glycans. (b) In unicellular eukaryotes, mucin‐type O‐glycans have been found initiated with an α‐linked GlcNAc residue generated by a pp‐a‐GnT family of enzymes. (c) β‐linked GlcNAc is a common post‐translational modification (PTM) observed in many organisms and is especially prevalent among multicellular eukaryotes. The attachment of this residue is mediated by O‐GlcNAc transferase (OGT) β‐linked GlcNAc is also transferred to the notch epidermal growth factor repeats by extracellular OGT. The differentiation of epimeric glycopeptides by mass spectrometry has not been reported previously, (d) Travelling wave ion mobility spectrometry mass spectrometry (TWIMS) arrival time distribution showing the discrimination of epimeric glycopeptides 19 and 20 and the distinction of HexNAc oxonium ions generated following collision induced dissociation (CID). CID of glycopeptides 19 and 20 before ion mobility separation results in the formation of epimeric oxonium ions that are distinguishable by TWIMS‐MS. Vertical dashed lines represent drift time as identified by full width half height. Reprinted by permission from Macmillan Publishers Ltd: Nature Chemistry,525 copyright 2014.

A very interesting approach for the measurement of enzyme activities using a nanostructured MALDI surface when the matrix is not needed for laser desorption/ionization was proposed by Northen et al.528 The nanostructured surface was prepared as described earlier by the same group with 10 nm nanostructured pores.529 The enzyme substrate for glycan processing enzymes (i.e., glycosyltransferase or glycosidase) with a fluorous tag was attached to a nanohole covered by fluorous‐containing silane molecules via a soft immobilization process allowing the efficient desorption/ionization by a laser.528 Moreover, the substrate contained easily ionizable arginine and a five‐carbon linker to avoid steric hindrance for the binding. Such an interface offered an extremely high S/N ratio of 20 for 200 amol of a substrate, and the method could detect 500 fg of the enzyme (∼5 amol). The method was applied to detect β‐1,4‐galactosidase activity in the lysate of E. coli and thermophilic microbial community and to analyze enzymatic inhibitors, as well.528 Recently, such an approach was extended by the same group using oxime derivatization for the rapid kinetic characterization of glycosyl hydrolases from Clostridium thermocellum, with a possibility to identify novel hydrolases applicable for the effective production of biofuels from plant biomass.530

Reichert´s group then built upon Wong´s approach using a hydrophobic SAM deposited on a gold surface, which was then applied for the reversible insertion/extraction of glycans with a lipid tag (Fig. 42).522 Such an approach was successfully applied for the analysis of activities of glycosyltransferases and glycosidases using MALDI‐TOF‐MS detection. Although the action of glycosyltransferases could be detected after 10 min of incubation, 60 hr was needed for the full conversion. For the analysis of the activity of glycosidases, 1.5 hr of incubation resulted in complete hydrolysis. In addition, the binding of lectins to glycan‐modified surfaces was performed.522 Later, the same group applied a slightly modified immobilization strategy (i.e., modification of the indium tin oxide [ITO] surface by hydrophobic silane, incubation with hydrophobic hydrocarbon terminated in active ester) for the covalent immobilization of either amine‐terminated glycans or lectins.531 Such a surface with arrayed ligands was then utilized to (i) study the enzyme activity of eight recombinant glycosyltransferases, (ii) determine the specificity of a fucosyltransferase, (iii) profile glycoproteins bound to immobilized lectins, and (iv) identify lectins bound to immobilized glycans with an on‐chip tryptic digestion and in situ peptide sequencing. A total of 54 glycan spots could be produced in 3 min, and 30 fmol of glycan could be detected by MS.531 Lipid and fluorous tags, if long enough, could resist their removal upon extensive washing.55 This approach for glycan immobilization resembles the insertion of glycans/glycoproteins within a cell membrane, offering free movement within a hydrophobic SAM.104, 532 Reichardt´s group also proved that ITO with controlled grain size (50–100 nm), roughness (1 nm), and film thickness (20–40 nm) affected by a sputtering could be applied for surface‐assisted laser desorption/ionization MS without the need to use a matrix,533 and such an approach has the potential to be applied in glycan enrichment due to the hydrophilic nature of the unmodified ITO surface. Another matrix‐free approach for laser desorption/ionization MS from the same group involved the use of nanostructured weathered steel (i.e., nanostructured rust layer formed on a polished steel plate with a roughness of 0.8 μm by its incubation at 37°C with 90% humidity for 2 months) hydrophobized by octadecyl trichlorosilane for sensitive glycan detection down to 5 fmol.534 Six different nanomaterials (AuNPs, Pt nanosponges, MNPs, TiO2 NPs, Se NPs, CdTe QDs) as a matrix were recently applied by Wang et al. in surface‐assisted laser desorption/ionization MS of peptides/proteins, with some of them being detected with an LOD down to 6 fmol, but glycans (glycopeptides) were not investigated in the study.535

Figure 42.

Figure 42

Formation of glycan‐functionalized surfaces for MALDI‐TOF‐MS analysis. Reproduced with permission from 522 by John Wiley & Sons.

9. MICROENGINE/MICROROCKET‐BASED ACTIVE GLYCOPROFILING

Nanotechnology has helped to develop novel devices that can be applied for the active glycoprofiling of various samples. Such devices are propelled by different means and, when modified by glycan binding agents (boronate functional groups or lectins), can selectively pick, transport, and release a glycan cargo (or cells) on demand. A polycarbonate membrane with 2 μm pores was applied by Joseph Wang et al.536 as a template for the preparation of microengines of tubular shape with a length of 6 μm and a diameter of 2 μm. The microengine was constructed using a sequential deposition of polyaniline and platinum within the pores of the membrane. Finally, the device was patterned by a thin adhesive layer of Ti (10 nm), 26 nm of Ni (a magnetic layer), and 12 nm of Au film (for the further patterning of the device). The Au surface was patterned by a mixed SAM composed of 11‐mercaptoundecanoic acid and 6‐mercaptohexanol for the covalent attachment of lectins (Con A and Ulex Europaeus agglutinin). The device could then be controlled magnetically and was propelled by the formation of oxygen bubbles generated by the catalytic decomposition of H2O2 (a fuel) by platinum (Fig. 43). The device selectively picked up E. coli cells even in the presence of yeast cells and transported them, and cargo release was triggered by a change of pH. The device could travel at a speed of 33 μm s−1, which is sufficient to remove bacterial cells fixed on a glass slide.536 In the next report from the same group, the overall concept of active glycoprofiling by a microengine/microrocket 10 μm long with ID = 800 nm and OD = 1000 nm was simplified.537 The device was in this case constructed from polyaminophenylboronic acid applied instead of polyaniline, which was used to selectively capture glycans. The body of the device consisted of Pt and Pt‐Ni layers within microtubules, which simplified the overall design. The device was applied for the selective capture of yeast cells via a glycan‐boronate interaction, and the cargo was released by the addition of a carbohydrate and could travel at a speed of 20 μm s−1 using H2O2 as a fuel.537

Figure 43.

Figure 43

Lectin‐modified microengines for bacteria isolation. Schemes depicting (A) the selective pick‐up, transport, and release of the target bacteria by a Con A‐modified microengine, and (B) surface chemistry involved on the microengines functionalization with the lectin receptor. Upon encountering the cells, the Con A‐functionalized microengines recognize the E. coli cell walls by O‐antigen structure binding‐allowing for selective pick‐up and transport. Inset (in Scheme A, top left side): a SEM image of a portion of a Con A‐modified microengine loaded with an E. coli cell. Scheme A, right side: Release of the capture bacteria by navigation in a 10 mM glycine solution, pH 2.5. Scheme B: Steps involved in the microengines gold surface functionalization. (1) Self‐assembling of 11‐mercaptoundecanoic acid/6‐mercaptohexanol binary monolayer; (2) activation of the carboxylic terminal groups of the MUA to amine‐reactive esters by the EDC and NHS coupling agents; and (3) reaction of NHS ester groups with the primary amines of the Con A to yield stable amide bonds. Reprinted with permission from 536. Copyright 2012 American Chemical Society.

Since the application of H2O2 as a fuel can negatively impact biomolecules/cells, other options for propulsion have been sought. Ultrasound was employed by the same group to propel a device 250 nm in diameter and 1.8 μm in length (a three‐segment Au/Ni/Au device).538 Most likely, the combination of the small size of the device with an optimized design and ultrasound propulsion resulted in the high speed of 255 μm s−1 at which the device could travel while it was guided magnetically. A Con A‐modified device was applied for the selective capture of E. coli cells, and when antibodies were immobilized on the device, other bacterial cells could be selectively captured.538 The highest speed of 6 m s−1 for such micromotors was achieved by Joseph Wang´s group using acoustic droplet vaporization, and such microengines have strength to penetrate tissues.539 Furthermore, the surface roughness of the devices propelled by ultrasound can be tuned by the deposition of an Au‐Ag alloy during device fabrication with a subsequent dealloying of the silver component forming pores of 4–8 nm for the enhanced sorption or loading of biorecognition elements.540 The application of activated carbon for the production of highly sorptive spherical micromotors was described.340 In addition to bubble‐based and ultrasound propulsion, other ways to propel microengines are available, including electrical, magnetic, and self‐electrophoretic propulsion,541 but other propulsion principles, including light‐driven, enzyme‐catalysed reaction‐driven, and via intact motile cells, are also possible.542 Microengines could be made smaller for the construction of tubular devices for membrane templated synthesis with pores as small as 5 nm,543 and spherical nanomotors less than 100 nm in size have already been prepared.544 Such small micromotors have been successful in blood/serum545, 546 and even inside living cells,542, 547, 548 with the potential to work as miniature mixers,549, 550 and such devices could also be used for active glycoprofiling/enrichment in blood/serum or other clinically relevant samples. Moreover, in order to avoid an immune response toward artificial micromotors, red blood cells were recently turned into functional micromotors with the ability to operate in blood/serum.551, 552 The most recent study suggests that microcannons acoustically firing cargoes with an average speed of 1.05 ± 0.26 m s−1 could penetrate tissues with higher effectivity than microengines.553

10. CONCLUSIONS

Since quite a few different fields are covered in this review, conclusions and perspectives will be addressed for every field covered separately in the following sections.

A. Nanoglycosensing

The section dedicated to nanomaterial‐based bioanalytical methods and biosensors described in detail some of the most commonly used nanomaterials in such applications, including metal NPs, carbon nanomaterials, polymer nanostructures, and QDs. Great attention was paid to the combination of two or more (nano)materials, called nanohybrids and nanocomposites. Although some properties of the nanomaterials are of great importance in the field of nanobiotechnology and nanobiosensing (high conductivity, large surface area, and unique shape allowing multivalent binding, optical properties, etc.),554, 555 few real applications (i.e., analysis of real samples) have been described in the current literature.556 Most of the presented papers dealt only with commercially available substances or model cell lines, although there is a growing number of papers trying to dynamically evaluate the number of membrane‐bound glycans on living cells for clinical diagnostics.557 When used in a real clinical laboratory, such cells have to be isolated from patient tissues (taken during biopsy); therefore, less invasive methods to isolate the samples are welcome. The use of human sera or even whole blood is limited, mostly because of a small level of a particular biomarker present in body fluids.558, 559, 560, 561 Using a combination of immobilized antibodies (able to specifically bind a biomarker from the real sample) together with a lectin able to “decipher” the biomarker´s glycocode might be a solution in some cases.562

B. Carbohydrate‐Based Vaccines and Therapeutics

To summarize the therapeutic applications of carbohydrates integrated with nanomaterials or carbohydrates synthetized with a controlled density on various supports at the nanoscale, three main application directions can be distinguished: (i) employment of carbohydrate‐containing immunogens, especially viral and bacterial glycans responsible for cell recognition and consequent immune response, and tumor‐associated antigens188; (ii) development of therapeutics based on the selective blocking of cell receptors via competitive lectin‐carbohydrate binding563; and (iii) employment of carbohydrates as building blocks to develop NPs with therapeutic effects of molecules other than carbohydrate‐based moieties.

The most recent progress in the development of carbohydrate nano‐vaccines is represented by the development of a method of chemoenzymatic synthesis allowing the tailored conjugation of glycans to carrier proteins leading to the increased immunoefficiency of the prepared NPs.188 Another promising achievement was to conjugate tumor‐associated antigens to NPs even though non‐carbohydrate antigens seem to provide more significant results in this field.564, 565

The therapeutic effect outlined in (ii) has recently led to the development of NP‐glycan conjugates with higher affinity to specific receptors than bacterial or viral glycans. In the majority of studies, such NPs were employed as antibacterial and antiviral drugs because of their ability to selectively inhibit the first phase of infection. Recent studies have suggested that a combination of multivalent glycans and the selectivity of lectin‐glycan binding could be a step further in the development of completely new class of antibiotics.566 It should be noted that, regardless of studies employing metallic and carbon NPs, (bio)polymers and synthetic micelles are the most preferable carriers for the same reasons as in the case of glycan nano‐vaccines.

C. Cell Targeting

While the nanomaterials used for delivery of carbohydrate‐based therapeutic agents (antigens or non‐immunogens) were mostly AuNPs, (bio)polymers, and dendrimers, there was much higher diversity of nanomaterials tested or developed as nanocarriers for drug delivery of drugs other than glycans, targeted by conjugated glycan moieties. Very intensive research is currently underway to explore targeting abilities, biocompatibility, and other advantages of HA, which has been used in many studies as an NP‐coating, securing selective internalization by tumor cells via their surface displayed CD44 receptors.567 In a typical approach, HA has been used for the decoration of gold,568, 569 carbon,288 or silica310 NPs or synthetic NPs570 conjugated with doxorubicin (a model cytostatic drug). Many studies have reported the inhibition of tumor growth after treatment by such NPs, but not at a significant rate. Nevertheless, efficient targeting is a crucial step in avoiding the severe adverse side effects of conventional cancer chemotherapy. In addition to glycan‐driven targeting, recent studies have also focused on the selective release of the delivered drug after internalization. Here, again, HA is an intriguing material because it could be degraded by intracellular hyaluronidases, liberating the drug from HA‐based NPs.571 For many nanocarriers, the final drug release was secured by a significantly lower pH in lysosomes, which the NP could enter only after surface receptor‐driven internalization.310, 568 Another recently studied way to keep the nanocarriers with their cargo intact until they reach the target is the introduction of disulfide bonds into the NP structure. This bond could be readily reduced by glutathione, which is typically present at an elevated concentration in the cytoplasm of cancer cells.310 Interesting results have also been achieved by the development of nanocarriers capable of passing through the blood brain barrier, for example, by the activation of a glucose transporter or by the conjugation of NPs with glycoproteins or lectins. This is important for the selective chemotherapy of brain tumors. In addition to drug delivery, carbohydrate‐targeted NPs were also promising as nonviral vectors, which has opened new possibilities in gene therapy for cancer.

In addition to chemo‐ and geno‐therapies, targeting delivery has also been recently used for so‐called photodynamic and photothermal therapies. While in the former case, photosensitizers are delivered into cells that generate cytotoxic ROS,375, 571, 572 the latter method relies on the delivery of NPs causing local overheating by irradiation after their internalization into selected cells.573 In both cases, the desired action is typically triggered by NIR irradiation, which is harmless to healthy tissues without internalized photosensitizers. Another advantage of these methods is that it is not necessary to release the cargo from the carriers; the only aim is to get into the desired cells as many nanocarrier particles as possible, while a minimal amount should be in healthy tissue, as indicated by recent progress in carbohydrate‐based targeting.

D. Cell Imaging

Upon the replacement of the therapeutic agents discussed in the previous section with imaging probes, efficient diagnostic tools can be obtained not only for the visualization of tissue with an unusual glycopattern (most often tumors390 or inflammation sites574) but also for the very precise detection and assessment of, for example, surface cell receptors, lectin‐binding properties, and other features necessary for the further development of a glycan‐based targeted therapy. While such assessments are typically performed in vitro, NIR or UV‐VIS imaging probes can be used. Organic dyes coupled to glycan‐based nanocarriers are typically used for imaging in this range, and recently, so‐called theranostic NPs have been developed where imaging probes together with therapeutic agents are incorporated (see for example 575); thus, drug delivery can be monitored and confirmed. It should be noted that some organic therapeutic agents could also simultaneously function as imaging probes (e.g., doxorubicin or most photosensitizers), making theranostic NPs less expensive and easier to fabricate. For efficient in vivo imaging, CT and MRI have been routinely used for many years. Recent studies have focused on the targeted delivery of contrast enhancers, allowing the efficient visualization of selected tissues. While selectively distributed AuNPs have typically been used for CT imaging,400 iron oxide containing NPs have been tested extensively as MRI imaging probes.576

E. Glycan Enrichment and Separation

It can be concluded that the application of nanomaterials or mesoporous materials with various functionalities present on the surface can significantly decrease the time needed for glycan enrichment (i.e., from a typical time of 160577 to 1515 min). Moreover, when using hybrid MNPs, the separation time can be as short as 15 sec by the simple application of an external magnet,476 thus rendering the use of additional equipment (centrifuge) with a much longer separation time (few minutes) unnecessary.

Nanomaterial‐based glycan enrichment could be applied for a minute amount of a starting material. Glycans can be enriched with commercially available hydrophilic beads with an LOD of 40 fmol,466 and the most sensitive enrichment procedure involving MNPs with thin SiO2 layer and zwitterion modification could detect as low as 100 amol475 of glycan. Thus, nanomaterials can help to enrich glycans with an LOD 3–9 orders of magnitude lower compared to commercially available supports, but some approaches can be quite sophisticated, involving five different components. The high effectivity of glycan enrichment also means that an ultralow amount of often precious samples is required, that is, 50 nL of human serum with an application of a carbonized mesoporous silica composite.460 Glycan enrichment can be effective in the presence of nonglycoprotein or nonglycopeptides being in excess over glycoproteins/glycopeptides with a ratio of 1000:1467 and also in a 1 million‐fold excess of a competing monosaccharide479 due to high affinity toward glycans.

Not only glycan enrichment can be made more effective using nanomaterial‐based approaches, but nanomaterial can also be applied as a support for the immobilization of trypsin or PNGase to perform an enzymatic reaction on a surface. The advantage of using immobilized enzymes is their reuse, since, for example, the stability of PNGase F covalently immobilized on GO was up to 8 weeks when stored at 4°C, and as little as 2 μg uL−1 of the enzyme complex was needed to analyze plasma extracts.465 Moreover, the reaction was completed within 2 min, while usually overnight incubation was needed with a soluble enzyme.465 When PNGase F was covalently immobilized on a porous silica column, the reaction was completed within 6 min.463 Time needed for on‐line glycan removal was even shorter compared to that needed for the microwave‐assisted release of glycans in the presence of PNGase F (30 min at 37°C).464 Immobilized trypsin was also applied for on‐line protein digestion,506 which could be used for continuous protein digestion suitable for automatic glycan‐detecting systems.

Nanomaterials can have additional beneficial effects on glycan analysis. For example, the addition of DNPs to the MALDI target in a layer‐by‐layer approach improved spot morphology and enhanced the sensitivity of MALDI‐TOF‐MS detection 79‐ or 7‐fold compared to the dried‐droplet (a mixture of matrix and sample) or thin‐layer (layer of sample deposited over a matrix layer) method, respectively.495 The main principle behind this is the mediation of heat transfer between matrix and glycans by controlled architecture.495 Considering the efficiency of energy absorption from the laser, the most effective way was the use of hydrazinonicotinic acid as both the matrix and glycan‐binding agent.505 Thus, glycan enrichment directly on a plate was applied with an impressive LOD for glycan MALDI‐TOF‐MS analysis down to 1 amol, which is 5 orders of magnitude lower than that of 2,5‐dihydroxybenzoic acid, which is traditionally applied as the matrix.505

MIP with a controlled thickness over imprinted analyte at the nanometer scale could offer a quite high imprinting ratio (i.e., ratio of glycoprotein attached to imprinted vs. nonimprinted NPs) of 22472 and a quite high selectivity for its analyte of 30 over other glycoproteins,470 which is useful for selecting a particular glycoprotein even from a quite complex sample.

11. PERSPECTIVES

A. Nanoglycosensing

Moreover, the next step for researchers dealing with lectin–glycan interactions should be to overcome lectin “promiscuity” by tuning their specificity (e.g., using recombinant technology to generate mutant proteins578) or to prepare more specific aptamers (DNA or peptide) with better binding properties for recognising glycans, which could be immobilized on surfaces with controlled orientation/precision because of their smaller size.579, 580 Molecular imprinting technology for the differentiation of two glycan moieties with the same composition but different glycosidic bond(s), as in the case of 3´‐ and 6´‐sialyllactose mentioned in the Section A..A, should also be investigated.581, 582 Most of the presented methods involve expensive equipment (SPR) or methods with a complicated theoretical background (EIS), which could be interpreted only by a skilled person. Cheap protocols (for instance, those using common microplates) with possible naked‐eye detection are welcome. In addition, some of the methods, even well understood, still cannot be used outside of the laboratory and thus integrated into commercially mass produced point‐of‐care devices. Such barriers to commercialization are significant problems in the case of impedimetric biosensors because of the lower stability and reliability of these biosensors compared to other types.583 Sensor regeneration and flow systems are an issue to focus on, even though they are not as important as the need for detection in an array format for highly parallel analysis. An array assay format in combination with more sensitive platforms compared to generally employed fluorescent techniques (ideally, electrochemical methods compatible with miniaturization and nanomaterial‐based modifications) still needs to be developed for a wider use.

B. Carbohydrate‐Based Vaccines and Therapeutics

From a different perspective, there are barely any studies exploring the use of nanomaterials other than AuNPs and synthetic micelles or biopolymer scaffolds. In this regard, reported iron oxide NPs conjugated with glycans226 can be considered a way for the future preparation of immunogenic nanoconjugates based on nanomaterials being cheaper than AuNPs. Natural polysaccharides are also known to increase the stability of vaccine NPs. More importantly, the immunogenicity of these materials and their use as excellent adjuvants has to be tested. From this point of view, chitosan and its derivatives are polysaccharides that are frequently applied for such purposes.202, 584

Also very important is the recent progress in the controlled synthesis585 and evaluation of iminosugars586 conjugated with NPs, that is, pharmacological chaperones responsible for partial functional restoration of glycosidases, whose misfolding results in lysosomal storage diseases. It seems that in this particular field, the synthesis of dendrimers or scaffolded iminosugar carriers requires a meticulously defined conformal structure, conjugate size, valency, and spacers between a carrier and an iminosugar moiety.586

C. Cell Targeting

The targeting, delivery, and release mechanisms are very similar to those employed in targeted drug delivery. Importantly, even though genotherapy itself may not provide the highest efficiency, it is possible to increase sensitivity of tumor cells to another treatment (e.g., to cytostatics) by the application of specific short nucleotides, thus allowing such a combined therapy to become more efficient.351 Furthermore, a reliable and specific gene delivery would probably be necessary for further progress in personalized medicine.

Finally, it should be noted that the most rapid tumor growth inhibition has been observed typically when a combination of methods was used; for example, chemophototherapy or chemothermal therapy.288 In the further development of carbohydrate‐based nano‐therapeutics, such synergy of effects would probably be the most promising path to follow.

D. Cell Imaging

Considering that AuNPs are excellent thermodynamic therapy agents, we see another way for the development of multifunctional NPs without any additional fabrication steps or additional components used. From this perspective, graphene and its derivatives were found to have even more promising attributes—they could be used as drug (and glycan‐based targeting moieties) carriers, thermodynamic therapy agents, and fluorophores.288, 587 Furthermore, graphene QDs, that is, nanometer‐sized graphene sheets, can replace conventional semiconductors and usually cytotoxic (unless they are made biocompatible, for example, by carbohydrate coating) QDs.588 It is anticipated that graphene derivatives will be investigated more intensively in years to come to obtain cheap, easy‐to‐fabricate and efficient theranostic NPs.

E. Glycan Enrichment and Separation

Finally, we can say that even though nanomaterials or nanoporous materials exhibit remarkable efficiency in glycan profiling due to their robustness, the reproducibility of the glycan enrichment process together with their mechanical/chemical stability has to be more rigorously compared, ideally in studies involving multiple institutions, as recently performed for the glycoprofiling of N‐glycans of IgG589, 590, 591 or O‐ and N‐glycans from cultured cell lines,592 to identify strong and weak attributes for each glycan enrichment technique.

The other class of affinity‐based molecules, which can be applied in the future to selectively detect glycoproteins/glycopeptides or for glycan enrichment, are DNA/RNA aptamers designed to recognize glycoproteins since their K D for glycans can be lower compared to lectins.459 There is however hope for the more frequent application of modified lectins in future glycan enrichment, when lectin modified with boronate will be applied for the more sensitive binding of glycans.485 Moreover, various types of microengines/microrockets can also be applied for active glycan enrichment from quite complex samples.

12. ABBREVIATIONS

AgNPs

silver nanoparticles

AuNPs

gold nanoparticles

AuNRs

gold nanorods

BSA

bovine serum albumin

CEA

carcinoembryonic antigen

cfu

colony‐forming unit

CNTs

carbon nanotubes

Con A

Concanavalin A

CT

computational tomography

CuAAC

CuI catalyzed Huisgen azide‐alkyne cycloaddition

CVD

chemical vapor deposition

DC‐SIGN

Dendritic Cell‐Specific Intercellular adhesion molecule‐3‐Grabbing Non‐integrin

DNPs

nanodiamond particles

DPV

differential pulse voltammetry

ECL

electrochemiluminiscence

EIS

electrochemical impedance spectroscopy

ESI

electrospray ionization

FimH

type 1 fimbrial adhesin

FITC

fluorescein isothiocyanate

GCE

glassy carbon electrode

GlcNAc

N‐acetylglucosamine

GO

graphene oxide

GOx

glucose oxidase

HA

hyaluronic acid

HRP

horseradish peroxidase

IgG

immunoglobulin G

ITO

indium tin oxide

LacNAc

N‐acetyl‐d‐lactosamine

Lea

Lewis a antigen

Lex

Lewis x antigen

Ley

Lewis y antigen

LOD

limit of detection

LPS

lipopolysaccharide

LSPR

localized surface plasmon resonance

MALDI

matrix‐assisted laser desorption/ionization

MALDI‐TOF‐MS

matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry

MIP

molecularly imprinted polymers

MNPs

magnetic nanoparticles

MS

mass spectrometry

MUC1

immunogenic synthetic mucin

MWCNTs

multiwalled carbon nanotubes

NIR

near infrared

NMR

nuclear magnetic resonance

NMRi

nuclear magnetic resonance imaging

NPs

nanoparticles

OEG

oligoethylene glycol

PAMAM

poly(amidoamine)

PBA

phenylboronic acid

PC

prostate cancer

PdNPs

palladium nanoparticles

PEG

polyethyleneglycol

PEI

poly(ethylenimine)

PNGase A

peptide‐N‐glycosidase A

PNGase F

peptide‐N‐glycosidase F

PSA

prostate‐specific antigen

PtNPs

platinum nanoparticles

QCM

quartz crystal microbalance

QDs

quantum dots

rHDL

reconstituted high‐density lipoprotein

ROS

reactive oxygen species

SAMs

self‐assembled monolayers

SERS

surface enhanced Raman scattering

SiNPs

silica NPs

siRNA

small interfering RNA

sLea

sialyl Lewis a antigen

sLex

sialyl Lewis x antigen

SNA

Sambucus nigra agglutinin

SPR

surface plasmon resonance

SR‐BI

Scavenger Receptor class B member 1

SWV

square‐wave voltammetry

RCA120

Ricinus communis agglutinin with M w = 120 kDa

rGO

reduced graphene oxide

SWCNTs

single‐walled carbon nanotubes

TEOS

tetraethylorthosilicate

TFag

Thomas Friedrich antigen

WGA

wheat germ agglutinin

ACKNOWLEDGMENTS

The financial support received from the Slovak Scientific Grant Agency VEGA 2/0162/14 and the Slovak Research and Development Agency APVV‐14‐0753 is acknowledged. The research leading to these results received funding from the European Research Council under the European Union's Seventh Framework Program (FP/2007‐2013)/ERC grant agreement number 311532. This publication was made possible by NPRP grant number 6‐381‐1‐078 from the Qatar National Research Fund (a member of the Qatar Foundation). The statements made herein are solely the responsibility of the authors. This publication is the result of the project implementation: Centre for materials, layers and systems for applications and chemical processes under extreme conditions – Stage I, ITMS No.: 26240120007, supported by the Research & Development Operational Program funded by the ERDF.

Biographies

Erika Dosekova obtained her Master´s degree in biochemistry in 2015 at the Comenius University, Faculty of Natural Sciences in Bratislava. Currently, she is a Ph.D. student at the Slovak University of Technology (studying biotechnology). She is also a co‐investigator on ERC Starting Grant at the Department of Glycobiotechnology, Institute of Chemistry, Slovak Academy of Sciences under the guidance of Tomas Bertok. Her research is focused on electrochemical biosensors and surface modification for medical purposes using nanotechnology. She already co‐authored two research papers.

Jaroslav Filip received his M.Sc. degree in environmental engineering at Tomas Bata University (Zlín, Czech Republic) in 2009 with diploma thesis aimed at biodegradation of biopolymer blends. In 2013, he completed his Ph.D. study in biotechnology with a focus on the application of nanomaterials in biofuel cells construction. He received the Ph.D. degree from Slovak Academy of Sciences, Institute of Chemistry (Bratislava, Slovakia) where he has continued his participation in the following research in the field of bioelectrochemistry. In January 2016, he started to work as a research fellow at Centre for Advanced Materials of Qatar University (Doha, Qatar). He authored 16 CC publications and 14 conference contributions with more than 30 citations so far. His research field covers electrochemical aspects of nanobiotechnology including development of affinity biosensors and effective integration of different nanomaterials with biocatalysts—both enzymes and microbial cells—converting efficiently chemical energy of substrates into electricity and their employment in biosensors and biofuel cells.

Tomas Bertok obtained his Ph.D. degree in biotechnology at the Slovak University of Technology in 2014. Since then, he has worked at the Institute of Chemistry, Slovak Academy of Sciences, as a research scientist on many national and international projects in the area of nanostructured, electrochemical biosensors and biochips for medical applications at the Department of Glycobiotechnology. He obtained several national scientific awards and grants for young scientists, and authored and co‐authored more than 20 scientific papers and three chapters in books so far with more than 80 citations. He was the student personality of Slovak republic in 2014 and obtained an Award from the president of the Slovak republic for his research in life sciences and chemistry.

Peter Both received his Ph.D. degree in Molecular and Structural Biology in 2009 from Université Joseph Fourier in Grenoble, France. Following a postdoctoral stay (2009–2010) at the Institute of Chemistry, Slovak Academy of Sciences in Bratislava and a further 6‐month stay (2010) at the University of Natural Resources and Life Sciences in Vienna, Austria, he moved to Manchester (UK) where he currently works as senior postdoctoral associate in the group of Professor Sabine L. Flitsch at the Manchester Institute of Biotechnology, University of Manchester, United Kingdom. His research is focused on glycan function, biosynthesis and analysis (e.g., glycol‐arrays, Ion Mobility MS, HILIC‐UPLC).

Peter Kasak graduated in 1998 and obtained his Ph.D. in 2003 at Department of Organic Chemistry at Comenius University in Bratislava. In 2001 he joined the group of Professor R. J. M. Nolte at Radboud University Nijmegen as an RA. He was a Lisa Meitner postdoctoral fellow at the University of Vienna before starting research at the Polymer Institute where he was a senior researcher. He currently works in the Centre for Advanced Materials at Qatar University. His interests include modification of surfaces, developing of biocompatible hydrogel matrices, and study of mechanism of free radical polymerization.

Jan Tkac received his Ph.D. degree in biotechnology in 2000 from Slovak University of Technology in Bratislava, Slovakia, and D.Sc. degree in analytical chemistry in 2011 from Slovak Academy of Sciences in Bratislava, Slovakia. He has done a few postdoctoral stays at Linkoping University, Sweden (2001−2003), Lund University, Sweden (2003−2006), and Oxford University, UK (2006−2008). Currently, he is a Head of Department of Glycobiotechnology and Head of the scientific council at the Institute of Chemistry, Slovak Academy of Sciences in Bratislava, Slovakia. His research activities cover label‐free and label‐based platforms of detection, nanoscale surface patterning protocols, catalytic biosensors and biofuel cells, glycan biochips/biosensors, and lectin/antibody‐based affinity biosensors/biochips. He was the recipient of an Individual Marie‐Curie Fellowship (2003−2006), and currently he is the holder of an ERC Starting Grant (2013−2017).

REFERENCES

  • 1. Taniguchi N. On the basic concept of nanotechnology. In: Proceedings of the International Conference on Production Engineering, Part II. Tokyo: Japan Society of Precision Engineering; 1974. p 18–23. [Google Scholar]
  • 2. Feynman RP. There's plenty of room at the bottom. Eng Sci 1960;23(5):22–36. [Google Scholar]
  • 3. Binnig G, Rohrer H, Gerber C, Weibel E. Tunneling through a controllable vacuum gap. Appl Phys Lett 1982;40(2):178–180. [Google Scholar]
  • 4. Love JC, Estroff LA, Kriebel JK, Nuzzo RG, Whitesides GM. Self‐assembled monolayers of thiolates on metals as a form of nanotechnology. Chem Rev 2005;105(4):1103–1170. [DOI] [PubMed] [Google Scholar]
  • 5. Kroto HW, Heath JR, O'Brien SC, Curl RF, Smalley RE. C60: Buckminsterfullerene. Nature 1985;318(6042):162–163. [Google Scholar]
  • 6. Novoselov K, Geim A, Morozov S, Jiang D, Zhang Y, Dubonos S, Grigorieva I, Firsov A. Electric field effect in atomically thin carbon films. Science 2004;306(5696):666–669. [DOI] [PubMed] [Google Scholar]
  • 7. Wang YZ, Qu K, Tang LH, Li ZL, Moore E, Zeng XQ, Liu Y, Li JH. Nanomaterials in carbohydrate biosensors. Trends Anal Chem 2014;58:54–70. [Google Scholar]
  • 8. Zhang ML, Qiu HD. Progress in stationary phases modified with carbonaceous nanomaterials for high‐performance liquid chromatography. Trends Anal Chem 2015;65:107–121. [Google Scholar]
  • 9. Reichardt NC, Martín‐Lomas M, Penadés S. Glyconanotechnology. Chem Soc Rev 2013;42(10):4358–4376. [DOI] [PubMed] [Google Scholar]
  • 10. Kruss S, Hilmer AJ, Zhang J, Reuel NF, Mu B, Strano MS. Carbon nanotubes as optical biomedical sensors. Adv Drug Deliv Rev 2013;65(15):1933–1950. [DOI] [PubMed] [Google Scholar]
  • 11. Majdalawieh A, Kanan MC, El‐Kadri O, Kanan SM. Recent advances in gold and silver nanoparticles: Synthesis and applications. J Nanosci Nanotechnol 2014;14(7):4757–4780. [DOI] [PubMed] [Google Scholar]
  • 12. Modugno G, Ménard‐Moyon C, Prato M, Bianco A. Carbon nanomaterials combined with metal nanoparticles for theranostic applications. Br J Pharmacol 2015;172(4):975–991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Ang CY, Tan SY, Zhao Y. Recent advances in biocompatible nanocarriers for delivery of chemotherapeutic cargoes towards cancer therapy. Org Biomol Chem 2014;12(27):4776–4806. [DOI] [PubMed] [Google Scholar]
  • 14. Su X, Wu Q, Li J, Xiao X, Lott A, Lu W, Sheldon BW, Wu J. Silicon‐based nanomaterials for lithium‐ion batteries: A review. Adv Energy Mater 2014;4(1):Article number 1300882. DOI:  10.1002/aenm.201300882. [DOI] [Google Scholar]
  • 15. Gabius H‐J, Kayser K. Introduction to glycopathology: The concept, the tools and the perspectives. Diagn Pathol 2014;9:4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Paleček E, Tkáč J, Bartošík M, Bertók T, Ostatná V, Paleček J. Electrochemistry of nonconjugated proteins and glycoproteins. Toward sensors for biomedicine and glycomics. Chem Rev 2015;115(5):2045–2108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Varki A. Essentials of Glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009. [PubMed] [Google Scholar]
  • 18. Endo T. Glycobiology of alpha‐dystroglycan and muscular dystrophy. J Biochem 2015;157(1):1–12. [DOI] [PubMed] [Google Scholar]
  • 19. Tan FYY, Tang CM, Exley RM. Sugar coating: Bacterial protein glycosylation and host—microbe interactions. Trends Biochem Sci 2015;40(7):342–350. [DOI] [PubMed] [Google Scholar]
  • 20. André S, Kaltner H, Manning J, Murphy P, Gabius H‐J. Lectins: Getting familiar with translators of the sugar code. Molecules 2015;20(2):1788–1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Alla AJ, Stine KJ. Development of monolithic column materials for the separation and analysis of glycans. Chromatography 2015;2(1):20–65. [Google Scholar]
  • 22. Tkac J, Bertok T, Nahalka J, Gemeiner P. Perspectives in glycomics and lectin engineering. Methods Mol Biol 2014;1200:421–445. [DOI] [PubMed] [Google Scholar]
  • 23. Corfield AP, Berry M. Glycan variation and evolution in the eukaryotes. Trends Biochem Sci 2015;40(7):351–359. [DOI] [PubMed] [Google Scholar]
  • 24. Stowell SR, Arthur CM, McBride R, Berger O, Razi N, Heimburg‐Molinaro J, Rodrigues LC, Gourdine J‐P, Noll AJ, von Gunten S. Microbial glycan microarrays define key features of host‐microbial interactions. Nat Chem Biol 2014;10(6):470–476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang G‐Y, Druz A, Doria‐Rose NA, Laub L, Sliepen K, van Gils MJ, de la Pena AT, Derking R, Klasse P‐J, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M. Broad and potent HIV‐1 neutralization by a human antibody that binds the gp41‐gp120 interface. Nature 2014;515(7525):138–142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, Bertozzi CR, Weaver VM. The cancer glycocalyx mechanically primes integrin‐mediated growth and survival. Nature 2014;511(7509):319–325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Stencel‐Baerenwald JE, Reiss K, Reiter DM, Stehle T, Dermody TS. The sweet spot: Defining virus‐sialic acid interactions. Nat Rev Microbiol 2014;12(11):739–749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Jones LH. Recent advances in the molecular design of synthetic vaccines. Nat Chem 2015;7(12):952–960. [DOI] [PubMed] [Google Scholar]
  • 29. Pinho SS, Reis CA. Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer 2015;15(9):540–555. [DOI] [PubMed] [Google Scholar]
  • 30. Zuegg J, Muldoon C, Adamson G, McKeveney D, Le Thanh G, Premraj R, Becker B, Cheng M, Elliott AG, Huang JX, Butler MS, Bajaj M, Seifert J, Singh L, Galley NF, Roper DI, Lloyd AJ, Dowson CG, Cheng TJ, Cheng WC, Demon D, Meyer E, Meutermans W, Cooper MA. Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity. Nat Commun 2015;6:Article number: 7719. DOI: 10.1038/ncomms8719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high‐affinity IgG binding. Proc Natl Acad Sci USA 2015;112(3):833–838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Macauley MS, Crocker PR, Paulson JC. Siglec‐mediated regulation of immune cell function in disease. Nat Rev Immunol 2014;14(10):653–666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA. Emerging principles for the therapeutic exploitation of glycosylation. Science 2014;343(6166):article number 1235681. DOi:  10.1126/science.1235681. [DOI] [PubMed] [Google Scholar]
  • 34. Schmaltz RM, Hanson SR, Wong C‐H. Enzymes in the synthesis of glycoconjugates. Chem Rev 2011;111(7):4259–4307. [DOI] [PubMed] [Google Scholar]
  • 35. Glavey SV, Huynh D, Reagan MR, Manier S, Moschetta M, Kawano Y, Roccaro AM, Ghobrial IM, Joshi L, O'Dwyer ME. The cancer glycome: Carbohydrates as mediators of metastasis. Blood Rev 2015;29(4):269–279. [DOI] [PubMed] [Google Scholar]
  • 36. Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL, Packer NH. Cell surface protein glycosylation in cancer. Proteomics 2014;14(4‐5):525–546. [DOI] [PubMed] [Google Scholar]
  • 37. Compagno D, Gentilini LD, Jaworski FM, Pérez IG, Contrufo G, Laderach DJ. Glycans and galectins in prostate cancer biology, angiogenesis and metastasis. Glycobiology 2014;24(10):899–906. [DOI] [PubMed] [Google Scholar]
  • 38. Häuselmann I, Borsig L. Altered tumor‐cell glycosylation promotes metastasis. Front Oncol 2014;4:28 DOI:  10.3389/fonc.2014.00028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Croci DO, Cerliani JP, Pinto NA, Morosi LG, Rabinovich GA. Regulatory role of glycans in the control of hypoxia‐driven angiogenesis and sensitivity to anti‐angiogenic treatment. Glycobiology 2014;24(12):1283–1290. [DOI] [PubMed] [Google Scholar]
  • 40. Kirwan A, Utratna M, O'Dwyer ME, Joshi L, Kilcoyne M. Glycosylation‐based serum biomarkers for cancer diagnostics and prognostics. BioMed Res Int 2015;2015:article ID 490531. DOI:  10.1155/2015/490531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Dall'Olio F, Vanhooren V, Chen CC, Slagboom PE, Wuhrer M, Franceschi C. N‐glycomic biomarkers of biological aging and longevity: A link with inflammaging. Ag Res Rev 2013;12(2):685–698. [DOI] [PubMed] [Google Scholar]
  • 42. Goulabchand R, Vincent T, Batteux F, Eliaou J‐F, Guilpain P. Impact of autoantibody glycosylation in autoimmune diseases. Autoimmun Rev 2014;13(7):742–750. [DOI] [PubMed] [Google Scholar]
  • 43. Zauner G, Selman MH, Bondt A, Rombouts Y, Blank D, Deelder AM, Wuhrer M. Glycoproteomic analysis of antibodies. Mol Cell Proteomics 2013;12(4):856–865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Hu D, Tateno H, Hirabayashi J. Lectin engineering, a molecular evolutionary approach to expanding the lectin utilities. Molecules 2015;20(5):7637–7656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Solis D, Bovin NV, Davis AP, Jimenez‐Barbero J, Romero A, Roy R, Smetana K, Gabius HJ. A guide into glycosciences: How chemistry, biochemistry and biology cooperate to crack the sugar code. Biochim Biophys Acta 2015;1850(1):186–235. [DOI] [PubMed] [Google Scholar]
  • 46. Wiersma VR, de Bruyn M, Helfrich W, Bremer E. Therapeutic potential of Galectin‐9 in human disease. Med Res Rev 2013;33:E102–E126. [DOI] [PubMed] [Google Scholar]
  • 47. Ribeiro JP, Mahal LK. Dot by dot: Analyzing the glycome using lectin microarrays. Curr Opin Chem Biol 2013;17(5):827–831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Miura Y, Hoshino Y, Seto H. Glycopolymer nanobiotechnology. Chem Rev 2016;116(4):1673–1692. [DOI] [PubMed] [Google Scholar]
  • 49. Hirabayashi J, Tateno H, Shikanai T, Aoki‐Kinoshita K, Narimatsu H. The lectin frontier database (LfDB), and data generation based on frontal affinity chromatography. Molecules 2015;20(1):951–973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Dan X, Liu W, Ng TB. Development and applications of lectins as biological tools in biomedical research. Med Res Rev 2016;36(2):221–247. [DOI] [PubMed] [Google Scholar]
  • 51. Gemeiner P, Mislovicova D, Tkac J, Svitel J, Patoprsty V, Hrabarova E, Kogan G, Kozar T. Lectinomics II. A highway to biomedical/clinical diagnostics. Biotechnol Adv 2009;27(1):1–15. [DOI] [PubMed] [Google Scholar]
  • 52. Katrlik J, Svitel J, Gemeiner P, Kozar T, Tkac J. Glycan and lectin microarrays for glycomics and medicinal applications. Med Res Rev 2010;30(2):394–418. [DOI] [PubMed] [Google Scholar]
  • 53. Hirabayashi J, Yamada M, Kuno A, Tateno H. Lectin microarrays: Concept, principle and applications. Chem Soc Rev 2013;42(10):4443–4458. [DOI] [PubMed] [Google Scholar]
  • 54. Hirabayashi J. Lectin‐based glycomics: How and when was the technology born? Methods Mol Biol 2014;1200:225–242. [DOI] [PubMed] [Google Scholar]
  • 55. Park S, Gildersleeve JC, Blixt O, Shin I. Carbohydrate microarrays. Chem Soc Rev 2013;42(10):4310–4326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Blixt O, Westerlind U. Arraying the post‐translational glycoproteome (PTG). Curr Opin Chem Biol 2014;18:62–69. [DOI] [PubMed] [Google Scholar]
  • 57. Hushegyi A, Tkac J. Are glycan biosensors an alternative to glycan microarrays? Anal Methods 2014;6(17):6610–6620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Hayat A, Catanante G, Marty JL. Current trends in nanomaterial‐based amperometric biosensors. Sensors 2014;14(12):23439–23461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Klukova L, Bertok T, Kasak P, Tkac J. Nanoscale‐controlled architecture for the development of ultrasensitive lectin biosensors applicable in glycomics. Anal Methods 2014;6(14):4922–4931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Hao N, Neranon K, Ramström O, Yan M. Glyconanomaterials for biosensing applications. Biosens Bioelectron 2016;76:113–130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Li X, Chen G. Glycopolymer‐based nanoparticles: Synthesis and application. Polym Chem 2015;6(9):1417–1430. [Google Scholar]
  • 62. Fernández‐Tejada A, Cañada FJ, Jiménez‐Barbero J. Recent developments in synthetic carbohydrate‐based diagnostics, vaccines, and therapeutics. Chem Eur J 2015;21(30):10616–10628. [DOI] [PubMed] [Google Scholar]
  • 63. Zhao H, Li Y, Hu Y. Nanotechnologies in glycoproteomics. Clin Proteomics 2014;11(1):21 DOI: 10.1186/1559-0275-11-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Pinho SS, Reis CA. Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer 2015;15(9):540–555. [DOI] [PubMed] [Google Scholar]
  • 65. Wang SK, Cheng CM. Glycan‐based diagnostic devices: Current progress, challenges and perspectives. Chem Commun 2015;51(94):16750–16762. [DOI] [PubMed] [Google Scholar]
  • 66. Song E, Mayampurath A, Yu C‐Y, Tang H, Mechref Y. Glycoproteomics: Identifying the glycosylation of prostate specific antigen at normal and high isoelectric points by LC—MS/MS. J Proteome Res 2014;13(12):5570–5580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Mu B, Zhang J, McNicholas TP, Reuel NF, Kruss S, Strano MS. Recent advances in molecular recognition based on nanoengineered platforms. Acc Chem Res 2014;47(4):979–988. [DOI] [PubMed] [Google Scholar]
  • 68. Adak AK, Li B‐Y, Lin C‐C. Advances in multifunctional glycosylated nanomaterials: Preparation and applications in glycoscience. Carbohydr Res 2015;405:2–12. [DOI] [PubMed] [Google Scholar]
  • 69. Yilmaz G, Becer CR. Glyconanoparticles and their interactions with lectins. Polym Chem 2015;6(31):5503–5514. [Google Scholar]
  • 70. Dan X, Liu W, Ng TB. Development and applications of lectins as biological tools in biomedical research. Med Res Rev 2016;36(2):221–247. [DOI] [PubMed] [Google Scholar]
  • 71. Daniel M‐C, Astruc D. Gold nanoparticles: Assembly, supramolecular chemistry, quantum‐size‐related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev 2004;104(1):293–346. [DOI] [PubMed] [Google Scholar]
  • 72. Wang Y, Qu K, Tang L, Li Z, Moore E, Zeng X, Liu Y, Li J. Nanomaterials in carbohydrate biosensors. Trends Anal Chem 2014;58:54–70. [Google Scholar]
  • 73. Kobayashi K, Wei J, Iida R, Ijiro K, Niikura K. Surface engineering of nanoparticles for therapeutic applications. Polym J 2014;46(8):460–468. [Google Scholar]
  • 74. Otsuka H, Muramatsu Y, Matsukuma D. Gold nanorods functionalized with self‐assembled glycopolymers for ultrasensitive detection of proteins. Chem Lett 2015;44(2):132–134. [Google Scholar]
  • 75. Huang C‐F, Yao G‐H, Liang R‐P, Qiu J‐D. Graphene oxide and dextran capped gold nanoparticles based surface plasmon resonance sensor for sensitive detection of concanavalin A. Biosens Bioelectron 2013;50:305–310. [DOI] [PubMed] [Google Scholar]
  • 76. Szunerits S, Maalouli N, Wijaya E, Vilcot JP, Boukherroub R. Recent advances in the development of graphene‐based surface plasmon resonance (SPR) interfaces. Anal Bioanal Chem 2013;405(5):1435–1443. [DOI] [PubMed] [Google Scholar]
  • 77. Craig D, Simpson J, Faulds K, Graham D. Formation of SERS active nanoparticle assemblies via specific carbohydrate‐protein interactions. Chem Commun 2013;49(1):30–32. [DOI] [PubMed] [Google Scholar]
  • 78. Alves I, Kurylo I, Coffinier Y, Siriwardena A, Zaitsev V, Harté E, Boukherroub R, Szunerits S. Plasmon waveguide resonance for sensing glycan—lectin interactions. Anal Chim Acta 2015;873:71–79. [DOI] [PubMed] [Google Scholar]
  • 79. Maalouli N, Barras A, Siriwardena A, Bouazaoui M, Boukherroub R, Szunerits S. Comparison of photo‐ and Cu(i)‐catalyzed “click” chemistries for the formation of carbohydrate SPR interfaces. Analyst 2013;138(3):805–812. [DOI] [PubMed] [Google Scholar]
  • 80. Bertok T, Sediva A, Katrlik J, Gemeiner P, Mikula M, Nosko M, Tkac J. Label‐free detection of glycoproteins by the lectin biosensor down to attomolar level using gold nanoparticles. Talanta 2013;108:11–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Bertok T, Sediva A, Vikartovska A, Tkac J. Comparison of the 2D and 3D nanostructured lectin‐based biosensors for in situ detection of sialic acid on glycoproteins. Int J Electrochem Sci 2014;9(2):890–900. [PMC free article] [PubMed] [Google Scholar]
  • 82. Jayawardena HSN, Jayawardana KW, Chen X, Yan M. Maltoheptaose promotes nanoparticle internalization by Escherichia coli . Chem Commun 2013;49(29):3034–3036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83. Marin MJ, Schofield CL, Field RA, Russell DA. Glyconanoparticles for colorimetric bioassays. Analyst 2015;140(1):59–70. [DOI] [PubMed] [Google Scholar]
  • 84. Poonthiyil V, Golovko VB, Fairbanks AJ. Size‐optimized galactose‐capped gold nanoparticles for the colorimetric detection of heat‐labile enterotoxin at nanomolar concentrations. Org Biomol Chem 2015;13(18):5215–5223. [DOI] [PubMed] [Google Scholar]
  • 85. Van Breedam W, Pöhlmann S, Favoreel HW, de Groot RJ, Nauwynck HJ. Bitter‐sweet symphony: Glycan—lectin interactions in virus biology. FEMS Microbiol Rev 2014;38(4):598–632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86. Wei J, Zheng L, Lv X, Bi Y, Chen W, Zhang W, Shi Y, Zhao L, Sun X, Wang F, Cheng S, Yan J, Liu W, Jiang X, Gao GF, Li X. Analysis of influenza virus receptor specificity using glycan‐functionalized gold nanoparticles. ACS Nano 2014;8(5):4600–4607. [DOI] [PubMed] [Google Scholar]
  • 87. Liu Y, Zhang L, Wei W, Zhao H, Zhou Z, Zhang Y, Liu S. Colorimetric detection of influenza A virus using antibody‐functionalized gold nanoparticles. Analyst 2015;140(12):3989–3995. [DOI] [PubMed] [Google Scholar]
  • 88. Daskhan GC, Berthet N, Thomas B, Fiore M, Renaudet O. Multivalent glycocyclopeptides: Toward nano‐sized glycostructures. Carbohydr Res 2015;405:13–22. [DOI] [PubMed] [Google Scholar]
  • 89. Adak AK, Lin H‐J, Lin C‐C. Multivalent glycosylated nanoparticles for studying carbohydrate‐protein interactions. Org Biomol Chem 2014;12(30):5563–5573. [DOI] [PubMed] [Google Scholar]
  • 90. Marradi M, Chiodo F, García I, Penadés S. Glyconanoparticles as multifunctional and multimodal carbohydrate systems. Chem Soc Rev 2013;42(11):4728–4745. [DOI] [PubMed] [Google Scholar]
  • 91. Marin MJ, Rashid A, Rejzek M, Fairhurst SA, Wharton SA, Martin SR, McCauley JW, Wileman T, Field RA, Russell DA. Glyconanoparticles for the plasmonic detection and discrimination between human and avian influenza virus. Org Biomol Chem 2013;11(41):7101–7107. [DOI] [PubMed] [Google Scholar]
  • 92. Osicka J, Ilčiková M, Popelka A, Filip J, Bertok T, Tkac J, Kasak P. Simple, reversible, and fast modulation in superwettability, gradient, and adsorption by counterion exchange on self‐assembled monolayer. Langmuir 2016;32(22):5491–5499. [DOI] [PubMed] [Google Scholar]
  • 93. Li Z, Fu Y, Fang W, Li Y. Electrochemical impedance immunosensor based on self‐assembled monolayers for rapid detection of Escherichia coli O157:H7 with Signal amplification using lectin. Sensors 2015;15(8):19212–19224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94. Hushegyi A, Bertok T, Damborsky P, Katrlik J, Tkac J. An ultrasensitive impedimetric glycan biosensor with controlled glycan density for detection of lectins and influenza hemagglutinins. Chem Commun 2015;51(35):7474–7477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95. Hushegyi A, Pihíková D, Bertok T, Adam V, Kizek R, Tkac J. Ultrasensitive detection of influenza viruses with a glycan‐based impedimetric biosensor. Biosens Bioelectron 2016;79:644–649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96. Tung Y‐T, Wu M‐F, Wang G‐J, Hsieh S‐L. Nanostructured electrochemical biosensor for th0065 detection of the weak binding between the dengue virus and the CLEC5A receptor. Nanomedicine 2014;10(6):1335–1341. [DOI] [PubMed] [Google Scholar]
  • 97. Hideshima S, Hinou H, Ebihara D, Sato R, Kuroiwa S, Nakanishi T, Nishimura S‐I, Osaka T. Attomolar detection of influenza A virus hemagglutinin human H1 and avian H5 using glycan‐blotted field effect transistor biosensor. Anal Chem 2013;85(12):5641–5644. [DOI] [PubMed] [Google Scholar]
  • 98. Olkhov RV, Weissenborn MJ, Flitsch SL, Shaw AM. Glycosylation characterization of human and porcine fibrinogen proteins by lectin‐binding biophotonic microarray imaging. Anal Chem 2014;86(1):621–628. [DOI] [PubMed] [Google Scholar]
  • 99. Hu X‐L, Jin H‐Y, He X‐P, James TD, Chen G‐R, Long Y‐T. Colorimetric and plasmonic detection of lectins using core—shell gold glyconanoparticles prepared by copper‐free click chemistry. ACS Appl Mater Interfaces 2015;7(3):1874–1878. [DOI] [PubMed] [Google Scholar]
  • 100. García I, Sánchez‐Iglesias A, Henriksen‐Lacey M, Grzelczak M, Penadés S, Liz‐Marzán LM. Glycans as biofunctional ligands for gold nanorods: Stability and targeting in protein‐rich media. J Am Chem Soc 2015;137(10):3686–3692. [DOI] [PubMed] [Google Scholar]
  • 101. Bertok T, Klukova L, Sediva A, Kasák P, Semak V, Micusik M, Omastova M, Chovanová L, Vlček M, Imrich R, Vikartovska A, Tkac J. Ultrasensitive Impedimetric Lectin Biosensors With Efficient Antifouling Properties Applied In Glycoprofiling Of Human Serum Samples. Anal Chem 2013;85(15):7324–7332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102. Bertok T, Šedivá A, Filip J, Ilcikova M, Kasak P, Velic D, Jane E, Mravcová M, Rovenský J, Kunzo P, Lobotka P, Šmatko V, Vikartovská A, Tkac J. Carboxybetaine modified interface for electrochemical glycoprofiling of antibodies isolated from human serum. Langmuir 2015;31(25):7148–7157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103. Bertok T, Dosekova E, Belicky S, Holazova A, Lorencova L, Mislovicova D, Paprckova D, Vikartovska A, Plicka R, Krejci J, Ilcikova M, Kasak P, Tkac J. Mixed Zwitterion‐based self‐assembled monolayer interface for impedimetric glycomic analyses of human IgG samples in an array format. Langmuir 2016;32(28):7070–7078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104. Tu Y, Peng F, Adawy A, Men Y, Abdelmohsen LK, Wilson DA. Mimicking the cell: Bio‐inspired functions of supramolecular assemblies. Chem Rev 2016;116(4):2023–2078. [DOI] [PubMed] [Google Scholar]
  • 105. Takara M, Toyoshima M, Seto H, Hoshino Y, Miura Y. Polymer‐modified gold nanoparticles via RAFT polymerization: A detailed study for a biosensing application. Polym Chem 2014;5(3):931–939. [Google Scholar]
  • 106. Xiong Z, Qin H, Wan H, Huang G, Zhang Z, Dong J, Zhang L, Zhang W, Zou H. Layer‐by‐layer assembly of multilayer polysaccharide coated magnetic nanoparticles for the selective enrichment of glycopeptides. Chem Commun 2013;49(81):9284–9286. [Google Scholar]
  • 107. Brust M, Walker M, Bethell D, Schiffrin DJ, Whyman R. Synthesis of thiol‐derivatised gold nanoparticles in a two‐phase liquid‐liquid system. J Chem Soc Chem Commun 1994(7):801–802. [Google Scholar]
  • 108. Avvakumova S, Fezzardi P, Pandolfi L, Colombo M, Sansone F, Casnati A, Prosperi D. Gold nanoparticles decorated by clustered multivalent cone‐glycocalixarenes actively improve the targeting efficiency toward cancer cells. Chem Commun 2014;50(75):11029–11032. [DOI] [PubMed] [Google Scholar]
  • 109. Yang W, Zhang H, Li M, Wang Z, Zhou J, Wang S, Lu G, Fu F. Early diagnosis of blast fungus, Magnaporthe oryzae, in rice plant by using an ultra‐sensitive electrically magnetic‐controllable electrochemical biosensor. Anal Chim Acta 2014;850:85–91. [DOI] [PubMed] [Google Scholar]
  • 110. Pandey B, Bhattarai JK, Pornsuriyasak P, Fujikawa K, Catania R, Demchenko AV, Stine KJ. Square‐wave voltammetry assays for glycoproteins on nanoporous gold. J Electroanal Chem 2014;717–718:47–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111. Tan YH, Fujikawa K, Pornsuriyasak P, Alla AJ, Vijaya Ganesh N, Demchenko AV, Stine KJ. Lectin‐carbohydrate interactions on nanoporous gold monoliths. New J Chem 2013;37(7):2150–2165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112. Alla AJ, d’ Andrea FB, Bhattarai JK, Cooper JA, Tan YH, Demchenko AV, Stine KJ. Selective capture of glycoproteins using lectin‐modified nanoporous gold monolith. J Chromatogr A 2015;1423:19–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113. Cao H, Yang D‐P, Ye D, Zhang X, Fang X, Zhang S, Liu B, Kong J. Protein‐inorganic hybrid nanoflowers as ultrasensitive electrochemical cytosensing Interfaces for evaluation of cell surface sialic acid. Biosens Bioelectron 2015;68:329–335. [DOI] [PubMed] [Google Scholar]
  • 114. Su M, Ge L, Kong Q, Zheng X, Ge S, Li N, Yu J, Yan M. Cyto‐sensing in electrochemical lab‐on‐paper cyto‐device for in‐situ evaluation of multi‐glycan expressions on cancer cells. Biosens Bioelectron 2015;63:232–239. [DOI] [PubMed] [Google Scholar]
  • 115. Su M, Ge L, Ge S, Li N, Yu J, Yan M, Huang J. Paper‐based electrochemical cyto‐device for sensitive detection of cancer cells and in situ anticancer drug screening. Anal Chim Acta 2014;847:1–9. [DOI] [PubMed] [Google Scholar]
  • 116. Hasanzadeh M, Shadjou N, de la Guardia M. Recent advances in nanostructures and nanocrystals as signal‐amplification elements in electrochemical cytosensing. Trends Anal Chem 2015;72:123–140. [Google Scholar]
  • 117. Xianyu Y, Sun J, Li Y, Tian Y, Wang Z, Jiang X. An ultrasensitive, non‐enzymatic glucose assay via gold nanorod‐assisted generation of silver nanoparticles. Nanoscale 2013;5(14):6303–6306. [DOI] [PubMed] [Google Scholar]
  • 118. Zhai D, Liu B, Shi Y, Pan L, Wang Y, Li W, Zhang R, Yu G. Highly sensitive glucose sensor based on Pt nanoparticle/polyaniline hydrogel heterostructures. ACS Nano 2013;7(4):3540–3546. [DOI] [PubMed] [Google Scholar]
  • 119. Akhtar N, El‐Safty SA, Abdelsalam ME, Shenashen MA, Kawarada H. Radially oriented nanostrand electrodes to boost glucose sensing in mammalian blood. Biosens Bioelectron 2016;77:656–665. [DOI] [PubMed] [Google Scholar]
  • 120. Li L, Gao F, Ye J, Chen Z, Li Q, Gao W, Ji L, Zhang R, Tang B. FRET‐based biofriendly Apo‐GOx‐modified gold nanoprobe for specific and sensitive glucose sensing and cellular imaging. Anal Chem 2013;85(20):9721–9727. [DOI] [PubMed] [Google Scholar]
  • 121. Trefulka M, Paleček E. Direct chemical modification and voltammetric detection of glycans in glycoproteins. Electrochem Commun 2014;48:52–55. [Google Scholar]
  • 122. Paleček E. Label‐free electrochemical analysis of chitosan and glucosamine‐containing oligosaccharides. Electrochim Acta 2016;187:375–380. [Google Scholar]
  • 123. Trefulka M, Paleček E. Modification of poly‐ and oligosaccharides with Os(VI)pyridine. Voltammetry of the Os(VI) adducts obtained by ligand exchange. Electroanalysis 2013;25(8):1813–1817. [Google Scholar]
  • 124. Vargová V, Helma R, Paleček E, Ostatná V. Electrochemical sensing of concanavalin A and ovalbumin interaction in solution. Anal Chim Acta 2016;935:97–103. [DOI] [PubMed] [Google Scholar]
  • 125. Kao J, Thorkelsson K, Bai P, Rancatore BJ, Xu T. Toward functional nanocomposites: Taking the best of nanoparticles, polymers, and small molecules. Chem Soc Rev 2013;42(7):2654–2678. [DOI] [PubMed] [Google Scholar]
  • 126. Zhang J, Chen S, Ruo Y, Zhong X, Wu X. An ultrasensitive electrochemiluminescent biosensor for the detection of concanavalin A based on poly(ethylenimine) reduced graphene oxide and hollow gold nanoparticles. Anal Bioanal Chem 2015;407(2):447–453. [DOI] [PubMed] [Google Scholar]
  • 127. Chen Z, Liu Y, Wang Y, Zhao X, Li J. Dynamic evaluation of cell surface N‐glycan expression via an electrogenerated chemiluminescence biosensor based on concanavalin A‐integrating gold‐nanoparticle‐modified Ru(bpy)32+‐doped silica nanoprobe. Anal Chem 2013;85(9):4431–4438. [DOI] [PubMed] [Google Scholar]
  • 128. Wang Y, Chen Z, Liu Y, Li J. A functional glycoprotein competitive recognition and signal amplification strategy for carbohydrate‐protein interaction profiling and cell surface carbohydrate expression evaluation. Nanoscale 2013;5(16):7349–7355. [DOI] [PubMed] [Google Scholar]
  • 129. Liu J, Xin X, Zhou H, Zhang S. A ternary composite based on graphene, hemin, and gold nanorods with high catalytic activity for the detection of cell‐surface glycan expression. Chem Eur J 2015;21(5):1908–1914. [DOI] [PubMed] [Google Scholar]
  • 130. Yang Z‐H, Zhuo Y, Yuan R, Chai Y‐Q. A nanohybrid of platinum nanoparticles‐porous ZnO—hemin with electrocatalytic activity to construct an amplified immunosensor for detection of influenza. Biosens Bioelectron 2016;78:321–327. [DOI] [PubMed] [Google Scholar]
  • 131. He Y, Li J, Liu Y. Reusable and dual‐potential responses electrogenerated chemiluminescence biosensor for synchronously cytosensing and dynamic cell surface N‐glycan evaluation. Anal Chem 2015;87(19):9777–9785. [DOI] [PubMed] [Google Scholar]
  • 132. Zhang J, Ruo Y, Chen S, Zhong X, Wu X. A sandwich‐like electrochemiluminescent biosensor for the detection of concanavalin A based on a C60‐reduced graphene oxide nanocomposite and glucose oxidase functionalized hollow gold nanospheres. RSC Adv 2014;4(89):48465–48471. [Google Scholar]
  • 133. Chen X, Wang Y, Zhang Y, Chen Z, Liu Y, Li Z, Li J. Sensitive electrochemical aptamer biosensor for dynamic cell surface N‐glycan evaluation featuring multivalent recognition and signal amplification on a dendrimer—graphene electrode interface. Anal Chem 2014;86(9):4278–4286. [DOI] [PubMed] [Google Scholar]
  • 134. Liu X, Ou X, Lu Q, Chen S, Wei S. A biorecognition system for concanavalin a using a glassy carbon electrode modified with silver nanoparticles, dextran and glucose oxidase. Microchim Acta 2015;182(3‐4):797–803. [Google Scholar]
  • 135. Li Y, He J, Niu Y, Yu C. Ultrasensitive electrochemical biosensor based on reduced graphene oxide‐tetraethylene pentamine‐BMIMPF6 hybrids for the detection of α2,6‐sialylated glycans in human serum. Biosens Bioelectron 2015;74:953–959. [DOI] [PubMed] [Google Scholar]
  • 136. Gilgunn S, Conroy PJ, Saldova R, Rudd PM, O'Kennedy RJ. Aberrant PSA glycosylation‐a sweet predictor of prostate cancer. Nat Rev Urol 2013;10(2):99–107. [DOI] [PubMed] [Google Scholar]
  • 137. Pihikova D, Pakanova Z, Nemcovic M, Barath P, Belicky S, Bertok T, Kasak P, Mucha J, Tkac J. Sweet characterisation of prostate specific antigen using electrochemical lectin‐based immunosensor assay and MALDI TOF/TOF analysis: Focus on sialic acid. Proteomics 2016, in press. DOI:  10.1002/pmic.201500463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138. Gao L, He J, Xu W, Zhang J, Hui J, Guo Y, Li W, Yu C. Ultrasensitive electrochemical biosensor based on graphite oxide, Prussian blue, and PTC‐NH2 for the detection of α2,6‐sialylated glycans in human serum. Biosens Bioelectron 2014;62:79–83. [DOI] [PubMed] [Google Scholar]
  • 139. Geisler C, Jarvis DL. Letter to the Glyco‐Forum: Effective glycoanalysis with Maackia amurensis lectins requires a clear understanding of their binding specificities. Glycobiology 2011;21(8):988–993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 140. Tiwari JN, Vij V, Kemp KC, Kim KS. Engineered carbon‐nanomaterial‐based electrochemical sensors for biomolecules. ACS Nano 2016;10(1):46–80. [DOI] [PubMed] [Google Scholar]
  • 141. Chen Y, Star A, Vidal S. Sweet carbon nanostructures: Carbohydrate conjugates with carbon nanotubes and graphene and their applications. Chem Soc Rev 2013;42(11):4532–4542. [DOI] [PubMed] [Google Scholar]
  • 142. Kong N, Shimpi MR, Park JH, Ramström O, Yan M. Carbohydrate conjugation through microwave‐assisted functionalization of single‐walled carbon nanotubes using perfluorophenyl azides. Carbohydr Res 2015;405:33–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 143. Ragoussi M‐E, Casado S, Ribeiro‐Viana R, Torre Gdl, Rojo J, Torres T. Selective carbohydrate‐lectin interactions in covalent graphene‐ and SWCNT‐based molecular recognition systems. Chem Sci 2013;4(10):4035–4041. [Google Scholar]
  • 144. Penezic A, Deokar G, Vignaud D, Pichonat E, Happy H, Subramanian P, Gasparović B, Boukherroub R, Szunerits S. Carbohydrate—lectin interaction on graphene‐coated surface plasmon resonance (SPR) interfaces. Plasmonics 2014;9(3):677–683. [Google Scholar]
  • 145. Zhang J, Landry MP, Barone PW, Kim J‐H, Lin S, Ulissi ZW, Lin D, Mu B, Boghossian AA, Hilmer AJ, Rwei A, Hinckley AC, Kruss S, Shandell MA, Nair N, Blake S, Sen F, Sen S, Croy RG, Li D, Yum K, Ahn J‐H, Jin H, Heller DA, Essigmann JM, Blankschtein D, Strano MS. Molecular recognition using corona phase complexes made of synthetic polymers adsorbed on carbon nanotubes. Nat Nanotechnol 2013;8(12):959–968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 146. Subramanian P, Barka‐Bouaifel F, Bouckaert J, Yamakawa N, Boukherroub R, Szunerits S. Graphene‐coated surface plasmon resonance interfaces for studying the interactions between bacteria and surfaces. ACS Appl Mater Interfaces 2014;6(8):5422–5431. [DOI] [PubMed] [Google Scholar]
  • 147. Yang H, Li Z, Shan M, Li C, Qi H, Gao Q, Wang J, Zhang C. Electrogenerated chemiluminescence biosensing for the detection of prostate PC‐3 cancer cells incorporating antibody as capture probe and ruthenium complex‐labelled wheat germ agglutinin as signal probe. Anal Chim Acta 2015;863:1–8. [DOI] [PubMed] [Google Scholar]
  • 148. Yang G, Cao J, Li L, Rana RK, Zhu J‐J. Carboxymethyl chitosan‐functionalized graphene for label‐free electrochemical cytosensing. Carbon 2013;51:124–133. [Google Scholar]
  • 149. Liu J, Wang J, Wang T, Li D, Xi F, Wang J, Wang E. Three‐dimensional electrochemical immunosensor for sensitive detection of carcinoembryonic antigen based on monolithic and macroporous graphene foam. Biosens Bioelectron 2015;65:281–286. [DOI] [PubMed] [Google Scholar]
  • 150. Cui L, Zhu B‐W, Qu S, He X‐P, Chen G‐R. “Clicked” galactosyl anthraquinone on graphene electrodes for the label‐free impedance detection of live cancer cells. Dyes Pigm 2015;121:312–315. [Google Scholar]
  • 151. Bojarova P, Rosencrantz RR, Elling L, Kren V. Enzymatic glycosylation of multivalent scaffolds. Chem Soc Rev 2013;42(11):4774–4797. [DOI] [PubMed] [Google Scholar]
  • 152. Cecioni S, Imberty A, Vidal S. Glycomimetics versus multivalent glycoconjugates for the design of high affinity lectin ligands. Chem Rev 2015;115(1):525–561. [DOI] [PubMed] [Google Scholar]
  • 153. Yilmaz G, Becer CR. Precision glycopolymers and their interactions with lectins. Eur Polym J 2013;49(10):3046–3051. [Google Scholar]
  • 154. Sunasee R, Narain R. Glycopolymers and glyco‐nanoparticles in biomolecular recognition processes and vaccine development. Macromol Biosci 2013;13(1):9–27. [DOI] [PubMed] [Google Scholar]
  • 155. Chen X, Ramström O, Yan M. Glyconanomaterials: Emerging applications in biomedical research. Nano Res 2014;7(10):1381–1403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 156. Munoz EM, Correa J, Riguera R, Fernandez‐Megia E. Real‐time evaluation of binding mechanisms in multivalent interactions: A surface plasmon resonance kinetic approach. J Am Chem Soc 2013;135(16):5966–5969. [DOI] [PubMed] [Google Scholar]
  • 157. Otsuka H, Hagiwara T, Yamamoto S. Carbohydrate‐based amphiphilic diblock copolymers with pyridine for the sensitive detection of protein binding. J Nanosci Nanotechnol 2014;14(9):6764–6773. [DOI] [PubMed] [Google Scholar]
  • 158. Lu J, Fu C, Wang S, Tao L, Yan L, Haddleton DM, Chen G, Wei Y. From polymer sequence control to protein recognition: Synthesis, self‐assembly and lectin binding. Macromolecules 2014;47(14):4676–4683. [Google Scholar]
  • 159. Schmidtke C, Kreuziger A‐M, Alpers D, Jacobsen A, Leshch Y, Eggers R, Kloust H, Tran H, Ostermann J, Schotten T, Thiem J, Thimm J, Weller H. Glycoconjugated amphiphilic polymers via click‐chemistry for the encapsulation of quantum dots. Langmuir 2013;29(40):12593–12600. [DOI] [PubMed] [Google Scholar]
  • 160. Assali M, Cid J‐J, Fernández I, Khiar N. Supramolecular diversity through click chemistry: Switching from nanomicelles to 1D‐nanotubes and tridimensional hydrogels. Chem Mater 2013;25(21):4250–4261. [Google Scholar]
  • 161. Fang J‐Y, Wang S‐W, Li Y‐C, Lee R‐S. Bio‐recognizable and photo‐cleavable block copolymers based on sugar and poly(4‐substituted‐ε‐caprolactone) bearing a photo‐cleavable junction. J Polym Res 2015;22(8):1–14. [Google Scholar]
  • 162. Wang X, Matei E, Deng L, Koharudin L, Gronenborn AM, Ramström O, Yan M. Sensing lectin—glycan interactions using lectin super‐microarrays and glycans labeled with dye‐doped silica nanoparticles. Biosens Bioelectron 2013;47:258–264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 163. Ahire JH, Chambrier I, Mueller A, Bao Y, Chao Y. Synthesis of D‐mannose capped silicon nanoparticles and their interactions with MCF‐7 human breast cancerous cells. ACS Appl Mater Interfaces 2013;5(15):7384–7391. [DOI] [PubMed] [Google Scholar]
  • 164. Ma F, Rehman A, Liu H, Zhang J, Zhu S, Zeng X. Glycosylation of quinone‐fused polythiophene for reagentless and label‐free detection of E. coli . Anal Chem 2015;87(3):1560–1568. [DOI] [PubMed] [Google Scholar]
  • 165. Jin S, Cheng Y, Reid S, Li M, Wang B. Carbohydrate recognition by boronolectins, small molecules, and lectins. Med Res Rev 2010;30(2):171–257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 166. Yan J, Fang H, Wang BH. Boronolectins and fluorescent boronolectins: An examination of the detailed chemistry issues important for the design. Med Res Rev 2005;25(5):490–520. [DOI] [PubMed] [Google Scholar]
  • 167. Gao X, Zhu M, Fan H, Yang W, Ni W, Karnati VVR, Gao S, Carson J, Weston B, Wang B. A fluorescent bisboronic acid compound that selectively labels cells expressing oligosaccharide Lewis X. Bioorg Med Chem Lett 2015;25(12):2501–2504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168. Dechtrirat D, Gajovic‐Eichelmann N, Wojcik F, Hartmann L, Bier FF, Scheller FW. Electrochemical displacement sensor based on ferrocene boronic acid tracer and immobilized glycan for saccharide binding proteins and E. coli . Biosens Bioelectron 2014;58:1–8. [DOI] [PubMed] [Google Scholar]
  • 169. Samaniego Lopez C, Lago Huvelle MA, Uhrig ML, Coluccio Leskow F, Spagnuolo CC. Recognition of saccharides in the NIR region with a novel fluorogenic boronolectin: In vitro and live cell labeling. Chem Commun 2015;51(23):4895–4898. [DOI] [PubMed] [Google Scholar]
  • 170. Khanal M, Barras A, Vausselin T, Feneant L, Boukherroub R, Siriwardena A, Dubuisson J, Szunerits S. Boronic acid‐modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry. Nanoscale 2015;7(4):1392–1402. [DOI] [PubMed] [Google Scholar]
  • 171. Chen G, Qiu J, Xu J, Xa Fang, Liu Y, Liu S, Wei S, Jiang R, Luan T, Zeng F, Zhu F, Ouyang G. A novel probe based on phenylboronic acid functionalized carbon nanotubes for ultrasensitive carbohydrate determination in biofluids and semi‐solid biotissues. Chem Sci 2016;7(2):1487–1495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 172. Jayawardena HSN, Wang X, Yan M. Classification of lectins by pattern recognition using glyconanoparticles. Anal Chem 2013;85(21):10277–10281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 173. Richards S‐J, Otten L, Gibson MI. Glycosylated gold nanoparticle libraries for label‐free multiplexed lectin biosensing. J Mater Chem B Mater Biol Med 2016;4:3046–3053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 174. Zeng S, Baillargeat D, Ho H‐P, Yong K‐T. Nanomaterials enhanced surface plasmon resonance for biological and chemical sensing applications. Chem Soc Rev 2014;43(10):3426–3452. [DOI] [PubMed] [Google Scholar]
  • 175. Geuijen KPM, Halim LA, Schellekens H, Schasfoort RB, Wijffels RH, Eppink MH. Label‐free glycoprofiling with multiplex surface plasmon resonance: A tool to quantify sialylation of erythropoietin. Anal Chem 2015;87(16):8115–8122. [DOI] [PubMed] [Google Scholar]
  • 176. Huang LD, Adak AK, Yu CC, Hsiao WC, Lin HJ, Chen ML, Lin CC. Fabrication of highly stable glyco‐gold nanoparticles and development of a glyco‐gold nanoparticle‐based oriented immobilized antibody microarray for lectin (GOAL) assay. Chem Eur J 2015;21(10):3956–3967. [DOI] [PubMed] [Google Scholar]
  • 177. Hayes J, Cosgrave EJ, Struwe W, Wormald M, Davey G, Jefferis R, Rudd P. Glycosylation and Fc receptors. Curr Top Microbiol Immunol; 2014;382:165–199. [DOI] [PubMed] [Google Scholar]
  • 178. Hao N, Sun P, Li C, Li L, Li X, Chen L, Jiang B. N‐acetylgalactosamine biosensor based on polydiacetylene nanovesicles: An indirectly colorimetric recognition of galactose‐deficient IgA1. Nano 2014;9(7):1450074 DOI:  10.1142/S179329201450074X. [DOI] [Google Scholar]
  • 179. Kameta N, Masuda M, Shimizu T. Qualitative/chiral sensing of amino acids by naked‐eye fluorescence change based on morphological transformation and hierarchizing in supramolecular assemblies of pyrene‐conjugated glycolipids. Chem Commun 2015;51(55):11104–11107. [DOI] [PubMed] [Google Scholar]
  • 180. Jayaraman N, Maiti K, Naresh K. Multivalent glycoliposomes and micelles to study carbohydrate‐protein and carbohydrate‐carbohydrate interactions. Chem Soc Rev 2013;42(11):4640–4656. [DOI] [PubMed] [Google Scholar]
  • 181. Frecker T, Bailey D, Arzeta‐Ferrer X, McBride J, Rosenthal SJ. Review—Quantum dots and their application in lighting, displays, and biology. ECS J Solid State Sci Technol 2016;5(1):R3019–R3031. [Google Scholar]
  • 182. Krejcova L, Nejdl L, Rodrigo MAM, Zurek M, Matousek M, Hynek D, Zitka O, Kopel P, Adam V, Kizek R. 3D printed chip for electrochemical detection of influenza virus labeled with CdS quantum dots. Biosens Bioelectron 2014;54:421–427. [DOI] [PubMed] [Google Scholar]
  • 183. Chen L, Neethirajan S. A homogenous fluorescence quenching based assay for specific and sensitive detection of influenza virus A hemagglutinin antigen. Sensors 2015;15(4):8852–8865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 184. Zhang X, Liu M, Liu H, Zhang S. Low‐toxic Ag2S quantum dots for photoelectrochemical detection glucose and cancer cells. Biosens Bioelectron 2014;56:307–312. [DOI] [PubMed] [Google Scholar]
  • 185. Adamo R, Nilo A, Castagner B, Boutureira O, Berti F, Bernardes GJL. Synthetically defined glycoprotein vaccines: Current status and future directions. Chem Sci 2013;4(8):2995–3008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 186. Salazar‐González JA, González‐Ortega O, Rosales‐Mendoza S. Gold nanoparticles and vaccine development. Expert Rev Vaccines 2015;14(9):1197–1211. [DOI] [PubMed] [Google Scholar]
  • 187. Smith JD, Morton LD, Ulery BD. Nanoparticles as synthetic vaccines. Curr Opin Biotechnol 2015;34:217–224. [DOI] [PubMed] [Google Scholar]
  • 188. Bhatia S, Dimde M, Haag R. Multivalent glycoconjugates as vaccines and potential drug candidates. MedChemComm 2014;5(7):862–878. [Google Scholar]
  • 189. Gaidzik N, Westerlind U, Kunz H. The development of synthetic antitumour vaccines from mucin glycopeptide antigens. Chem Soc Rev 2013;42(10):4421–4442. [DOI] [PubMed] [Google Scholar]
  • 190. Cai H, Sun Z‐Y, Chen M‐S, Zhao Y‐F, Kunz H, Li Y‐M. Synthetic multivalent glycopeptide‐lipopeptide antitumor vaccines: Impact of the cluster effect on the killing of tumor cells. Angew Chem Int Ed 2014;53(6):1699–1703. [DOI] [PubMed] [Google Scholar]
  • 191. Abdel‐Aal A‐BM, Lakshminarayanan V, Thompson P, Supekar N, Bradley JM, Wolfert MA, Cohen PA, Gendler SJ, Boons G‐J. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist. ChemBioChem 2014;15(10):1508–1513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 192. Huang YL, Hung JT, Cheung SKC, Lee HY, Chu KC, Li ST, Lin YC, Ren CT, Cheng TJR, Hsu TL, Yu AL, Wu CY, Wong CH. Carbohydrate‐based vaccines with a glycolipid adjuvant for breast cancer. Proc Acad Sci Natl USA 2013;110(7):2517–2522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 193. Hu QY, Allan M, Adamo R, Quinn D, Zhai H, Wu G, Clark K, Zhou J, Ortiz S, Wang B, Danieli E, Crotti S, Tontini M, Brogioni G, Berti F. Synthesis of a well‐defined glycoconjugate vaccine by a tyrosine‐selective conjugation strategy. Chem Sci 2013;4(10):3827–3832. [Google Scholar]
  • 194. Adamo R, Hu QY, Torosantucci A, Crotti S, Brogioni G, Allan M, Chiani P, Bromuro C, Quinn D, Tontini M, Berti F. Deciphering the structure‐immunogenicity relationship of anti‐Candida glycoconjugate vaccines. Chem Sci 2014;5(11):4302–4311. [Google Scholar]
  • 195. Nilo A, Morelli L, Passalacqua I, Brogioni B, Allan M, Carboni F, Pezzicoli A, Zerbini F, Maione D, Fabbrini M, Romano MR, Hu QY, Margarit I, Berti F, Adamo R. Anti‐group B Streptococcus glycan‐conjugate vaccines using pilus protein GBS80 as carrier and antigen: Comparing lysine and tyrosine‐directed conjugation. ACS Chem Biol 2015;10(7):1737–1746. [DOI] [PubMed] [Google Scholar]
  • 196. McCarthy PC, Saksena R, Peterson DC, Lee CH, An Y, Cipollo JF, Vann WF. Chemoenzymatic synthesis of immunogenic meningococcal group C polysialic acid‐tetanus Hc fragment glycoconjugates. Glycoconjugate J 2013;30(9):857–870. [DOI] [PubMed] [Google Scholar]
  • 197. Ganesh NV, Sadowska JM, Sarkar S, Howells L, McGiven J, Bundle DR. Molecular recognition of brucella A and M antigens dissected by synthetic oligosaccharide glycoconjugates leads to a disaccharide diagnostic for brucellosis. J Am Chem Soc 2014;136(46):16260–16269. [DOI] [PubMed] [Google Scholar]
  • 198. Ravi G, Venkatesh YP. Recognition of flavin mononucleotide, Haemophilus influenzae type b and its capsular polysaccharide vaccines by antibodies specific to D‐ribitol‐5‐phosphate. Glycoconjugate J 2014;31(8):573–585. [DOI] [PubMed] [Google Scholar]
  • 199. Sukhova EV, Yashunsky DV, Tsvetkov YE, Kurbatova EA, Nifantiev NE. Synthesis of oligosaccharide fragments of the Streptococcus pneumoniae type 14 capsular polysaccharide and their neoglycoconjugates with bovine serum albumin. Russ Chem Bull 2014;63(2):511–521. [Google Scholar]
  • 200. Gao Q, Tontini M, Brogioni G, Nilo A, Filippini S, Harfouche C, Polito L, Romano MR, Costantino P, Berti F, Adamo R, Lay L. Immunoactivity of protein conjugates of carba analogues from neisseria meningitidis a capsular polysaccharide. ACS Chem Biol 2013;8(11):2561–2567. [DOI] [PubMed] [Google Scholar]
  • 201. Johannes M, Reindl M, Gerlitzki B, Schmitt E, Hoffmann‐Röder A. Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'‐deoxy‐4'‐fluoro‐Thomsen‐Friedenreich epitope. Beilstein J Org Chem 2015;11:155–161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 202. Li X, Min M, Du N, Gu Y, Hode T, Naylor M, Chen D, Nordquist RE, Chen WR. Chitin, chitosan, and glycated chitosan regulate immune responses: The novel adjuvants for cancer vaccine. Clin Develop Immunol 2013;2013:article number 387023. DOI:  10.1155/2013/387023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 203. Li P, Luo Z, Liu P, Gao N, Zhang Y, Pan H, Liu L, Wang C, Cai L, Ma Y. Bioreducible alginate‐poly(ethylenimine) nanogels as an antigen‐delivery system robustly enhance vaccine‐elicited humoral and cellular immune responses. J Control Release 2013;168(3):271–279. [DOI] [PubMed] [Google Scholar]
  • 204. Liu Z, Lv D, Liu S, Gong J, Wang D, Xiong M, Chen X, Xiang R, Tan X. Alginic acid‐coated chitosan nanoparticles loaded with legumain DNA vaccine: Effect against breast cancer in mice. PLoS One 2013;8(4):e60190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 205. Bento D, Staats HF, Borges O. Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination. Vaccine 2015;33(31):3609–3613. [DOI] [PubMed] [Google Scholar]
  • 206. Bento D, Staats HF, Gonçalves T, Borges O. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity. Eur J Pharm Biopharm 2015;93:149–164. [DOI] [PubMed] [Google Scholar]
  • 207. Lu F, Mencia A, Bi L, Taylor A, Yao Y, HogenEsch H. Dendrimer‐like alpha‐D‐glucan nanoparticles activate dendritic cells and are effective vaccine adjuvants. J Control Release 2015;204:51–59. [DOI] [PubMed] [Google Scholar]
  • 208. Liao G, Zhou Z, Burgula S, Liao J, Yuan C, Wu Q, Guo Z. Synthesis and immunological studies of linear oligosaccharides of β‐glucan as antigens for antifungal vaccine development. Bioconj Chem 2015;26(3):466–476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 209. Saade F, Honda‐Okubo Y, Trec S, Petrovsky N. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 2013;31(15):1999–2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 210. Nagatomo D, Taniai M, Ariyasu H, Taniguchi M, Aga M, Ariyasu T, Ohta T, Fukuda S. Cholesteryl pullulan encapsulated TNF‐α nanoparticles are an effective mucosal vaccine adjuvant against influenza virus. BioMed Res Intern 2015;2015: Article ID 471468. DOI:  10.1155/2015/471468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 211. Zhou Z, Mondal M, Liao G, Guo Z. Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self‐adjuvanting glycoconjugate cancer vaccine carriers. Org Biomol Chem 2014;12(20):3238–3245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 212. Cui Z, Han D, Sun X, Zhang M, Feng X, Sun C, Gu J, Tong C, Lei L, Han W. Mannose‐modified chitosan microspheres enhance OprF‐OprI‐mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity. Appl Microbiol Biotechnol 2014;99(2):667–680. [DOI] [PubMed] [Google Scholar]
  • 213. Yao W, Peng Y, Du M, Luo J, Zong L. Preventative vaccine‐loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity. Mol Pharm 2013;10(8):2904–2914. [DOI] [PubMed] [Google Scholar]
  • 214. Fagan V, Toth I, Simerska P. Convergent synthetic methodology for the construction of self‐adjuvanting lipopeptide vaccines using a novel carbohydrate scaffold. Beilstein J Org Chem 2014;10:1741–1748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 215. Wang N, Wang T, Zhang M, Chen R, Niu R, Deng Y. Mannose derivative and lipid A dually decorated cationic liposomes as an effective cold chain free oral mucosal vaccine adjuvant‐delivery system. Eur J Pharm Biopharm 2014;88(1):194–206. [DOI] [PubMed] [Google Scholar]
  • 216. Xu Z, Wang Y, Zhang L, Huang L. Nanoparticle‐delivered transforming growth factor‐β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano 2014;8(4):3636–3645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 217. Kim T, Lee H, Kim Y, Nam JM, Lee M. Protein‐coated nanofibers for promotion of T cell activity. Chem Commun 2013;49(38):3949–3951. [DOI] [PubMed] [Google Scholar]
  • 218. Orr MT, Fox CB, Baldwin SL, Sivananthan SJ, Lucas E, Lin S, Phan T, Moon JJ, Vedvick TS, Reed SG, Coler RN. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release 2013;172(1):190–200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 219. van Beuge MM, Prakash J, Lacombe M, Post E, Reker‐Smit C, Beljaars L, Poelstra K. Enhanced Effectivity of an ALK5‐inhibitor after cell‐specific delivery to hepatic stellate cells in mice with liver injury. PLoS One 2013;8(2):e56442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 220. Shah M, Badwaik VD, Dakshinamurthy R. Biological applications of gold nanoparticles. J Nanosci Nanotechnol 2014;14(1):344–362. [DOI] [PubMed] [Google Scholar]
  • 221. Cao‐Milán R, Liz‐Marzán LM. Gold nanoparticle conjugates: Recent advances toward clinical applications. Exp Opin Drug Deliv 2014;11(5):741–752. [DOI] [PubMed] [Google Scholar]
  • 222. Torres AG, Gregory AE, Hatcher CL, Vinet‐Oliphant H, Morici LA, Titball RW, Roy CJ. Protection of non‐human primates against glanders with a gold nanoparticle glycoconjugate vaccine. Vaccine 2015;33(5):686–692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 223. Parry AL, Clemson NA, Ellis J, Bernhard SSR, Davis BG, Cameron NR. 'Multicopy multivalent' glycopolymer‐stabilized gold nanoparticles as potential synthetic cancer vaccines. J Am Chem Soc 2013;135(25):9362–9365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 224. Arosio D, Chiodo F, Reina JJ, Marelli M, Penadés S, Van Kooyk Y, Garcia‐Vallejo JJ, Bernardi A. Effective targeting of DC‐sign by α‐fucosylamide functionalized gold nanoparticles. Bioconjugate Chem 2014;25(12):2244–2251. [DOI] [PubMed] [Google Scholar]
  • 225. Fallarini S, Paoletti T, Battaglini CO, Ronchi P, Lay L, Bonomi R, Jha S, Mancin F, Scrimin P, Lombardi G. Factors affecting T cell responses induced by fully synthetic glyco‐gold‐nanoparticles. Nanoscale 2013;5(1):390–400. [DOI] [PubMed] [Google Scholar]
  • 226. Sungsuwan S, Yin Z, Huang X. Lipopeptide‐coated iron oxide nanoparticles as potential glycoconjugate‐based synthetic anticancer vaccines. ACS Appl Mater Interfaces 2015;7(31):17535–17544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 227. Barhate G, Gautam M, Gairola S, Jadhav S, Pokharkar V. Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosan‐functionalized gold nanoparticles and botanical adjuvant: Characterization, immunogenicity, and stability assessment. J Pharm Sci 2014;103(11):3448–3456. [DOI] [PubMed] [Google Scholar]
  • 228. Bernardi A, Jiménez‐Barbero J, Casnati A, De Castro C, Darbre T, Fieschi F, Finne J, Funken H, Jaeger KE, Lahmann M, Lindhorst TK, Marradi M, Messner P, Molinaro A, Murphy PV, Nativi C, Oscarson S, Penadés S, Peri F, Pieters RJ, Renaudet O, Reymond JL, Richichi B, Rojo J, Sansone F, Schäffer C, Turnbull WB, Velasco‐Torrijos T, Vidal S, Vincent S, Wennekes T, Zuilhof H, Imberty A. Multivalent glycoconjugates as anti‐pathogenic agents. Chem Soc Rev 2013;42(11):4709–4727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 229. Chabre YM, Roy R. Multivalent glycoconjugate syntheses and applications using aromatic scaffolds. Chem Soc Rev 2013;42(11):4657–4708. [DOI] [PubMed] [Google Scholar]
  • 230. Hatano K, Matsuoka K, Terunuma D. Carbosilane glycodendrimers. Chem Soc Rev 2013;42(11):4574–4598. [DOI] [PubMed] [Google Scholar]
  • 231. Reymond JL, Bergmann M, Darbre T. Glycopeptide dendrimers as Pseudomonas aeruginosa biofilm inhibitors. Chem Soc Rev 2013;42(11):4814–4822. [DOI] [PubMed] [Google Scholar]
  • 232. Jiménez Blanco JL, Ortiz Mellet C, García Fernández JM. Multivalency in heterogeneous glycoenvironments: Hetero‐glycoclusters, ‐glycopolymers and ‐glycoassemblies. Chem Soc Rev 2013;42(11):4518–4531. [DOI] [PubMed] [Google Scholar]
  • 233. Ehmann HMA, Breitwieser D, Winter S, Gspan C, Koraimann G, Maver U, Sega M, Köstler S, Stana‐Kleinschek K, Spirk S, Ribitsch V. Gold nanoparticles in the engineering of antibacterial and anticoagulant surfaces. Carbohydr Polym 2014;117:34–42. [DOI] [PubMed] [Google Scholar]
  • 234. Breitwieser D, Spirk S, Fasl H, Ehmann HMA, Chemelli A, Reichel VE, Gspan C, Stana‐Kleinschek K, Ribitsch V. Design of simultaneous antimicrobial and anticoagulant surfaces based on nanoparticles and polysaccharides. J Mater Chem B Mater Biol Med 2013;1(15):2022–2030. [DOI] [PubMed] [Google Scholar]
  • 235. Cheng F, Betts JW, Kelly SM, Hector AL. Green synthesis of highly concentrated aqueous colloidal solutions of large starch‐stabilised silver nanoplatelets. Mater Sci Eng C Mater Biol Appl 2015;46:530–537. [DOI] [PubMed] [Google Scholar]
  • 236. Cheng F, Betts JW, Kelly SM, Schaller J, Heinze T. Synthesis and antibacterial effects of aqueous colloidal solutions of silver nanoparticles using aminocellulose as a combined reducing and capping reagent. Green Chem 2013;15(4):989–998. [Google Scholar]
  • 237. Ramtenki V, Raju D, Mehta UJ, Ramana CV, Prasad BLV. Synthesis of Ag‐glyconanoparticles using C‐glycosides, their lectin binding studies and antibacterial activity. New J Chem 2013;37(11):3716–3720. [Google Scholar]
  • 238. Raval YS, Stone R, Fellows B, Qi B, Huang G, Mefford OT, Tzeng TRJ. Synthesis and application of glycoconjugate‐functionalized magnetic nanoparticles as potent anti‐adhesion agents for reducing enterotoxigenic Escherichia coli infections. Nanoscale 2015;7(18):8326–8331. [DOI] [PubMed] [Google Scholar]
  • 239. Park S, Kim GH, Park SH, Pai J, Rathwell D, Park JY, Kang YS, Shin I. Probing cell‐surface carbohydrate binding proteins with dual‐modal glycan‐conjugated nanoparticles. J Am Chem Soc 2015;137(18):5961–5968. [DOI] [PubMed] [Google Scholar]
  • 240. Barras A, Martin FA, Bande O, Baumann JS, Ghigo JM, Boukherroub R, Beloin C, Siriwardena A, Szunerits S. Glycan‐functionalized diamond nanoparticles as potent E. coli anti‐adhesives. Nanoscale 2013;5(6):2307–2316. [DOI] [PubMed] [Google Scholar]
  • 241. Khanal M, Larsonneur F, Raks V, Barras A, Baumann JS, Martin FA, Boukherroub R, Ghigo JM, Ortiz Mellet C, Zaitsev V, Garcia Fernandez JM, Beloin C, Siriwardena A, Szunerits S. Inhibition of type 1 fimbriae‐mediated Escherichia coli adhesion and biofilm formation by trimeric cluster thiomannosides conjugated to diamond nanoparticles. Nanoscale 2015;7(6):2325–2335. [DOI] [PubMed] [Google Scholar]
  • 242. Ragoussi ME, Casado S, Ribeiro‐Viana R, Torre GDL, Rojo J, Torres T. Selective carbohydrate‐lectin interactions in covalent graphene‐ and SWCNT‐based molecular recognition systems. Chem Sci 2013;4(10):4035–4041. [Google Scholar]
  • 243. Luczkowiak J, Muñoz A, Sánchez‐Navarro M, Ribeiro‐Viana R, Ginieis A, Illescas BM, Martín N, Delgado R, Rojo J. Glycofullerenes inhibit viral infection. Biomacromolecules 2013;14(2):431–437. [DOI] [PubMed] [Google Scholar]
  • 244. Percec V, Leowanawat P, Sun HJ, Kulikov O, Nusbaum CD, Tran TM, Bertin A, Wilson DA, Peterca M, Zhang S, Kamat NP, Vargo K, Moock D, Johnston ED, Hammer DA, Pochan DJ, Chen Y, Chabre YM, Shiao TC, Bergeron‐Brlek M, S André, Roy R, Gabius HJ, Heiney PA. Modular synthesis of amphiphilic Janus glycodendrimers and their self‐assembly into glycodendrimersomes and other complex architectures with bioactivity to biomedically relevant lectins. J Am Chem Soc 2013;135(24):9055–9077. [DOI] [PubMed] [Google Scholar]
  • 245. Garcia‐Vallejo JJ, Koning N, Ambrosini M, Kalay H, Vuist I, Sarrami‐Forooshani R, Geijtenbeek TBH, van Kooyk Y. Glycodendrimers prevent HIV transmission via DC‐SIGN on dendritic cells. Int Immunol 2013;25(4):221–233. [DOI] [PubMed] [Google Scholar]
  • 246. Ligeour C, Audfray A, Gillon E, Meyer A, Galanos N, Vidal S, Vasseur JJ, Imberty A, Morvan F. Synthesis of branched‐phosphodiester and mannose‐centered fucosylated glycoclusters and their binding studies with Burkholderia ambifaria lectin (BambL). RSC Adv 2013;3(42):19515–19524. [Google Scholar]
  • 247. Mattarella M, Garcia‐Hartjes J, Wennekes T, Zuilhof H, Siegel JS. Nanomolar cholera toxin inhibitors based on symmetrical pentavalent ganglioside GM1os‐sym‐corannulenes. Org Biomol Chem 2013;11(26):4333–4339. [DOI] [PubMed] [Google Scholar]
  • 248. Rodrigue J, Ganne G, Blanchard B, Saucier C, Giguère D, Shiao TC, Varrot A, Imberty A, Roy R. Aromatic thioglycoside inhibitors against the virulence factor LecA from Pseudomonas aeruginosa . Org Biomol Chem 2013;11(40):6906–6918. [DOI] [PubMed] [Google Scholar]
  • 249. Ligeour C, Vidal O, Dupin L, Casoni F, Gillon E, Meyer A, Vidal S, Vergoten G, Lacroix JM, Souteyrand E, Imberty A, Vasseur JJ, Chevolot Y, Morvan F. Mannose‐centered aromatic galactoclusters inhibit the biofilm formation of Pseudomonas aeruginosa . Org Biomol Chem 2015;13(31):8433–8444. [DOI] [PubMed] [Google Scholar]
  • 250. Sicard D, Chevolot Y, Souteyrand E, Imberty A, Vidal S, Phaner‐Goutorbe M. Molecular arrangement between multivalent glycocluster and Pseudomonas aeruginosa LecA (PA‐IL) by atomic force microscopy: Influence of the glycocluster concentration. J Mol Recogn 2013;26(12):694–699. [DOI] [PubMed] [Google Scholar]
  • 251. Yan X, Sivignon A, Yamakawa N, Crepet A, Travelet C, Borsali R, Dumych T, Li Z, Bilyy R, Deniaud D, Fleury E, Barnich N, Darfeuille‐Michaud A, Gouin SG, Bouckaert J, Bernard J. Glycopolymers as antiadhesives of E. coli strains inducing inflammatory bowel diseases. Biomacromolecules 2015;16(6):1827–1836. [DOI] [PubMed] [Google Scholar]
  • 252. Ghirardello M, Öberg K, Staderini S, Renaudet O, Berthet N, Dumy P, Hed Y, Marra A, Malkoch M, Dondoni A. Thiol‐ene and thiol‐yne‐based synthesis of glycodendrimers as nanomolar inhibitors of wheat germ agglutinin. J Polymer Sci A1 2014;52(17):2422–2433. [Google Scholar]
  • 253. Sharma R, Naresh K, Chabre YM, Rej R, Saadeh NK, Roy R. Onion peel dendrimers: A straightforward synthetic approach towards highly diversified architectures. Polym Chem 2014;5(14):4321–4331. [Google Scholar]
  • 254. Campo VL, Ivanova IM, Carvalho I, Lopes CD, Carneiro ZA, Saalbach G, Schenkman S, Da Silva JS, Nepogodiev SA, Field RA. Click chemistry oligomerisation of azido‐alkyne‐functionalised galactose accesses triazole‐linked linear oligomers and macrocycles that inhibit Trypanosoma cruzi macrophage invasion. Tetrahedron 2015;71(39):7334–7353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 255. Kadam RU, Bergmann M, Garg D, Gabrieli G, Stocker A, Darbre T, Reymond JL. Structure‐based optimization of the terminal tripeptide in glycopeptide dendrimer inhibitors of Pseudomonas aeruginosa biofilms targeting LecA. Chem Eur J 2013;19(50):17054–17063. [DOI] [PubMed] [Google Scholar]
  • 256. Bouckaert J, Li Z, Xavier C, Almant M, Caveliers V, Lahoutte T, Weeks SD, Kovensky J, Gouin SG. Heptyl α‐D‐mannosides grafted on a β‐cyclodextrin core to interfere with escherichia coli adhesion: An in vivo multivalent effect. Chem Eur J 2013;19(24):7847–7855. [DOI] [PubMed] [Google Scholar]
  • 257. Thomas B, Berthet N, Garcia J, Dumy P, Renaudet O. Expanding the scope of oxime ligation: Facile synthesis of large cyclopeptide‐based glycodendrimers. Chem Commun 2013;49(92):10796–10798. [DOI] [PubMed] [Google Scholar]
  • 258. Branson TR, McAllister TE, Garcia‐Hartjes J, Fascione MA, Ross JF, Warriner SL, Wennekes T, Zuilhof H, Turnbull WB. A protein‐based pentavalent inhibitor of the cholera toxin B‐subunit. Angew Chem Int Ed 2014;53(32):8323–8327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 259. Nazemi A, Haeryfar SMM, Gillies ER. Multifunctional dendritic sialopolymersomes as potential antiviral agents: Their lectin binding and drug release properties. Langmuir 2013;29(21):6420–6428. [DOI] [PubMed] [Google Scholar]
  • 260. Wu F, Jin J, Wang L, Sun P, Yuan H, Yang Z, Chen G, Fan QH, Liu D. Functionalization of DNA‐dendron supramolecular fibers and application in regulation of escherichia coli association. ACS Appl Mater Interfaces 2015;7(13):7351–7356. [DOI] [PubMed] [Google Scholar]
  • 261. Yu G, Ma Y, Han C, Yao Y, Tang G, Mao Z, Gao C, Huang F. A sugar‐functionalized amphiphilic pillar[5]arene: Synthesis, self‐assembly in water, and application in bacterial cell agglutination. J Am Chem Soc 2013;135(28):10310–10313. [DOI] [PubMed] [Google Scholar]
  • 262. Restuccia A, Tian YF, Collier JH, Hudalla GA. Self‐assembled glycopeptide nanofibers as modulators of galectin‐1 bioactivity. Cell Mol Bioeng 2015;8(3):471–487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 263. Ulloa‐Aguirre A, Janovick JA, Brothers SP, Conn PM. Pharmacologic rescue of conformationally‐defective proteins: Implications for the treatment of human disease. Traffic 2004;5(11):821–837. [DOI] [PubMed] [Google Scholar]
  • 264. Rísquez‐Cuadro R, García Fernández JM, Nierengarten JF, Ortiz Mellet C. Fullerene‐sp2‐iminosugar balls as multimodal ligands for lectins and glycosidases: A mechanistic hypothesis for the inhibitory multivalent effect. Chem Eur J 2013;19(49):16791–16803. [DOI] [PubMed] [Google Scholar]
  • 265. Brissonnet Y, Ortiz Mellet C, Morandat S, Garcia Moreno MI, Deniaud D, Matthews SE, Vidal S, Šesták S, El Kirat K, Gouin SG. Topological effects and binding modes operating with multivalent iminosugar‐based glycoclusters and mannosidases. J Am Chem Soc 2013;135(49):18427–18435. [DOI] [PubMed] [Google Scholar]
  • 266. Moreno‐Clavijo E, Carmona AT, Moreno‐Vargas AJ, Molina L, Wright DW, Davies GJ, Robina I. Exploring a multivalent approach to α‐L‐fucosidase inhibition. Eur J Org Chem 2013;2013(32):7328–7336. [Google Scholar]
  • 267. Bonduelle C, Huang J, Mena‐Barragán T, Ortiz Mellet C, Decroocq C, E Etamé, Heise A, Compain P, Lecommandoux S. Iminosugar‐based glycopolypeptides: Glycosidase inhibition with bioinspired glycoprotein analogue micellar self‐assemblies. Chem Commun 2014;50(25):3350–3352. [DOI] [PubMed] [Google Scholar]
  • 268. Joosten A, Schneider JP, Lepage ML, Tarnus C, Bodlenner A, Compain P. A convergent strategy for the synthesis of second‐generation iminosugar clusters using “clickable” trivalent dendrons. Eur J Org Chem 2014;2014(9):1866–1872. [Google Scholar]
  • 269. Lepage ML, Meli A, Bodlenner A, Tarnus C, De Riccardis F, Izzo I, Compain P. Synthesis of the first examples of iminosugar clusters based on cyclopeptoid cores. Beilstein J Org Chem 2014;10:1406–1412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 270. Joosten A, Decroocq C, De Sousa J, Schneider JP, E Etamé, Bodlenner A, Butters TD, Compain P. A systematic investigation of iminosugar click clusters as pharmacological chaperones for the treatment of gaucher disease. ChemBioChem 2014;15(2):309–319. [DOI] [PubMed] [Google Scholar]
  • 271. Compain P, Decroocq C, Joosten A, de Sousa J, Rodríguez‐Lucena D, Butters TD, Bertrand J, Clément R, Boinot C, Becq F, Norez C. Rescue of functional CFTR channels in cystic fibrosis: A dramatic multivalent effect using iminosugar cluster‐based correctors. ChemBioChem 2013;14(15):2050–2058. [DOI] [PubMed] [Google Scholar]
  • 272. Rodríguez‐Lavado J, De La Mata M, Jiménez‐Blanco JL, García‐Moreno MI, Benito JM, Díaz‐Quintana A, Sánchez‐Alcázar JA, Higaki K, Nanba E, Ohno K, Suzuki Y, Ortiz Mellet C, García Fernández JM. Targeted delivery of pharmacological chaperones for Gaucher disease to macrophages by a mannosylated cyclodextrin carrier. Org Biomol Chem 2014;12(14):2289–2301. [DOI] [PubMed] [Google Scholar]
  • 273. Brissonnet Y, Ladevèze S, D Tezé, Fabre E, Deniaud D, Daligault F, Tellier C, Šesták S, Remaud‐Simeon M, Potocki‐Veronese G, Gouin SG. Polymeric iminosugars improve the activity of carbohydrate‐processing enzymes. Bioconjug Chem 2015;26(4):766–772. [DOI] [PubMed] [Google Scholar]
  • 274. Biswas S, Medina SH, Barchi JJ. Synthesis and cell‐selective antitumor properties of amino acid conjugated tumor‐associated carbohydrate antigen‐coated gold nanoparticles. Carbohydr Res 2015;405:93–101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 275. Tyler PC, Guimond SE, Turnbull JE, Zubkova OV. Single‐entity heparan sulfate glycomimetic clusters for therapeutic applications. Angew Chem Int Ed 2015;54(9):2718–2723. [DOI] [PubMed] [Google Scholar]
  • 276. Muñoz‐Bonilla A, Fernández‐García M. Glycopolymeric materials for advanced applications. Materials 2015;8(5):2276–2296. [Google Scholar]
  • 277. Singh RS, Kaur N, Kennedy JF. Pullulan and pullulan derivatives as promising biomolecules for drug and gene targeting. Carbohydr Polym 2015;123:190–207. [DOI] [PubMed] [Google Scholar]
  • 278. Shelke NB, James R, Laurencin CT, Kumbar SG. Polysaccharide biomaterials for drug delivery and regenerative engineering. Polym Adv Technol 2014;25(5):448–460. [Google Scholar]
  • 279. Jiang G, Jiang T, Chen H, Li L, Liu Y, Zhou H, Feng Y, Zhou, J . Preparation of multi‐responsive micelles for controlled release of insulin. Colloid Polym Sci 2015;293(1):209–215. [Google Scholar]
  • 280. Li Y, Liao K, Lee S. A comparative study of antioxidant‐loaded carbon nanoparticles as drug delivery vehicles. RSC Adv 2014;4(100):56992–56997. [Google Scholar]
  • 281. Song E, Han W, Li C, Cheng D, Li L, Liu L, Zhu G, Song Y, Tan W. Hyaluronic acid‐decorated graphene oxide nanohybrids as nanocarriers for targeted and pH‐responsive anticancer drug delivery. ACS Appl Mater Interfaces 2014;6(15):11882–11890. [DOI] [PubMed] [Google Scholar]
  • 282. Zhang YM, Cao Y, Yang Y, Chen JT, Liu Y. A small‐sized graphene oxide supramolecular assembly for targeted delivery of camptothecin. Chem Commun 2014;50(86):13066–13069. [DOI] [PubMed] [Google Scholar]
  • 283. Song F, Hu W, Xiao L, Cao Z, Li X, Zhang C, Liao L, Liu L. Enzymatically cross‐linked hyaluronic acid/graphene oxide nanocomposite hydrogel with pH‐responsive release. J Biomater Sci Polym Ed 2015;26(6):339–352. [DOI] [PubMed] [Google Scholar]
  • 284. Miao W, Shim G, Kang CM, Lee S, Choe YS, Choi HG, Oh YK. Cholesteryl hyaluronic acid‐coated, reduced graphene oxide nanosheets for anti‐cancer drug delivery. Biomaterials 2013;34(37):9638–9647. [DOI] [PubMed] [Google Scholar]
  • 285. Nahain AA, Lee JE, Jeong JH, Park SY. Photoresponsive fluorescent reduced graphene oxide by spiropyran conjugated hyaluronic acid for in vivo imaging and target delivery. Biomacromolecules 2013;14(11):4082–4090. [DOI] [PubMed] [Google Scholar]
  • 286. Filip J, Tkac J. Is graphene worth using in biofuel cells? Electrochim Acta 2014;136:340–354. [Google Scholar]
  • 287. Wu H, Shi H, Wang Y, Jia X, Tang C, Zhang J, Yang S. Hyaluronic acid conjugated graphene oxide for targeted drug delivery. Carbon 2014;69:379–389. [Google Scholar]
  • 288. Khatun Z, Nurunnabi M, Nafiujjaman M, Reeck GR, Khan HA, Cho KJ, Lee YK. A hyaluronic acid nanogel for photo‐chemo theranostics of lung cancer with simultaneous light‐responsive controlled release of doxorubicin. Nanoscale 2015;7(24):10680–10689. [DOI] [PubMed] [Google Scholar]
  • 289. Yang H, Bremner DH, Tao L, Li H, Hu J, Zhu L. Carboxymethyl chitosan‐mediated synthesis of hyaluronic acid‐targeted graphene oxide for cancer drug delivery. Carbohydr Polym 2016;135:72–78. [DOI] [PubMed] [Google Scholar]
  • 290. Xu C, Yang D, Mei L, Li Q, Zhu H, Wang T. Targeting chemophotothermal therapy of hepatoma by gold nanorods/graphene oxide core/shell nanocomposites. ACS Appl Mater Interfaces 2013;5(24):12911–12920. [DOI] [PubMed] [Google Scholar]
  • 291. He C, Shi ZX, Ma L, Cheng C, Nie CX, Zhou M, Zhao CS. Graphene oxide based heparin‐mimicking and hemocompatible polymeric hydrogels for versatile biomedical applications. J Mater Chem B 2015;3:592–602. [DOI] [PubMed] [Google Scholar]
  • 292. Cao X, Tao L, Wen S, Hou W, Shi X. Hyaluronic acid‐modified multiwalled carbon nanotubes for targeted delivery of doxorubicin into cancer cells. Carbohydr Res 2015;405:70–77. [DOI] [PubMed] [Google Scholar]
  • 293. Mu S, Liang Y, Chen S, Zhang L, Liu T. MWNT‐hybrided supramolecular hydrogel for hydrophobic camptothecin delivery. Mater Sci Eng C Mater Biol Appl 2015;50:294–299. [DOI] [PubMed] [Google Scholar]
  • 294. Martinez A, Ortiz Mellet C, Garcia Fernandez JM. Cyclodextrin‐based multivalent glycodisplays: covalent and supramolecular conjugates to assess carbohydrate‐protein interactions. Chem Soc Rev 2013;42(11):4746–4773. [DOI] [PubMed] [Google Scholar]
  • 295. Ferreira TH, Hollanda LM, Lancellotti M, De Sousa EMB. Boron nitride nanotubes chemically functionalized with glycol chitosan for gene transfection in eukaryotic cell lines. J Biomed Mater Res A 2015;103(6):2176–2185. [DOI] [PubMed] [Google Scholar]
  • 296. Zhou L, Dong K, Chen Z, Ren J, Qu X. Near‐infrared absorbing mesoporous carbon nanoparticle as an intelligent drug carrier for dual‐triggered synergistic cancer therapy. Carbon 2015;82:479–488. [Google Scholar]
  • 297. Kennedy DC, Orts‐Gil G, Lai CH, Müller L, Haase A, Luch A, Seeberger PH. Carbohydrate functionalization of silver nanoparticles modulates cytotoxicity and cellular uptake. J Nanobiotechnol 2014;12(1):59. DOI:  10.1186/s12951-014-0059-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 298. Shahbazi S, Wang X, Yang JL, Jiang XC, Ryan R, Yu AB. Synthesis and surface modification of magnetic nanoparticles for potential applications in sarcomas. J Nanopart Res 2015;17(6):257. DOI: 10.1007/s11051-015-3065-7. [DOI] [Google Scholar]
  • 299. Zhang D, Pan X, Wang S, Zhai Y, Guan J, Fu Q, Hao X, Qi W, Wang Y, Lian H, Liu X, Wang Y, Sun Y, He Z, Sun J. Multifunctional poly(methyl vinyl ether‐co‐maleic anhydride)‐graft‐hydroxypropyl‐β‐cyclodextrin amphiphilic copolymer as an oral high‐performance delivery carrier of tacrolimus. Mol Pharm 2015;12(7):2337–2351. [DOI] [PubMed] [Google Scholar]
  • 300. Aykaç A, Martos‐Maldonado MC, Casas‐Solvas JM, Quesada‐Soriano I, García‐Maroto F, García‐Fuentes L, Vargas‐Berenguel A. β‐Cyclodextrin‐bearing gold glyconanoparticles for the development of site specific drug delivery systems. Langmuir 2014;30(1):234–242. [DOI] [PubMed] [Google Scholar]
  • 301. Adokoh CK, Quan S, Hitt M, Darkwa J, Kumar P, Narain R. Synthesis and evaluation of glycopolymeric decorated gold nanoparticles functionalized with gold‐triphenyl phosphine as anti‐cancer agents. Biomacromolecules 2014;15(10):3802–3810. [DOI] [PubMed] [Google Scholar]
  • 302. Wang Z, Chen Z, Liu Z, Shi P, Dong K, Ju E, Ren J, Qu X. A multi‐stimuli responsive gold nanocage‐hyaluronic platform for targeted photothermal and chemotherapy. Biomaterials 2014;35(36):9678–9688. [DOI] [PubMed] [Google Scholar]
  • 303. Zeng L, Chen J, Ji S, Chan L, Zheng W, Chen T. Construction of a cancer‐targeted nanosystem as a payload of iron complexes to reverse cancer multidrug resistance. J Mater Chem B Mater Biol Med 2015;3(21):4345–4354. [DOI] [PubMed] [Google Scholar]
  • 304. Liu E, Zhou Y, Liu Z, Li J, Zhang D, Chen J, Cai Z. Cisplatin loaded hyaluronic acid modified TiO2 nanoparticles for neoadjuvant chemotherapy of ovarian cancer. J Nanomater 2015;2015:Article ID 390358. DOI:  10.1155/2015/390358. [DOI] [Google Scholar]
  • 305. Guo H, Chen W, Sun X, Liu YN, Li J, Wang J. Theranostic magnetoliposomes coated by carboxymethyl dextran with controlled release by low‐frequency alternating magnetic field. Carbohydr Polym 2015;118:209–217. [DOI] [PubMed] [Google Scholar]
  • 306. Lai CH, Chang TC, Chuang YJ, Tzou DL, Lin CC. Stepwise orthogonal click chemistry toward fabrication of paclitaxel/galactose functionalized fluorescent nanoparticles for hepg2 cell targeting and delivery. Bioconjugate Chem 2013;24(10):1698–1709. [DOI] [PubMed] [Google Scholar]
  • 307. Chen X, Yao X, Wang C, Chen L, Chen X. Mesoporous silica nanoparticles capped with fluorescence‐conjugated cyclodextrin for pH‐activated controlled drug delivery and imaging. Microporous Mesoporous Mater 2015;217:46–53. [Google Scholar]
  • 308. Yu M, Jambhrunkar S, Thorn P, Chen J, Gu W, Yu C. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44‐overexpressing cancer cells. Nanoscale 2013;5(1):178–183. [DOI] [PubMed] [Google Scholar]
  • 309. Zhao Q, Geng H, Wang Y, Gao Y, Huang J, Wang Y, Zhang J, Wang S. Hyaluronic acid oligosaccharide modified redox‐responsive mesoporous silica nanoparticles for targeted drug delivery. ACS Appl Mater Interfaces 2014;6(22):20290–20299. [DOI] [PubMed] [Google Scholar]
  • 310. Zhao Q, Liu J, Zhu W, Sun C, Di D, Zhang Y, Wang P, Wang Z, Wang S. Dual‐stimuli responsive hyaluronic acid‐conjugated mesoporous silica for targeted delivery to CD44‐overexpressing cancer cells. Acta Biomater 2015;23:147–156. [DOI] [PubMed] [Google Scholar]
  • 311. Niemelä E, Desai D, Nkizinkiko Y, Eriksson JE, Rosenholm JM. Sugar‐decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celastrol enables targeted induction of apoptosis in cancer cells. Eur J Pharm Biopharm 2015;96:11–21. [DOI] [PubMed] [Google Scholar]
  • 312. Sinha A, Chakraborty A, Jana NR. Dextran‐gated, multifunctional mesoporous nanoparticle for glucose‐responsive and targeted drug delivery. ACS Appl Mater Interfaces 2014;6(24):22183–22191. [DOI] [PubMed] [Google Scholar]
  • 313. Zhou J, Hao N, De Zoyza T, Yan M, Ramström O. Lectin‐gated, mesoporous, photofunctionalized glyconanoparticles for glutathione‐responsive drug delivery. Chem Commun 2015;51(48):9833–9836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 314. Wu H, Zhao Y, Mu X, Wu H, Chen L, Liu W, Mu Y, Liu J, Wei X. A silica‐polymer composite nano system for tumor‐targeted imaging and p53 gene therapy of lung cancer. J Biomater Sci Polym Ed 2015;26(6):384–400. [DOI] [PubMed] [Google Scholar]
  • 315. Xiao Y, Zhang H, Zhang Z, Yan M, Lei M, Zeng K, Zhao C. Synthesis of novel tetravalent galactosylated DTPA‐DSPE and study on hepatocyte‐targeting efficiency in vitro and in vivo. Int J Nanomed 2013;8:3033–3050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 316. Zhao C, Feng Q, Dou Z, Yuan W, Sui C, Zhang X, Xia G, Sun H, Ma J. Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin. PLoS One 2013;8(9):e73860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 317. Feng L, Yu H, Liu Y, Hu X, Li J, Xie A, Zhang J, Dong W. Construction of efficacious hepatoma‐targeted nanomicelles non‐covalently functionalized with galactose for drug delivery. Polym Chem 2014;5(24):7121–7130. [Google Scholar]
  • 318. Wang Y, Hong CY, Pan CY. Galactose‐based amphiphilic block copolymers: Synthesis, micellization, and bioapplication. Biomacromolecules 2013;14(5):1444–1451. [DOI] [PubMed] [Google Scholar]
  • 319. Wang Y, Zhang X, Yu P, Li C. Glycopolymer micelles with reducible ionic cores for hepatocytes‐targeting delivery of DOX. Int J Pharm 2013;441(1‐2):170–180. [DOI] [PubMed] [Google Scholar]
  • 320. Zhong Y, Yang W, Sun H, Cheng R, Meng F, Deng C, Zhong Z. Ligand‐directed reduction‐sensitive shell‐sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells. Biomacromolecules 2013;14(10):3723–3730. [DOI] [PubMed] [Google Scholar]
  • 321. Park HK, Lee SJ, Oh JS, Lee SG, Jeong YIL, Lee HC. Smart nanoparticles based on hyaluronic acid for redox‐responsive and CD44 receptor‐mediated targeting of tumor. Nanoscale Res Lett 2015;10(1):981. DOI:  10.1186/s11671-015-0981-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 322. Chen Z, Li Z, Wang J, Ju E, Zhou L, Ren J, Qu X. A multi‐synergistic platform for sequential irradiation‐activated high‐performance apoptotic cancer therapy. Adv Funct Mater 2014;24(4):522–529. [Google Scholar]
  • 323. Wang B, Chen K, Yang RD, Yang F, Liu J. Photoresponsive nanogels synthesized using spiropyrane‐modified pullulan as potential drug carriers. J Appl Polym Sci 2014;131(10):40288. [Google Scholar]
  • 324. Dag A, Zhao J, Stenzel MH. Origami with ABC triblock terpolymers based on glycopolymers: Creation of virus‐like morphologies. ACS Macro Lett 2015;4(5):579–583. [DOI] [PubMed] [Google Scholar]
  • 325. Craparo EF, Sardo C, Serio R, Zizzo MG, ML Bondì, Giammona G, Cavallaro G. Galactosylated polymeric carriers for liver targeting of sorafenib. Int J Pharm 2014;466(1‐2):172–180. [DOI] [PubMed] [Google Scholar]
  • 326. Glisoni RJ, Sosnik A. Novel poly(ethylene oxide)‐b‐poly(propylene oxide) copolymer‐glucose conjugate by the microwave‐assisted ring opening of a sugar lactone. Macromol Biosci 2014;14(11):1639–1651. [DOI] [PubMed] [Google Scholar]
  • 327. Nguyen TX, Huang L, Liu L, Elamin Abdalla AM, Gauthier M, Yang G. Chitosan‐coated nano‐liposomes for the oral delivery of berberine hydrochloride. J Mater Chem B Mater Biol Med 2014;2(41):7149–7159. [DOI] [PubMed] [Google Scholar]
  • 328. Wang J, Cui S, Bao Y, Xing J, Hao W. Tocopheryl pullulan‐based self assembling nanomicelles for anti‐cancer drug delivery. Mater Sci Eng C Mater Biol Appl 2014;43:614–621. [DOI] [PubMed] [Google Scholar]
  • 329. Liang D, Wang AT, Yang ZZ, Liu YJ, Qi XR. Enhance cancer cell recognition and overcome drug resistance using hyaluronic acid and α‐tocopheryl succinate based multifunctional nanoparticles. Mol Pharm 2015;12(6):2189–2202. [DOI] [PubMed] [Google Scholar]
  • 330. Singh MS, Juvale K, Wiese M, Lamprecht A. Evaluation of dual P‐gp‐BCRP inhibitors as nanoparticle formulation. Eur J Pharm Sci 2015;77:1–8. [DOI] [PubMed] [Google Scholar]
  • 331. Liu L, He H, Zhang M, Zhang S, Zhang W, Liu J. Hyaluronic acid‐decorated reconstituted high density lipoprotein targeting atherosclerotic lesions. Biomaterials 2014;35(27):8002–8014. [DOI] [PubMed] [Google Scholar]
  • 332. Chen S, Wang J, Cheng H, Guo W, Yu M, Zhao Q, Wu Z, Zhao L, Yin Z, Hong Z. Targeted delivery of NK007 to macrophages to treat colitis. J Pharm Sci 2015;104(7):2276–2284. [DOI] [PubMed] [Google Scholar]
  • 333. Jain K, Verma AK, Mishra PR, Jain NK. Characterization and evaluation of amphotericin B loaded MDP conjugated poly(propylene imine) dendrimers. Nanomedicine 2015;11(3):705–713. [DOI] [PubMed] [Google Scholar]
  • 334. Zheng C, Guo Q, Wu Z, Sun L, Zhang Z, Li C, Zhang X. Amphiphilic glycopolymer nanoparticles as vehicles for nasal delivery of peptides and proteins. Eur J Pharm Sci 2013;49(4):474–482. [DOI] [PubMed] [Google Scholar]
  • 335. Yang H, Sun X, Liu G, Ma R, Li Z, An Y, Shi L. Glucose‐responsive complex micelles for self‐regulated release of insulin under physiological conditions. Soft Matter 2013;9(35):8589–8599. [Google Scholar]
  • 336. Battistini FD, Flores‐Martin J, Olivera ME, Genti‐Raimondi S, Manzo RH. Hyaluronan as drug carrier. The in vitro efficacy and selectivity of Hyaluronan‐Doxorubicin complexes to affect the viability of overexpressing CD44 receptor cells. Eur J Pharm Sci 2014;65:122–129. [DOI] [PubMed] [Google Scholar]
  • 337. Li H, Bian S, Huang Y, Liang J, Fan Y, Zhang X. High drug loading pH‐sensitive pullulan‐DOX conjugate nanoparticles for hepatic targeting. J Biomed Mater Res A 2014;102(1):150–159. [DOI] [PubMed] [Google Scholar]
  • 338. Li H, Cui Y, Sui J, Bian S, Sun Y, Liang J, Fan Y, Zhang X. Efficient delivery of DOX to nuclei of hepatic carcinoma cells in the subcutaneous tumor model using ph‐sensitive pullulan‐DOX conjugates. ACS Appl Mater Interfaces 2015;7(29):15855–15865. [DOI] [PubMed] [Google Scholar]
  • 339. Zhan X, Jia L, Niu Y, Qi H, Chen X, Zhang Q, Zhang J, Wang Y, Dong L, Wang C. Targeted depletion of tumour‐associated macrophages by an alendronate‐glucomannan conjugate for cancer immunotherapy. Biomaterials 2014;35(38):10046–10057. [DOI] [PubMed] [Google Scholar]
  • 340. Yu M, Chen Z, Guo W, Wang J, Feng Y, Kong X, Hong Z. Specifically targeted delivery of protein to phagocytic macrophages. Int J Nanomedicine 2015;10:1743–1757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 341. Huang Y, Wang YJ, Wang Y, Yi S, Fan Z, Sun L, Lin D, Anreddy N, Zhu H, Schmidt M, Chen ZS, Zhang M. Exploring naturally occurring ivy nanoparticles as an alternative biomaterial. Acta Biomater 2015;25:268–283. [DOI] [PubMed] [Google Scholar]
  • 342. Chen P, Zhang X, Jia L, Prud'Homme RK, Szekely Z, Sinko PJ. Optimal structural design of mannosylated nanocarriers for macrophage targeting. J Control Release 2014;194:341–349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 343. Thomas A, Shukla A, Sivakumar S, Verma S. Assembly, postsynthetic modification and hepatocyte targeting by multiantennary, galactosylated soft structures. Chem Commun 2014;50(99):15752–15755. [DOI] [PubMed] [Google Scholar]
  • 344. Zhang C, Chen J, Feng C, Shao X, Liu Q, Zhang Q, Pang Z, Jiang X. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease. Int J Pharm 2014;461(1‐2):192–202. [DOI] [PubMed] [Google Scholar]
  • 345. Meng F, Asghar S, Gao S, Su Z, Song J, Huo M, Meng W, Ping Q, Xiao Y. A novel LDL‐mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer's disease. Colloids Surf B Biointerfaces 2015;134:88–97. [DOI] [PubMed] [Google Scholar]
  • 346. Wei M, Guo X, Zou Q, Li Q, Tang C, Chen B, Xu Y, Wu C. Lactoferrin‐modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma. Int J Nanomed 2015;10:5123–5137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 347. Kuo YC, Lee CH. Inhibition against growth of glioblastoma multiforme in vitro using etoposide‐loaded solid lipid nanoparticles with p‐aminophenyl‐α‐D‐manno‐pyranoside and folic acid. J Pharm Sci 2015;104(5):1804–1814. [DOI] [PubMed] [Google Scholar]
  • 348. Ahmed M, Wattanaarsakit P, Narain R. Cationic glyco‐nanogels for epidermal growth factor receptor (EGFR) specific siRNA delivery in ovarian cancer cells. Polym Chem 2013;4(13):3829–3836. [Google Scholar]
  • 349. Kim SJ, Ise H, Kim E, Goto M, Akaike T, Chung BH. Imaging and therapy of liver fibrosis using bioreducible polyethylenimine/siRNA complexes conjugated with N‐acetylglucosamine as a targeting moiety. Biomaterials 2013;34(27):6504–6514. [DOI] [PubMed] [Google Scholar]
  • 350. Wang C, Li M, Yang T, Ding X, Bao X, Ding Y, Xiong H, Wu Y, Wang W, Zhou J. A self‐assembled system for tumor‐targeted co‐delivery of drug and gene. Mater Sci Eng C Mater Biol Appl 2015;56:280–285. [DOI] [PubMed] [Google Scholar]
  • 351. Yang X, Iyer AK, Singh A, Milane L, Choy E, Hornicek FJ, Amiji MM, Duan Z. Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer. Pharm Res 2015;32(6):2097–2109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 352. Bansal R, Singh AK, Gandhi RP, Pant AB, Kumar P, Gupta KC. Galactomannan‐PEI based non‐viral vectors for targeted delivery of plasmid to macrophages and hepatocytes. Eur J Pharm Biopharm 2014;87(3):461–471. [DOI] [PubMed] [Google Scholar]
  • 353. Wu Y, Wang M, Sprouse D, Smith AE, Reineke TM. Glucose‐containing diblock polycations exhibit molecular weight, charge, and cell‐type dependence for pdna delivery. Biomacromolecules 2014;15(5):1716–1726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 354. Obata M, Kobori T, Hirohara S, Tanihara M. Aqueous RAFT synthesis of block and statistical copolymers of 2‐(α‐d‐mannopyranosyloxy)ethyl methacrylate with 2‐(N,N‐dimethylamino)ethyl methacrylate and their application for nonviral gene delivery. Polym Chem 2015;6(10):1793–1804. [Google Scholar]
  • 355. Sizovs A, Xue L, Tolstyka ZP, Ingle NP, Wu Y, Cortez M, Reineke TM. Poly(trehalose): Sugar‐coated nanocomplexes promote stabilization and effective polyplex‐mediated siRNA delivery. J Am Chem Soc 2013;135(41):15417–15424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 356. Kim YK, Singh B, Jiang HL, Park TE, Jiang T, Park IK, Cho MH, Kang SK, Choi YJ, Cho CS. N‐acetylglucosamine‐conjugated block copolymer consisting of poly(ethylene oxide) and cationic polyaspartamide as a gene carrier for targeting vimentin‐expressing cells. Eur J Pharm Sci 2014;51(1):165–172. [DOI] [PubMed] [Google Scholar]
  • 357. Hu Y, Haynes MT, Wang Y, Liu F, Huang L. A highly efficient synthetic vector: Nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano 2013;7(6):5376–5384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 358. Yu SS, Lau CM, Barham WJ, Onishko HM, Nelson CE, Li H, Smith CA, Yull FE, Duvall CL, Giorgio TD. Macrophage‐specific RNA interference targeting via “click”, mannosylated polymeric micelles. Mol Pharm 2013;10(3):975–987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 359. Li P, Chen S, Jiang Y, Jiang J, Zhang Z, Sun X. Dendritic cell targeted liposomes‐protamine‐DNA complexes mediated by synthetic mannosylated cholesterol as a potential carrier for DNA vaccine. Nanotechnology 2013;24(29):295101. [DOI] [PubMed] [Google Scholar]
  • 360. Peng Y, Yao W, Wang B, Zong L. Mannosylated chitosan nanoparticles based macrophage‐targeting gene delivery system enhanced cellular uptake and improved transfection efficiency. J Nanosci Nanotechnol 2015;15(4):2619–2627. [DOI] [PubMed] [Google Scholar]
  • 361. Kono Y, Kawakami S, Higuchi Y, Maruyama K, Yamashita F, Hashida M. Tumour‐associated macrophages targeted transfection with NF‐κB decoy/mannose‐modified bubble lipoplexes inhibits tumour growth in tumour‐bearing mice. J Drug Target 2014;22(5):439–449. [DOI] [PubMed] [Google Scholar]
  • 362. Kono Y, Kawakami S, Higuchi Y, Maruyama K, Yamashita F, Hashida M. Antitumor effect of nuclear factor‐κB decoy transfer by mannose‐modified bubble lipoplex into macrophages in mouse malignant ascites. Cancer Sci 2014;105(8):1049–1055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 363. Ortega RA, Barham WJ, Kumar B, Tikhomirov O, McFadden ID, Yull FE, Giorgio TD. Biocompatible mannosylated endosomal‐escape nanoparticles enhance selective delivery of short nucleotide sequences to tumor associated macrophages. Nanoscale 2015;7(2):500–510. [DOI] [PubMed] [Google Scholar]
  • 364. Gooding M, Malhotra M, McCarthy DJ, Godinho BMDC, Cryan JF, Darcy R, O'Driscoll CM. Synthesis and characterization of rabies virus glycoprotein‐tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: In vitro analysis. Eur J Pharm Sci 2015;71:80–92. [DOI] [PubMed] [Google Scholar]
  • 365. Kim MG, Park JY, Shim G, Choi HG, Oh YK. Biomimetic DNA nanoballs for oligonucleotide delivery. Biomaterials 2015;62:155–163. [DOI] [PubMed] [Google Scholar]
  • 366. Matsuda S, Keiser K, Nair JK, Charisse K, Manoharan RM, Kretschmer P, Peng CG, Kel'in AV, Kandasamy P, Willoughby JLS, Liebow A, Querbes W, Yucius K, Nguyen T, Milstein S, Maier MA, Rajeev KG, Manoharan M. siRNA conjugates carrying sequentially assembled trivalent N‐acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem Biol 2015;10(5):1181–1187. [DOI] [PubMed] [Google Scholar]
  • 367. Østergaard ME, Yu J, Kinberger GA, Wan WB, Migawa MT, Vasquez G, Schmidt K, Gaus HJ, Murray HM, Low A, Swayze EE, Prakash TP, Seth PP. Efficient synthesis and biological evaluation of 5′‐GalNAc conjugated antisense oligonucleotides. Bioconjug Chem 2015;26(8):1451–1455. [DOI] [PubMed] [Google Scholar]
  • 368. Rajeev KG, Nair JK, Jayaraman M, Charisse K, Taneja N, O'Shea J, Willoughby JLS, Yucius K, Nguyen T, Shulga‐Morskaya S, Milstein S, Liebow A, Querbes W, Borodovsky A, Fitzgerald K, Maier MA, Manoharan M. Hepatocyte‐specific delivery of siRNAs conjugated to novel non‐nucleosidic trivalent N‐acetylgalactosamine elicits robust gene silencing in vivo. ChemBioChem 2015;16(6):903–908. [DOI] [PubMed] [Google Scholar]
  • 369. Reyes‐Darias JA, Sánchez‐Luque FJ, Morales JC, Pérez‐Rentero S, Eritja R, Berzal‐Herranz A. Glucose conjugation of anti‐HIV‐1 oligonucleotides containing unmethylated CpG motifs reduces their immunostimulatory activity. ChemBioChem 2015;16(4):584–591. [DOI] [PubMed] [Google Scholar]
  • 370. Li J, Hu Y, Yang J, Wei P, Sun W, Shen M, Zhang G, Shi X. Hyaluronic acid‐modified Fe3O4 at Au core/shell nanostars for multimodal imaging and photothermal therapy of tumors. Biomaterials 2015;38:10–21. [DOI] [PubMed] [Google Scholar]
  • 371. Jiang BP, Zhang L, Zhu Y, Shen XC, Ji SC, Tan XY, Cheng L, Liang H. Water‐soluble hyaluronic acid‐hybridized polyaniline nanoparticles for effectively targeted photothermal therapy. J Mater Chem B Mater Biol Med 2015;3(18):3767–3776. [DOI] [PubMed] [Google Scholar]
  • 372. Kumar P, Srivastava R. IR 820 stabilized multifunctional polycaprolactone glycol chitosan composite nanoparticles for cancer therapy. RSC Adv 2015;5(69):56162–56170. [Google Scholar]
  • 373. Song Y, Wang Z, Li L, Shi W, Li X, Ma H. Gold nanoparticles functionalized with cresyl violet and porphyrin via hyaluronic acid for targeted cell imaging and phototherapy. Chem Commun 2014;50(99):15696–15698. [DOI] [PubMed] [Google Scholar]
  • 374. Hu C, Niestroj M, Yuan D, Chang S, Chen J. Treating cancer stem cells and cancer metastasis using glucose‐coated gold nanoparticles. Int J Nanomed 2015;10:2065–2077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 375. Lu J, Zhang W, Yuan L, Ma W, Li X, Lu W, Zhao Y, Chen G. One‐pot synthesis of glycopolymer‐porphyrin conjugate as photosensitizer for targeted cancer imaging and photodynamic therapy. Macromol Biosci 2014;14(3):340–346. [DOI] [PubMed] [Google Scholar]
  • 376. Maiolino S, Moret F, Conte C, Fraix A, Tirino P, Ungaro F, Sortino S, Reddi E, Quaglia F. Hyaluronan‐decorated polymer nanoparticles targeting the CD44 receptor for the combined photo/chemo‐therapy of cancer. Nanoscale 2015;7(13):5643–5653. [DOI] [PubMed] [Google Scholar]
  • 377. Fu J, Zhu Y, Zhao Y. Controlled free radical generation against tumor cells by pH‐responsive mesoporous silica nanocomposite. J Mater Chem B Mater Biol Med 2014;2(22):3538–3548. [DOI] [PubMed] [Google Scholar]
  • 378. Yang K, Feng L, Shi X, Liu Z. Nano‐graphene in biomedicine: Theranostic applications. Chem Soc Rev 2013;42(2):530–547. [DOI] [PubMed] [Google Scholar]
  • 379. Li F, Park SJ, Ling D, Park W, Han JY, Na K, Char K. Hyaluronic acid‐conjugated graphene oxide/photosensitizer nanohybrids for cancer targeted photodynamic therapy. J Mater Chem B 2013;1(12):1678–1686. [DOI] [PubMed] [Google Scholar]
  • 380. Miao W, Shim G, Kim G, Lee S, Lee HJ, Kim YB, Byun Y, Oh YK. Image‐guided synergistic photothermal therapy using photoresponsive imaging agent‐loaded graphene‐based nanosheets. J Control Release 2015;211(1):28–36. [DOI] [PubMed] [Google Scholar]
  • 381. Lai CH, Lai NC, Chuang YJ, Chou FI, Yang CM, Lin CC. Trivalent galactosyl‐functionalized mesoporous silica nanoparticles as a target‐specific delivery system for boron neutron capture therapy. Nanoscale 2013;5(19):9412–9418. [DOI] [PubMed] [Google Scholar]
  • 382. Marradi M, Chiodoa F, Garcia I. Glyconanotechnology and disease: Gold nanoparticles coated with glycosides as multivalent systems for potential applications in diagnostics and therapy. Jimenez‐Barbero J, Javier Canada F, Martin‐Santamaria S, Eds. Carbohydrates in Drug Design and Discovery. Cambridge In: RSC Drug Discov Series, Vol. 2015 p 89–131. [Google Scholar]
  • 383. Fu L, Sun C, Yan L. Galactose targeted pH‐responsive copolymer conjugated with near infrared fluorescence probe for imaging of intelligent drug delivery. ACS Appl Mater Interfaces 2015;7(3):2104–2115. [DOI] [PubMed] [Google Scholar]
  • 384. An J, Zhang X, Guo Q, Zhao Y, Wu Z, Li C. Glycopolymer modified magnetic mesoporous silica nanoparticles for MR imaging and targeted drug delivery. Colloids Surf A Physicochem Eng Asp 2015;482:98–108. [Google Scholar]
  • 385. Ladmiral V, Semsarilar M, Canton I, Armes SP. Polymerization‐induced self‐assembly of galactose‐functionalized biocompatible diblock copolymers for intracellular delivery. J Am Chem Soc 2013;135(36):13574–13581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 386. Kim SJ, Bae PK, Chung BH. Self‐assembled levan nanoparticles for targeted breast cancer imaging. Chem Commun 2014;51(1):107–110. [DOI] [PubMed] [Google Scholar]
  • 387. Craparo EF, Licciardi M, Conigliaro A, Palumbo FS, Giammona G, Alessandro R, De Leo G, Cavallaro G. Hepatocyte‐targeted fluorescent nanoparticles based on a polyaspartamide for potential theranostic applications. Polymer 2015;70:257–270. [Google Scholar]
  • 388. Jeong HS, Na KS, Hwang H, Oh PS, Kim DH, Lim ST, Sohn MH, Jeong HJ. Effect of space length of mannose ligand on uptake of mannosylated liposome in RAW 264.7 cells: In vitro and in vivo studies. J Biomed Mater Res A 2014;102(12):4545–4553. [DOI] [PubMed] [Google Scholar]
  • 389. Wang KR, An HW, Rong RX, Cao ZR, Li XL. Fluorescence turn‐on sensing of protein based on mannose functionalized perylene bisimides and its fluorescence imaging. Biosens Bioelectron 2014;58:27–32. [DOI] [PubMed] [Google Scholar]
  • 390. Wu X, Lin B, Yu M, Yang L, Han J, Han S. A carbohydrate‐grafted nanovesicle with activatable optical and acoustic contrasts for dual modality high performance tumor imaging. Chem Sci 2015;6(3):2002–2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 391. Mäkilä J, Jadhav S, Kiviniemi A, Käkelä M, Liljenbäck H, Poijärvi‐Virta P, Laitala‐Leinonen T, Lönnberg H, Roivainen A, Virta P. Synthesis of multi‐galactose‐conjugated 2′‐O‐methyl oligoribonucleotides and their in vivo imaging with positron emission tomography. Bioorg Med Chem 2014;22(24):6806–6813. [DOI] [PubMed] [Google Scholar]
  • 392. Lu Z, Mei L, Zhang X, Wang Y, Zhao Y, Li C. Water‐soluble BODIPY‐conjugated glycopolymers as fluorescent probes for live cell imaging. Polym Chem 2013;4(24):5743–5750. [Google Scholar]
  • 393. Wang K, Zhang X, Zhang X, Ma C, Li Z, Huang Z, Zhang Q, Wei Y. Preparation of emissive glucose‐containing polymer nanoparticles and their cell imaging applications. Polym Chem 2015;6(24):4455–4461. [Google Scholar]
  • 394. Zhou J, Butchosa N, Jayawardena HSN, Zhou Q, Yan M, RamstroÌ̂m O. Glycan‐functionalized fluorescent chitin nanocrystals for biorecognition applications. Bioconjugate Chem 2014;25(4):640–643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 395. Zhou J, Butchosa N, Jayawardena HSN, Park J, Zhou Q, Yan M, Ramström O. Synthesis of multifunctional cellulose nanocrystals for lectin recognition and bacterial imaging. Biomacromolecules 2015;16(4):1426–1432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 396. Azad AK, Rajaram MVS, Metz WL, Cope FO, Blue MS, Vera DR, Schlesinger LS. γ‐Tilmanocept, a new radiopharmaceutical tracer for cancer sentinel lymph nodes, binds to the mannose receptor (CD206). J Immunol 2015;195(5):2019–2029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 397. Lepage ML, Mirloup A, Ripoll M, Stauffert F, Bodlenner A, Ziessel R, Compain P. Design, synthesis and photochemical properties of the first examples of iminosugar clusters based on fluorescent cores. Beilstein J Org Chem 2015;11:659–667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 398. Li K, Liu B. Polymer‐encapsulated organic nanoparticles for fluorescence and photoacoustic imaging. Chem Soc Rev 2014;43(18):6570–6597. [DOI] [PubMed] [Google Scholar]
  • 399. Le Guével X, Perez Perrino M, Fernández TD, Palomares F, Torres MJ, Blanca M, Rojo J, Mayorga C. Multivalent glycosylation of fluorescent gold nanoclusters promotes increased human dendritic cell targeting via multiple endocytic pathways. ACS Appl Mater Interfaces 2015;7(37):20945–20956. [DOI] [PubMed] [Google Scholar]
  • 400. Cao Y, He Y, Liu H, Luo Y, Shen M, Xia J, Shi X. Targeted CT imaging of human hepatocellular carcinoma using low‐generation dendrimer‐entrapped gold nanoparticles modified with lactobionic acid. J Mater Chem B Mater Biol Med 2014;3(2):286–295. [DOI] [PubMed] [Google Scholar]
  • 401. Feng G, Kong B, Xing J, Chen J. Enhancing multimodality functional and molecular imaging using glucose‐coated gold nanoparticles. Clin Radiol 2014;69(11):1105–1111. [DOI] [PubMed] [Google Scholar]
  • 402. Frigell J, García I, Gómez‐Vallejo V, Llop J, Penadés S. 68Ga‐labeled gold glyconanoparticles for exploring blood‐brain barrier permeability: Preparation, biodistribution studies, and improved brain uptake via neuropeptide conjugation. J Am Chem Soc 2014;136(1):449–457. [DOI] [PubMed] [Google Scholar]
  • 403. Sun S. Chemical synthesis of monodisperse magnetic nanoparticles for sensitive cancer detection. J Inorg Organomet Polym Mater 2014;24(1):33–38. [Google Scholar]
  • 404. Borase T, Ninjbadgar T, Kapetanakis A, Roche S, O'Connor R, Kerskens C, Heise A, Brougham DF. Stable aqueous dispersions of glycopeptide‐grafted selectably functionalized magnetic nanoparticles. Angew Chem Int Ed 2013;52(11):3164–3167. [DOI] [PubMed] [Google Scholar]
  • 405. Kouyoumdjian H, Zhu DC, El‐Dakdouki MH, Lorenz K, Chen J, Li W, Huang X. Glyconanoparticle aided detection of β‐amyloid by magnetic resonance imaging and attenuation of β‐amyloid induced cytotoxicity. ACS Chem Neurosci 2013;4(4):575–584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 406. Basuki JS, Esser L, Duong HTT, Zhang Q, Wilson P, Whittaker MR, Haddleton DM, Boyer C, Davis TP. Magnetic nanoparticles with diblock glycopolymer shells give lectin concentration‐dependent MRI signals and selective cell uptake. Chem Sci 2014;5(2):715–726. [Google Scholar]
  • 407. Yang RM, Fu CP, Li NN, Wang L, Xu XD, Yang DY, Fang JZ, Jiang XQ, Zhang LM. Glycosaminoglycan‐targeted iron oxide nanoparticles for magnetic resonance imaging of liver carcinoma. Mater Sci Eng C Mater Biol Appl 2014;45:556–563. [DOI] [PubMed] [Google Scholar]
  • 408. El‐Dakdouki MH, El‐Boubbou K, Kamat M, Huang R, Abela GS, Kiupel M, Zhu DC, Huang X. CD44 targeting magnetic glyconanoparticles for atherosclerotic plaque imaging. Pharm Res 2014;31(6):1426–1437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 409. Farr TD, Lai CH, Grünstein D, Orts‐Gil G, Wang CC, Boehm‐Sturm P, Seeberger PH, Harms C. Imaging early endothelial inflammation following stroke by core shell silica superparamagnetic glyconanoparticles that target selectin. Nano Lett 2014;14(4):2130–2134. [DOI] [PubMed] [Google Scholar]
  • 410. Caltagirone C, Bettoschi A, Garau A, Montis R. Silica‐based nanoparticles: A versatile tool for the development of efficient imaging agents. Chem Soc Rev 2015;44(14):4645–4671. [DOI] [PubMed] [Google Scholar]
  • 411. Mitra J, Sharma A. Luminescent, ferromagnetic silver glyconanoparticles: Synthesis to annealing‐induced substrate specific transformation. RSC Adv 2015;5(37):28901–28907. [Google Scholar]
  • 412. Irure A, Marradi M, Arnáiz B, Genicio N, Padro D, Penadés S. Sugar/gadolinium‐loaded gold nanoparticles for labelling and imaging cells by magnetic resonance imaging. Biomater Sci 2013;1(6):658–668. [DOI] [PubMed] [Google Scholar]
  • 413. Schmidtke C, Kreuziger AM, Alpers D, Jacobsen A, Leshch Y, Eggers R, Kloust H, Tran H, Ostermann J, Schotten T, Thiem J, Thimm J, Weller H. Glycoconjugated amphiphilic polymers via click‐chemistry for the encapsulation of quantum dots. Langmuir 2013;29(40):12593–12600. [DOI] [PubMed] [Google Scholar]
  • 414. Benito‐Alifonso D, Tremel S, Hou B, Lockyear H, Mantell J, Fermin DJ, Verkade P, Berry M, Galan MC. Lactose as a “trojan horse” for quantum dot cell transport. Angew Chem Int Ed 2014;53(3):810–814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 415. Kara A, Ünak P, Selçuki C, Akça O, Medine EI, Sakarya S. PHA‐L lectin and carbohydrate relationship: Conjugation with CdSe/CdS nanoparticles, radiolabeling and in vitro affinities on MCF‐7 cells. J Radioanal Nucl Chem 2014;299(1):807–813. [Google Scholar]
  • 416. Yeh YC, Kim ST, Tang R, Yan B, Rotello VM. Insulin‐based regulation of glucose‐functionalized nanoparticle uptake in muscle cells. J Mater Chem B Mater Biol Med 2014;2(29):4610–4614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 417. Shinchi H, Wakao M, Nagata N, Sakamoto M, Mochizuki E, Uematsu T, Kuwabata S, Suda Y. Cadmium‐free sugar‐chain‐immobilized fluorescent nanoparticles containing low‐toxicity ZnS‐AgInS2 cores for probing lectin and cells. Bioconjug Chem 2014;25(2):286–295. [DOI] [PubMed] [Google Scholar]
  • 418. Zhai Y, Dasog M, Snitynsky RB, Purkait TK, Aghajamali M, Hahn AH, Sturdy CB, Lowary TL, Veinot JGC. Water‐soluble photoluminescent D‐mannose and L‐alanine functionalized silicon nanocrystals and their application to cancer cell imaging. J Mater Chem B Mater Biol Med 2015;2(47):8427–8433. [DOI] [PubMed] [Google Scholar]
  • 419. Ahire JH, Chambrier I, Mueller A, Bao Y, Chao Y. Synthesis of D‐mannose capped silicon nanoparticles and their interactions with MCF‐7 human breast cancerous cells. ACS Appl Mater Interfaces 2013;5(15):7384–7391. [DOI] [PubMed] [Google Scholar]
  • 420. Bilyy R, Podhorodecki A. Can we use rare‐earth nanocrystals to target glycans for the visualization of melanoma? Nanomedicine 2015;10(13):1997–2000. [DOI] [PubMed] [Google Scholar]
  • 421. Kante B, Couvreur P, Dubois‐Krack G, de Meester C, Guiot P, Roland M, Mercier M, Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles I: Free nanoparticles. J Pharm Sci 1982;71(7):786–790. [DOI] [PubMed] [Google Scholar]
  • 422. Dhawan A, Sharma V. Toxicity assessment of nanomaterials: Methods and challenges. Anal Bioanal Chem 2010;398(2):589–605. [DOI] [PubMed] [Google Scholar]
  • 423. Aillon KL, Xie Y, El‐Gendy N, Berkland CJ, Forrest ML. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev 2009;61(6):457–466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 424. Buzea C, Pacheco II, Robbie K. Nanomaterials and nanoparticles: Sources and toxicity. Biointerphases 2007;2(4):MR17–MR71. [DOI] [PubMed] [Google Scholar]
  • 425. Kunzmann A, Andersson B, Thurnherr T, Krug H, Scheynius A, Fadeel B. Toxicology of engineered nanomaterials: Focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta 2011;1810(3):361–373. [DOI] [PubMed] [Google Scholar]
  • 426. Liu S, Hu M, Zeng TH, Wu R, Jiang R, Wei J, Wang L, Kong J, Chen Y. Lateral dimension‐dependent antibacterial activity of graphene oxide sheets. Langmuir 2012;28(33):12364–12372. [DOI] [PubMed] [Google Scholar]
  • 427. Akhavan O, Ghaderi E, Esfandiar A. Wrapping bacteria by graphene nanosheets for isolation from environment, reactivation by sonication, and inactivation by near‐infrared irradiation. J Phys Chem B 2011;115(19):6279–6288. [DOI] [PubMed] [Google Scholar]
  • 428. Moyano DF, Liu Y, Peer D, Rotello VM. Modulation of immune response using engineered nanoparticle surfaces. Small 2016;12(1):76–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 429. Sharifi S, Behzadi S, Laurent S, Laird Forrest M, Stroeve P, Mahmoudi M. Toxicity of nanomaterials. Chem Soc Rev 2012;41(6):2323–2343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 430. Huang B‐Y, Yang C‐K, Liu C‐P, Liu C‐Y. Stationary phases for the enrichment of glycoproteins and glycopeptides. Electrophoresis 2014;35(15):2091–2107. [DOI] [PubMed] [Google Scholar]
  • 431. Alley WR, Mann BF, Novotny MV. High‐sensitivity analytical approaches for the structural characterization of glycoproteins. Chem Rev 2013;113(4):2668–2732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 432. Kolli V, Schumacher KN, Dodds ED. Engaging challenges in glycoproteomics: Recent advances in MS‐based glycopeptide analysis. Bioanalysis 2015;7(1):113–131. [DOI] [PubMed] [Google Scholar]
  • 433. Harvey DJ. Analysis of carbohydrates and glycoconjugates by matrix‐assisted laser desorption/ionization mass spectrometry: An update for 2009–2010. Mass Spectrom Rev 2015;34(3):268–422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 434. Stavenhagen K, Kolarich D, Wuhrer M. Clinical glycomics employing graphitized carbon liquid chromatography—mass spectrometry. Chromatographia 2015;78(5‐6):307–320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 435. Kailemia MJ, Ruhaak LR, Lebrilla CB, Amster IJ. Oligosaccharide analysis by mass spectrometry: A review of recent developments. Anal Chem 2014;86(1):196–212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 436. Palmisano G, Larsen MR, Packer NH, Thaysen‐Andersen M. Structural analysis of glycoprotein sialylation ‐ Part II: LC‐MS based detection. RSC Adv 2013;3(45):22706–22726. [Google Scholar]
  • 437. Thaysen‐Andersen M, Larsen MR, Packer NH, Palmisano G. Structural analysis of glycoprotein sialylation ‐ Part I: Pre‐LC‐MS analytical strategies. RSC Adv 2013;3(45):22683–22705. [Google Scholar]
  • 438. Kronewitter SR, Marginean I, Cox JT, Zhao R, Hagler CD, Shukla AK, Carlson TS, Adkins JN, Camp DG, Moore RJ, Rodland KD, Smith RD. Polysialylated N‐glycans identified in human serum through combined developments in sample preparation, separations, and electrospray ionization‐mass spectrometry. Anal Chem 2014;86(17):8700–8710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 439. Kronewitter SR, Slysz GW, Marginean I, Hagler CD, LaMarche BL, Zhao R, Harris MY, Monroe ME, Polyukh CA, Crowell KL, Fillmore TL, Carlson TS, Camp DG, Moore RJ, Payne SH, Anderson GA, Smith RD. GlyQ‐IQ: Glycomics quintavariate‐informed quantification with high‐performance computing and GlycoGrid 4D visualization. Anal Chem 2014;86(13):6268–6276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 440. Li L, Xu L, Li Z, Bai Y, Liu H. Novel nanomaterials used for sample preparation for protein analysis. Anal Bioanal Chem 2014;406(1):35–47. [DOI] [PubMed] [Google Scholar]
  • 441. Li D, Chen Y, Liu Z. Boronate affinity materials for separation and molecular recognition: Structure, properties and applications. Chem Soc Rev 2015;44(22):8097–8123. [DOI] [PubMed] [Google Scholar]
  • 442. Stine KJ, Ed. Glycans in mesoporous and nanoporous materials In: Carbohydrate Nanotechnology. Hoboken, New Jersey: John Wiley & Sons; 2016. p 233–266. [Google Scholar]
  • 443. Wu X, Li Z, Chen X‐X, Fossey JS, James TD, Jiang Y‐B. Selective sensing of saccharides using simple boronic acids and their aggregates. Chem Soc Rev 2013;42(20):8032–8048. [DOI] [PubMed] [Google Scholar]
  • 444. Bie Z, Chen Y, Li H, Wu R, Liu Z. Off‐line hyphenation of boronate affinity monolith‐based extraction with matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry for efficient analysis of glycoproteins/glycopeptides. Anal Chim Acta 2014;834:1–8. [DOI] [PubMed] [Google Scholar]
  • 445. Zhang H, Li X‐J, Martin D, Aebersold R. Identification and quantification of N‐linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21(6):660–666. [DOI] [PubMed] [Google Scholar]
  • 446. Li H, Liu Z. Recent advances in monolithic column‐based boronate‐affinity chromatography. Trends Anal Chem 2012;37:148–161. [Google Scholar]
  • 447. Zhang Y, Yu M, Zhang C, Ma WF, Zhang YT, Wang CC, Lu HJ. Highly selective and ultra fast solid‐phase extraction of n‐glycoproteome by oxime click chemistry using aminooxy‐functionalized magnetic nanoparticles. Anal Chem 2014;86(15):7920–7924. [DOI] [PubMed] [Google Scholar]
  • 448. Hudson KL, Bartlett GJ, Diehl RC, Agirre J, Gallagher T, Kiessling LL, Woolfson DN. Carbohydrate‐aromatic interactions in proteins. J Am Chem Soc 2015;137(48):15152–15160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 449. Nagae M, Yamaguchi Y. Sugar recognition and protein—protein interaction of mammalian lectins conferring diverse functions. Curr Opin Struct Biol 2015;34:108–115. [DOI] [PubMed] [Google Scholar]
  • 450. Rouquerol J, Avnir D, Fairbridge CW, Everett DH, Haynes JM, Pernicone N, Ramsay JDF, Sing KSW, Unger KK. Recommendations for the characterization of porous solids (technical report). Pure Appl Chem 1994;66(8):1739–1758. [Google Scholar]
  • 451. Ongay S, Boichenko A, Govorukhina N, Bischoff R. Glycopeptide enrichment and separation for protein glycosylation analysis. J Sep Sci 2012;35(18):2341–2372. [DOI] [PubMed] [Google Scholar]
  • 452. Sproß J, Sinz A. Monolithic media for applications in affinity chromatography. J Sep Sci 2011;34(16‐17):1958–1973. [DOI] [PubMed] [Google Scholar]
  • 453. Li QJ, Tu XY, Ye J, Bie ZJ, Bi XD, Liu Z. Nanoconfining affinity materials for pH‐mediated protein capture‐release. Chem Sci 2014;5(10):4065–4069. [Google Scholar]
  • 454. Chen Y, Wang SS, Ye J, Li DJ, Liu Z, Wu XC. Insights into the effect of nanoconfinement on molecular interactions. Nanoscale 2014;6(16):9563–9567. [DOI] [PubMed] [Google Scholar]
  • 455. Lin Z, Wang J, Yu RF, Yin XF, He Y. Incorporation of graphene oxide nanosheets into boronate‐functionalized polymeric monolith to enhance the electrochromatographic separation of small molecules. Electrophoresis 2015;36(4):596–606. [DOI] [PubMed] [Google Scholar]
  • 456. Yan Y, Deng C, Zheng Z, Zhang X, Yang P. Synthesis of polyboronic acid functionalized hierarchically ordered macro‐/mesoporous silica for selective enrichment of glycopeptides for mass spectrometric analysis. ChemPlusChem 2014;79(1):31–34. [DOI] [PubMed] [Google Scholar]
  • 457. Mann BF, Mann AKP, Skrabalak SE, Novotny MV. Sub 2‐μm macroporous silica particles derivatized for enhanced lectin affinity enrichment of glycoproteins. Anal Chem 2013;85(3):1905–1912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 458. Lu Y, Bie Z, Liu Y, Liu Z. Fine‐tuning the specificity of boronate affinity monoliths toward glycoproteins through pH manipulation. Analyst 2013;138(1):290–298. [DOI] [PubMed] [Google Scholar]
  • 459. Nie H, Chen Y, C Lü, Liu Z. Efficient selection of glycoprotein‐binding DNA aptamers via boronate affinity monolithic capillary. Anal Chem 2013;85(17):8277–8283. [DOI] [PubMed] [Google Scholar]
  • 460. Qin H, Hu Z, Wang F, Zhang Y, Zhao L, Xu G, Ra Wu, Zou H. Facile preparation of ordered mesoporous silica‐carbon composite nanoparticles for glycan enrichment. Chem Commun 2013;49(45):5162–5164. [DOI] [PubMed] [Google Scholar]
  • 461. Sun N, Deng C, Li Y, Zhang X. Highly selective enrichment of N‐linked glycan by carbon‐functionalized ordered graphene/mesoporous silica composites. Anal Chem 2014;86(4):2246–2250. [DOI] [PubMed] [Google Scholar]
  • 462. Zhao Y, Szeto SSW, Kong RPW, Law CH, Li G, Quan Q, Zhang Z, Wang Y, Chu IK. Online two‐dimensional porous graphitic carbon/reversed phase liquid chromatography platform applied to shotgun proteomics and glycoproteomics. Anal Chem 2014;86(24):12172–12179. [DOI] [PubMed] [Google Scholar]
  • 463. Jmeian Y, Hammad LA, Mechref Y. Fast and efficient online release of N‐glycans from glycoproteins facilitating liquid chromatography—tandem mass spectrometry glycomic profiling. Anal Chem 2012;84(20):8790–8796. [DOI] [PubMed] [Google Scholar]
  • 464. Tzeng Y‐K, Chang C‐C, Huang C‐N, Wu C‐C, Han C‐C, Chang H‐C. Facile MALDI‐MS analysis of neutral glycans in NaOH‐doped matrixes: Microwave‐assisted deglycosylation and one‐step purification with diamond nanoparticles. Anal Chem 2008;80(17):6809–6814. [DOI] [PubMed] [Google Scholar]
  • 465. Ren XJ, Bai HH, Pan YT, Tong W, Qin PB, Yan H, Deng SS, Zhong RG, Qin WJ, Qian XH. A graphene oxide‐based immobilized PNGase F reagent for highly efficient N‐glycan release and MALDI‐TOF MS profiling. Anal Methods 2014;6(8):2518–2525. [Google Scholar]
  • 466. Jin T, Xiong ZC, Zhu X, Mehio N, Chen YJ, Hu J, Zhang WB, Zou HF, Liu HL, Dai S. Template‐free synthesis of mesoporous polymers for highly selective enrichment of glycopeptides. ACS Macro Lett 2015;4(5):570–574. [DOI] [PubMed] [Google Scholar]
  • 467. Wu C, Liang Y, Zhao Q, Qu Y, Zhang S, Wu Q, Liang Z, Zhang L, Zhang Y. Boronate affinity monolith with a gold nanoparticle‐modified hydrophilic polymer as a matrix for the highly specific capture of glycoproteins. Chem Eur J 2014;20(28):8737–8743. [DOI] [PubMed] [Google Scholar]
  • 468. Liu Y, Lu Y, Liu Z. Restricted access boronate affinity porous monolith as a protein A mimetic for the specific capture of immunoglobulin G. Chem Sci 2012;3(5):1467–1471. [Google Scholar]
  • 469. Lin Z, Wang J, Tan X, Sun L, Yu R, Yang H, Chen G. Preparation of boronate‐functionalized molecularly imprinted monolithic column with polydopamine coating for glycoprotein recognition and enrichment. J Chromatogr A 2013;1319:141–147. [DOI] [PubMed] [Google Scholar]
  • 470. Stephenson‐Brown A, Acton AL, Preece JA, Fossey JS, Mendes PM. Selective glycoprotein detection through covalent templating and allosteric click‐imprinting. Chem Sci 2015;6(9):5114–5119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 471. Wu G, Li JY, Qu X, Zhang YX, Hong H, Liu CS. Template size matched film thickness for effectively in situ surface imprinting: A model study of glycoprotein imprints. RSC Adv 2015;5(58):47010–47021. [Google Scholar]
  • 472. Bie ZJ, Chen Y, Ye J, Wang SS, Liu Z. Boronate‐affinity glycan‐oriented surface imprinting: A new strategy to mimic lectins for the recognition of an intact glycoprotein and its characteristic fragments. Angew Chem‐Int Ed 2015;54(35):10211–10215. [DOI] [PubMed] [Google Scholar]
  • 473. Zheng JN, Xiao Y, Wang L, Lin Z, Yang HH, Zhang L, Chen GN. Click synthesis of glucose‐functionalized hydrophilic magnetic mesoporous nanoparticles for highly selective, enrichment of glycopeptides and glycans. J Chromatogr A 2014;1358:29–38. [DOI] [PubMed] [Google Scholar]
  • 474. Cao Q, Ma C, Bai H, Li X, Yan H, Zhao Y, Ying W, Qian X. Multivalent hydrazide‐functionalized magnetic nanoparticles for glycopeptide enrichment and identification. Analyst 2014;139(3):603–609. [DOI] [PubMed] [Google Scholar]
  • 475. Chen YJ, Xiong ZC, Zhang LY, Zhao JY, Zhang QQ, Peng L, Zhang WB, Ye ML, Zou HF. Facile synthesis of zwitterionic polymer‐coated core‐shell magnetic nanoparticles for highly specific capture of N‐linked glycopeptides. Nanoscale 2015;7(7):3100–3108. [DOI] [PubMed] [Google Scholar]
  • 476. Dong LP, Feng S, Li SS, Song PP, Wang JD. Preparation of concanavalin A‐chelating magnetic nanoparticles for selective enrichment of glycoproteins. Anal Chem 2015;87(13):6849–6853. [DOI] [PubMed] [Google Scholar]
  • 477. Fang CL, Xiong ZC, Qin HQ, Huang G, Liu J, Ye ML, Feng S, Zou HF. One‐pot synthesis of magnetic colloidal nanocrystal clusters coated with chitosan for selective enrichment of glycopeptides. Anal Chim Acta 2014;841:99–105. [DOI] [PubMed] [Google Scholar]
  • 478. Sun NR, Zhang XM, Deng CH. Designed synthesis of MOF‐derived magnetic nanoporous carbon materials for selective enrichment of glycans for glycomics analysis. Nanoscale 2015;7(15):6487–6491. [DOI] [PubMed] [Google Scholar]
  • 479. Wang H, Bie Z, Lu C, Liu Z. Magnetic nanoparticles with dendrimer‐assisted boronate avidity for the selective enrichment of trace glycoproteins. Chem Sci 2013;4(11):4298–4303. [Google Scholar]
  • 480. Wang MY, Zhang XM, Deng CH. Facile synthesis of magnetic poly(styrene‐co‐4‐vinylbenzene‐boronic acid) microspheres for selective enrichment of glycopeptides. Proteomics 2015;15(13):2158–2165. [DOI] [PubMed] [Google Scholar]
  • 481. Wang YL, Liu MB, Xie LQ, Fang CY, Xiong HM, Lu HJ. Highly efficient enrichment method for glycopeptide analyses: Using specific and nonspecific nanoparticles synergistically. Anal Chem 2014;86(4):2057–2064. [DOI] [PubMed] [Google Scholar]
  • 482. Zhang Y, Kuang M, Zhang L, Yang P, Lu H. An accessible protocol for solid‐phase extraction of N‐linked glycopeptides through reductive amination by amine‐functionalized magnetic nanoparticles. Anal Chem 2013;85(11):5535–5541. [DOI] [PubMed] [Google Scholar]
  • 483. Zhang ST, He XW, Chen LX, Zhang YK. Boronic acid functionalized magnetic nanoparticles via thiol‐ene click chemistry for selective enrichment of glycoproteins. New J Chem 2014;38(9):4212–4218. [Google Scholar]
  • 484. Zhang XH, He XW, Chen LX, Zhang YH. A combination of distillation‐precipitation polymerization and click chemistry: Fabrication of boronic acid functionalized Fe3O4 hybrid composites for enrichment of glycoproteins. J Mater Chem B Mater Biol Med 2014;2(21):3254–3262. [DOI] [PubMed] [Google Scholar]
  • 485. Lu Y‐W, Chien C‐W, Lin P‐C, Huang L‐D, Chen C‐Y, Wu S‐W, Han C‐L, Khoo K‐H, Lin C‐C, Chen Y‐J. BAD‐lectins: Boronic acid‐decorated lectins with enhanced binding affinity for the selective enrichment of glycoproteins. Anal Chem 2013;85(17):8268–8276. [DOI] [PubMed] [Google Scholar]
  • 486. Alwael H, Connolly D, Clarke P, Thompson R, Twamley B, O'Connor B, Paull B. Pipette‐tip selective extraction of glycoproteins with lectin modified gold nano‐particles on a polymer monolithic phase. Analyst 2011;136(12):2619–2628. [DOI] [PubMed] [Google Scholar]
  • 487. Liu M, Zhang L, Xu Y, Yang P, Lu H. Mass spectrometry signal amplification for ultrasensitive glycoprotein detection using gold nanoparticle as mass tag combined with boronic acid based isolation strategy. Anal Chim Acta 2013;788:129–134. [DOI] [PubMed] [Google Scholar]
  • 488. Morris NJ, Anderson H, Thibeault B, Vertes A, Powell MJ, Razunguzwa TT. Laser desorption ionization (LDI) silicon nanopost array chips fabricated using deep UV projection lithography and deep reactive ion etching. RSC Adv 2015;5(88):72051–72057. [Google Scholar]
  • 489. Tran T, Park S, Lee H, Park S, Kim B, Kim O‐H, B‐c Oh, Lee D, Lee H. Ultrasmall gold nanoparticles for highly specific isolation/enrichment of N‐linked glycosylated peptides. Analyst 2012;137(4):991–998. [DOI] [PubMed] [Google Scholar]
  • 490. Huang G, Xiong Z, Qin H, Zhu J, Sun Z, Zhang Y, Peng X, Ou J, Zou H. Synthesis of zwitterionic polymer brushes hybrid silica nanoparticles via controlled polymerization for highly efficient enrichment of glycopeptides. Anal Chim Acta 2014;809:61–68. [DOI] [PubMed] [Google Scholar]
  • 491. Zhang WJ, Han HH, Bai HH, Tong W, Zhang YJ, Ying WT, Qin WJ, Qian XH. A highly efficient and visualized method for glycan enrichment by self‐assembling pyrene derivative functionalized free graphene oxide. Anal Chem 2013;85(5):2703–2709. [DOI] [PubMed] [Google Scholar]
  • 492. Bai HH, Pan YT, Tong W, Zhang WJ, Ren XJ, Tian F, Peng B, Wang X, Zhang YJ, Deng YL, Qin WJ, Qian XH. Graphene based soft nanoreactors for facile “one‐step” glycan enrichment and derivatization for MALDI‐TOF‐MS analysis. Talanta 2013;117:1–7. [DOI] [PubMed] [Google Scholar]
  • 493. Xu G, Zhang W, Wei L, Lu H, Yang P. Boronic acid‐functionalized detonation nanodiamond for specific enrichment of glycopeptides in glycoproteome analysis. Analyst 2013;138(6):1876‐1885. [DOI] [PubMed] [Google Scholar]
  • 494. Yeap WS, Tan YY, Loh KP. Using detonation nanodiamond for the specific capture of glycoproteins. Anal Chem 2008;80(12):4659–4665. [DOI] [PubMed] [Google Scholar]
  • 495. Wu C‐L, Wang C‐C, Lai Y‐H, Lee H, Lin J‐D, Lee YT, Wang Y‐S. Selective enhancement of carbohydrate ion abundances by diamond nanoparticles for mass spectrometric analysis. Anal Chem 2013;85(8):3836–3841. [DOI] [PubMed] [Google Scholar]
  • 496. Mu B, Zhang JQ, McNicholas TP, Reuel NF, Kruss S, Strano MS. Recent advances in molecular recognition based on nanoengineered platforms. Acc Chem Res 2014;47(4):979–988. [DOI] [PubMed] [Google Scholar]
  • 497. Reuel NF, Grassbaugh B, Kruss S, Mundy JZ, Opel C, Ogunniyi AO, Egodage K, Wahl R, Helk B, Zhang JQ, Kalcioglu ZI, Tvrdy K, Bellisario DO, Mu B, Blake SS, Van Vliet KJ, Love JC, Wittrup KD, Strano MS. Emergent properties of nanosensor arrays: Applications for monitoring IgG affinity distributions, weakly affined hypermannosylation, and colony selection for biomanufacturing. ACS Nano 2013;7(9):7472–7482. [DOI] [PubMed] [Google Scholar]
  • 498. Mu B, Ahn J, McNicholas TP, Strano MS. Generating selective saccharide binding affinity of phenyl boronic acids by using single‐walled carbon nanotube corona phases. Chem Eur J 2015;21(12):4523–4528. [DOI] [PubMed] [Google Scholar]
  • 499. Bi CF, Jiang RD, He XW, Chen LX, Zhang YK. Synthesis of a hydrophilic maltose functionalized Au NP/PDA/Fe3O4‐RGO magnetic nanocomposite for the highly specific enrichment of glycopeptides. RSC Adv 2015;5(73):59408–59416. [Google Scholar]
  • 500. Hu JJ, Ma RN, Liu F, Chen YL, Ju HX. Mercaptophenylboronic acid modified gold nanoparticle@silica bubbles for buoyant separation and specific enrichment of glycopeptides. RSC Adv 2014;4(55):28856–28859. [Google Scholar]
  • 501. Ma RN, Hu JJ, Cai ZW, Ju HX. Facile synthesis of boronic acid‐functionalized magnetic carbon nanotubes for highly specific enrichment of glycopeptides. Nanoscale 2014;6(6):3150–3156. [DOI] [PubMed] [Google Scholar]
  • 502. Wan H, Huang JF, Liu ZS, Li JA, Zhang WB, Zou HF. A dendrimer‐assisted magnetic graphene‐silica hydrophilic composite for efficient and selective enrichment of glycopeptides from the complex sample. Chem Commun 2015;51(45):9391–9394. [DOI] [PubMed] [Google Scholar]
  • 503. Qu YY, Liu JX, Yang KG, Liang Z, Zhang LH, Zhang YK. Boronic acid functionalized core‐shell polymer nanoparticles prepared by distillation precipitation polymerization for glycopeptide enrichment. Chem Eur J 2012;18(29):9056–9062. [DOI] [PubMed] [Google Scholar]
  • 504. Wang JX, Wang YN, Gao MX, Zhang XM, Yang PY. Multi layer hydrophilic poly(phenol‐formaldehyde resin)‐coated magnetic graphene for boronic acid immobilization as a novel matrix for glycoproteome analysis. ACS Appl Mater Interfaces 2015;7(29):16011–16017. [DOI] [PubMed] [Google Scholar]
  • 505. Jiao J, Zhang Y, Yang PY, Lu HJ. Hydrazinonicotinic acid as a novel matrix for highly sensitive and selective MALDI‐MS analysis of oligosaccharides. Analyst 2015;140(1):156–161. [DOI] [PubMed] [Google Scholar]
  • 506. Kim JY, Lee SY, Kim SK, Park SR, Kang D, Moon MH. Development of an online microbore hollow fiber enzyme reactor coupled with nanoflow liquid chromatography‐tandem mass spectrometry for global proteomics. Anal Chem 2013;85(11):5506–5513. [DOI] [PubMed] [Google Scholar]
  • 507. Kim JY, Oh D, Kim SK, Kang D, Moon MH. Isotope‐coded carbamidomethylation for quantification of N‐glycoproteins with online microbore hollow fiber enzyme reactor‐nanoflow liquid chromatography‐tandem mass spectrometry. Anal Chem 2014;86(15):7650–7657. [DOI] [PubMed] [Google Scholar]
  • 508. Li LL, Jiao J, Cai Y, Zhang Y, Lu HJ. Fluorinated carbon tag derivatization combined with fluorous solid‐phase extraction: A new method for the highly sensitive and selective mass spectrometric analysis of glycans. Anal Chem 2015;87(10):5125–5131. [DOI] [PubMed] [Google Scholar]
  • 509. Li Z, Zhang YW, Xin YL, Bai Y, Zhou HH, Liu HW. A lithium‐rich composite metal oxide used as a SALDI‐MS matrix for the determination of small biomolecules. Chem Commun 2014;50(97):15397–15399. [DOI] [PubMed] [Google Scholar]
  • 510. Niziol J, Rode W, Zielinski Z, Ruman T. Matrix‐free laser desorption‐ionization with silver nanoparticle‐enhanced steel targets. Int J Mass Spectrom 2013;335:22–32. [Google Scholar]
  • 511. Sekula J, Niziol J, Rode W, Ruman T. Silver nanostructures in laser desorption/ionization mass spectrometry and mass spectrometry imaging. Analyst 2015;140(18):6195–6209. [DOI] [PubMed] [Google Scholar]
  • 512. Xu Y, Zhang L, Lu H, Yang P. On plate enrichment of glycopeptides by using boronic acid functionalized goldcoated Si wafer. Proteomics 2010;10(5):1079–1086. [DOI] [PubMed] [Google Scholar]
  • 513. Zeng ZF, Wang YD, Guo XH, Wang L, Lu N. On‐plate glycoproteins/glycopeptides selective enrichment and purification based on surface pattern for direct MALDI MS analysis. Analyst 2013;138(10):3032–3037. [DOI] [PubMed] [Google Scholar]
  • 514. Xiong Z, Qin H, Wan H, Huang G, Zhang Z, Dong J, Zhang L, Zhang W, Zou H. Layer‐by‐layer assembly of multilayer polysaccharide coated magnetic nanoparticles for the selective enrichment of glycopeptides. Chem Commun 2013;49(81):9284–9286. [Google Scholar]
  • 515. Ma W‐F, Li L‐L, Zhang Y, An Q, You L‐J, Li J‐M, Zhang Y‐T, Xu S, Yu M, Guo J, Lu H‐J, Wang C‐C. Ligand‐free strategy for ultrafast and highly selective enrichment of glycopeptides using Ag‐coated magnetic nanoarchitectures. J Mater Chem 2012;22(45):23981–23988. [Google Scholar]
  • 516. Bai HH, Fan C, Zhang WJ, Pan YT, Ma L, Ying WT, Wang JH, Deng YL, Qian XH, Qin WJ. A pH‐responsive soluble polymer‐based homogeneous system for fast and highly efficient N‐glycoprotein/glycopeptide enrichment and identification by mass spectrometry. Chem Sci 2015;6(7):4234–4241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 517. Zhang YW, Li Z, Zhao Q, Zhou YL, Liu HW, Zhang XX. A facilely synthesized amino‐functionalized metal‐organic framework for highly specific and efficient enrichment of glycopeptides. Chem Commun 2014;50(78):11504–11506. [DOI] [PubMed] [Google Scholar]
  • 518. Ban L, Mrksich M. On‐chip synthesis and label‐free assays of oligosaccharide arrays. Angew Chem Int Ed 2008;47(18):3396–3399. [DOI] [PubMed] [Google Scholar]
  • 519. Su J, Mrksich M. Using mass spectrometry to characterize self‐assembled monolayers presenting peptides, proteins, and carbohydrates. Angew Chem Int Ed 2002;41(24):4715–4718. [DOI] [PubMed] [Google Scholar]
  • 520. Laurent N, Haddoub R, Voglmeir J, Wong SCC, Gaskell SJ, Flitsch SL. SPOT synthesis of peptide arrays on self‐assembled monolayers and their evaluation as enzyme substrates. ChemBioChem 2008;9(16):2592–2596. [DOI] [PubMed] [Google Scholar]
  • 521. Laurent N, Voglmeir J, Wright A, Blackburn J, Pham NT, Wong SCC, Gaskell SJ, Flitsch SL. Enzymatic glycosylation of peptide arrays on gold surfaces. ChemBioChem 2008;9(6):883–887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 522. Sanchez‐Ruiz A, Serna S, Ruiz N, Martin‐Lomas M, Reichardt N‐C. MALDI‐TOF mass spectrometric analysis of enzyme activity and lectin trapping on an array of N‐glycans. Angew Chem Int Ed 2011;50(8):1801–1804. [DOI] [PubMed] [Google Scholar]
  • 523. Zhi Z‐L, Laurent N, Powell AK, Karamanska R, Fais, M , Voglmeir J, Wright A, Blackburn JM, Crocker PR, Russell DA, Flitsch S, Field, RA , Turnbull JE. A versatile gold surface approach for fabrication and interrogation of glycoarrays. ChemBioChem 2008;9(10):1568–1575. [DOI] [PubMed] [Google Scholar]
  • 524. Ban L, Pettit N, Li L, Stuparu AD, Cai L, Chen W, Guan W, Han W, Wang PG, Mrksich M. Discovery of glycosyltransferases using carbohydrate arrays and mass spectrometry. Nat Chem Biol 2012;8(9):769–773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 525. Both P, Green AP, Gray CJ, Šardzík R, Voglmeir J, Fontana C, Austeri M, Rejzek M, Richardson D, Field RA, Widmalm G, Flitsch SL, Eyers CE. Discrimination of epimeric glycans and glycopeptides using IM‐MS and its potential for carbohydrate sequencing. Nat Chem 2014;6(1):65–74. [DOI] [PubMed] [Google Scholar]
  • 526. Hofmann J, Hahm HS, Seeberger PH, Pagel K. Identification of carbohydrate anomers using ion mobility‐mass spectrometry. Nature 2015;526(7572):241–244. [DOI] [PubMed] [Google Scholar]
  • 527. Hinneburg H, Stavenhagen K, Schweiger‐Hufnagel U, Pengelley S, Jabs W, Seeberger PH, Silva DV, Wuhrer M, Kolarich D. The art of destruction: Optimizing collision energies in quadrupole‐time of flight (Q‐TOF) instruments for glycopeptide‐based glycoproteomics. J Am Soc Mass Spectrom 2016;27(3):507–519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 528. Northen TR, Lee J‐C, Hoang L, Raymond J, Hwang D‐R, Yannone SM, Wong C‐H, Siuzdak G. A nanostructure‐initiator mass spectrometry‐based enzyme activity assay. Proc Natl Acad Sci USA 2008;105(10):3678–3683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 529. Northen TR, Yanes O, Northen MT, Marrinucci D, Uritboonthai W, Apon J, Golledge SL, Nordstrom A, Siuzdak G. Clathrate nanostructures for mass spectrometry. Nature 2007;449(7165):1033–1036. [DOI] [PubMed] [Google Scholar]
  • 530. Deng K, Takasuka TE, Heins R, Cheng XL, Bergeman LF, Shi J, Aschenbrener R, Deutsch S, Singh S, Sale KL, Simmons BA, Adams PD, Singh AK, Fox BG, Northen TR. Rapid kinetic characterization of glycosyl hydrolases based on oxime derivatization and nanostructure‐initiator mass spectrometry (NIMS). ACS Chem Biol 2014;9(7):1470–1479. [DOI] [PubMed] [Google Scholar]
  • 531. Beloqui A, Calvo J, Serna S, Yan S, Wilson IBH, Martin‐Lomas M, Reichardt NC. Analysis of microarrays by MALDI‐TOF MS. Angew Chem Int Ed 2013;52(29):7477–7481. [DOI] [PubMed] [Google Scholar]
  • 532. Garcia‐Parajo MF, Cambi A, Torreno‐Pina JA, Thompson N, Jacobson K. Nanoclustering as a dominant feature of plasma membrane organization. J Cell Sci 2014;127(23):4995–5005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 533. de Laorden CL, Beloqui A, Yate L, Calvo J, Puigivila M, Llop J, Reichardt NC. Nanostructured indium tin oxide slides for small‐molecule profiling and imaging mass spectrometry of metabolites by surface‐assisted laser desorption ionization MS. Anal Chem 2015;87(1):431–440. [DOI] [PubMed] [Google Scholar]
  • 534. Etxebarria J, Calvo J, Reichardt NC. Nanostructured weathering steel for matrix‐free laser desorption ionisation mass spectrometry and imaging of metabolites, drugs and complex glycans. Analyst 2014;139(11):2873–2883. [DOI] [PubMed] [Google Scholar]
  • 535. Wang FL, Hong M, Xu LD, Geng ZR. Nanomaterial‐based surface‐assisted laser desorption ionization mass spectroscopy. Prog Chem 2015;27(5):571–584. [Google Scholar]
  • 536. Campuzano S, Orozco J, Kagan D, Guix M, Gao W, Sattayasamitsathit S, Claussen JC, Merkoci A, Wang J. Bacterial isolation by lectin‐modified microengines. Nano Lett 2012;12(1):396–401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 537. Kuralay F, Sattayasamitsathit S, Gao W, Uygun A, Katzenberg A, Wang J. Self‐propelled carbohydrate‐sensitive microtransporters with built‐in boronic acid recognition for isolating sugars and cells. J Am Chem Soc 2012;134(37):15217–15220. [DOI] [PubMed] [Google Scholar]
  • 538. Garcia‐Gradilla V, Orozco J, Sattayasamitsathit S, Soto F, Kuralay F, Pourazary A, Katzenberg A, Gao W, Shen Y, Wang J. Functionalized ultrasound‐propelled magnetically guided nanomotors: Toward practical biomedical applications. ACS Nano 2013;7(10):9232–9240. [DOI] [PubMed] [Google Scholar]
  • 539. Kagan D, Benchimol MJ, Claussen JC, Chuluun‐Erdene E, Esener S, Wang J. Acoustic droplet vaporization and propulsion of perfluorocarbon‐loaded microbullets for targeted tissue penetration and deformation. Angew Chem Int Ed 2012;51(30):7519–7522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 540. Garcia‐Gradilla V, Sattayasamitsathit S, Soto F, Kuralay F, Yardımcı C, Wiitala D, Galarnyk M, Wang J. Ultrasound‐propelled nanoporous gold wire for efficient drug loading and release. Small 2014;10(20):4154–4159. [DOI] [PubMed] [Google Scholar]
  • 541. Wang J, Gao W. Nano/microscale motors: Biomedical opportunities and challenges. ACS Nano 2012;6(7):5745–5751. [DOI] [PubMed] [Google Scholar]
  • 542. Wang H, Pumera M. Fabrication of micro/nanoscale motors. Chem Rev 2015;115(16):8704–8735. [DOI] [PubMed] [Google Scholar]
  • 543. Martin CR. Nanomaterials—A membrane‐based synthetic approach. Science 1994;266(5193):1961–1966. [DOI] [PubMed] [Google Scholar]
  • 544. Xuan M, Shao J, Lin X, Dai L, He Q. Self‐propelled janus mesoporous silica nanomotors with sub‐100 nm diameters for drug encapsulation and delivery. ChemPhysChem 2014;15(11):2255–2260. [DOI] [PubMed] [Google Scholar]
  • 545. Venugopalan PL, Sai R, Chandorkar Y, Basu B, Shivashankar S, Ghosh A. Conformal cytocompatible ferrite coatings facilitate the realization of a nanovoyager in human blood. Nano Lett 2014;14(4):1968–1975. [DOI] [PubMed] [Google Scholar]
  • 546. Mou F, Chen C, Zhong Q, Yin Y, Ma H, Guan J. Autonomous motion and temperature‐controlled drug delivery of Mg/Pt‐Poly (N‐isopropylacrylamide) Janus micromotors driven by simulated body fluid and blood plasma. ACS Appl Mater Interfaces 2014;6(12):9897–9903. [DOI] [PubMed] [Google Scholar]
  • 547. Wang W, Li S, Mair L, Ahmed S, Huang TJ, Mallouk TE. Acoustic propulsion of nanorod motors inside living cells. Angew Chem Int Ed 2014;53(12):3201–3204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 548. Rao KJ, Li F, Meng L, Zheng H, Cai F, Wang W. A force to be reckoned with: A review of synthetic microswimmers powered by ultrasound. Small 2015;11(24):2836–2846. [DOI] [PubMed] [Google Scholar]
  • 549. Orozco J, Jurado‐Sánchez B, Wagner G, Gao W, Vazquez‐Duhalt R, Sattayasamitsathit S, Galarnyk M, Cortés A, Saintillan D, Wang J. Bubble‐propelled micromotors for enhanced transport of passive tracers. Langmuir 2014;30(18):5082–5087. [DOI] [PubMed] [Google Scholar]
  • 550. Orozco J, Pan G, Sattayasamitsathit S, Galarnyk M, Wang J. Micromotors to capture and destroy anthrax simulant spores. Analyst 2015;140(5):1421–1427. [DOI] [PubMed] [Google Scholar]
  • 551. Wu Z, Li T, Li J, Gao W, Xu T, Christianson C, Gao W, Galarnyk M, He Q, Zhang L, Wang J. Turning erythrocytes into functional micromotors. ACS Nano 2014;8(12):12041–12048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 552. Wu Z, Esteban‐Fernandez de Avila B, Martin A, Christianson C, Gao W, Thamphiwatana SK, Escarpa A, He Q, Zhang L, Wang J. RBC micromotors carrying multiple cargos towards potential theranostic applications. Nanoscale 2015;7(32):13680–13686. [DOI] [PubMed] [Google Scholar]
  • 553. Soto F, Martin A, Ibsen S, Vaidyanathan M, Garcia‐Gradilla V, Levin Y, Escarpa A, Esener SC, Wang J. Acoustic microcannons: Toward advanced microballistics. ACS Nano 2016;10(1):1522–1528. [DOI] [PubMed] [Google Scholar]
  • 554. Zhang A, Lieber CM. Nano‐bioelectronics. Chem Rev 2016;116(1):215–257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 555. McKeating KS, Aube A, Masson J‐F. Biosensors and nanobiosensors for therapeutic drug and response monitoring. Analyst 2016;141(2):429–449. [DOI] [PubMed] [Google Scholar]
  • 556. Ahmed MU, Hossain MM, Safavieh M, Wong YL, Rahman IA, Zourob M, Tamiya E. Toward the development of smart and low cost point‐of‐care biosensors based on screen printed electrodes. Crit Rev Biotechnol 2016;36(3):495–505. [DOI] [PubMed] [Google Scholar]
  • 557. Chang L, Hu J, Chen F, Chen Z, Shi J, Yang Z, Li Y, Lee LJ. Nanoscale bio‐platforms for living cell interrogation: Current status and future perspectives. Nanoscale 2016;8(6):3181–3206. [DOI] [PubMed] [Google Scholar]
  • 558. Justino CIL, Rocha‐Santos TAP, Duarte AC, Rocha‐Santos TAP. Advances in point‐of‐care technologies with biosensors based on carbon nanotubes. Trends Anal Chem 2013;45:24–36. [Google Scholar]
  • 559. Howes PD, Chandrawati R, Stevens MM. Bionanotechnology. Colloidal nanoparticles as advanced biological sensors. Science 2014;346(6205):1247390. [DOI] [PubMed] [Google Scholar]
  • 560. Ravalli A, Marrazza G. Gold and magnetic nanoparticles‐based electrochemical biosensors for cancer biomarker determination. J Nanosci Nanotechnol 2015;15(5):3307–3319. [DOI] [PubMed] [Google Scholar]
  • 561. Viswambari Devi R, Doble M, Verma RS. Nanomaterials for early detection of cancer biomarker with special emphasis on gold nanoparticles in immunoassays/sensors. Biosens Bioelectron 2015;68:688‐698. [DOI] [PubMed] [Google Scholar]
  • 562. Pihikova D, Belicky S, Kasak P, Bertok T, Tkac J. Sensitive detection and glycoprofiling of a prostate specific antigen using impedimetric assays. Analyst 2016;141(3):1044–1051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 563. Cid Martin JJ, Assali M, Fernandez‐Garcia E, Valdivia V, Sanchez‐Fernandez EM, Garcia Fernandez JM, Wellinger RE, Fernandez I, Khiar N. Tuning of glyconanomaterial shape and size for selective bacterial cell agglutination. J Mater Chem B 2016;4(11):2028–2037. [DOI] [PubMed] [Google Scholar]
  • 564. Yin Z, Huang X. Boosting humoral immune responses to tumor‐associated carbohydrate antigens with virus‐like particles. In: Jimenez‐Barbero J, Javier Canada F, Martin‐Santamaria S, Eds. Carbohydrates in Drug Design and Discovery. Cambridge: Royal Society of Chemistry; 2015. p 132–150.
  • 565. Saleh T, Shojaosadati SA. Multifunctional nanoparticles for cancer immunotherapy. Hum Vaccin Immunother 2016;12(7):1863–1875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 566. Sattin S, Bernardi A. Glycoconjugates and glycomimetics as microbial anti‐adhesives. Trends Biotechnol 2016;34(6):483–495. [DOI] [PubMed] [Google Scholar]
  • 567. Arpicco S, Milla P, Stella B, Dosio F. Hyaluronic acid conjugates as vectors for the active targeting of drugs, genes and nanocomposites in cancer treatment. Molecules 2014;19(3):3193–3230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 568. Bang D, Lee T, Choi J, Park Y, Kim E, Huh Y‐M, Haam S. A multistep photothermic‐driven drug release system using wire‐framed Au nanobundles. Adv Health Mater 2015;4(2):255–263. [DOI] [PubMed] [Google Scholar]
  • 569. Li N, Chen Y, Zhang Y‐M, Yang Y, Su Y, Chen J‐T, Liu Y. Polysaccharide‐gold nanocluster supramolecular conjugates as a versatile platform for the targeted delivery of anticancer drugs. Sci Rep 2014;4:4164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 570. Qi X, Fan Y, He H, Wu Z. Hyaluronic acid‐grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneously. Carbohydr Polym 2015;126:231–239. [DOI] [PubMed] [Google Scholar]
  • 571. Li W, Zheng C, Pan Z, Chen C, Hu D, Gao G, Kang S, Cui H, Gong P, Cai L. Smart hyaluronidase‐actived theranostic micelles for dual‐modal imaging guided photodynamic therapy. Biomaterials 2016;101:10–19. [DOI] [PubMed] [Google Scholar]
  • 572. Yang L, He J, Wen Y, Yi W, Li Q, Lin L, Miao X, Chen W, Xiong L. Nanoscale photodynamic agents for colorectal cancer treatment: A review. J Biomed Nanotechnol 2016;12(7):1348–1373. [DOI] [PubMed] [Google Scholar]
  • 573. Hwang S, Nam J, Jung S, Song J, Doh H, Kim S. Gold nanoparticle‐mediated photothermal therapy: Current status and future perspective. Nanomedicine 2014;9(13):2003–2022. [DOI] [PubMed] [Google Scholar]
  • 574. Yu M, Wu X, Lin B, Han J, Yang L, Han S. Lysosomal pH decrease in inflammatory cells used to enable activatable imaging of inflammation with a sialic acid conjugated profluorophore. Anal Chem 2015;87(13):6688–6695. [DOI] [PubMed] [Google Scholar]
  • 575. Blau R, Krivitsky A, Epshtein Y, Satchi‐Fainaro R. Are nanotheranostics and nanodiagnostics‐guided drug delivery stepping stones towards precision medicine? Drug Resist Updat 2016;27:39–58. [DOI] [PubMed] [Google Scholar]
  • 576. Li J, He Y, Sun W, Luo Y, Cai H, Pan Y, Shen M, Xia J, Shi X. Hyaluronic acid‐modified hydrothermally synthesized iron oxide nanoparticles for targeted tumor MR imaging. Biomaterials 2014;35(11):3666–3677. [DOI] [PubMed] [Google Scholar]
  • 577. Kolarich D, Jensen PH, Altmann F, Packer NH. Determination of site‐specific glycan heterogeneity on glycoproteins. Nat Protoc 2012;7(7):1285–1298. [DOI] [PubMed] [Google Scholar]
  • 578. Oliveira C, Teixeira JA, Domingues L. Recombinant lectins: An array of tailor‐made glycan‐interaction biosynthetic tools. Crit Rev Biotechnol 2013;33(1):66–80. [DOI] [PubMed] [Google Scholar]
  • 579. Škrlec K, Štrukelj B, Berlec A. Non‐immunoglobulin scaffolds: A focus on their targets. Trends Biotechnol 2015;33(7):408–418. [DOI] [PubMed] [Google Scholar]
  • 580. Johnson A, Song Q, Ko Ferrigno P, Bueno PR, Davis JJ. Sensitive affimer and antibody based impedimetric label‐free assays for C‐reactive protein. Anal Chem 2012;84(15):6553–6560. [DOI] [PubMed] [Google Scholar]
  • 581. Scognamiglio V, Antonacci A, Lambreva MD, Litescu SC, Rea G. Synthetic biology and biomimetic chemistry as converging technologies fostering a new generation of smart biosensors. Biosens Bioelectron 2015;74:1076–1086. [DOI] [PubMed] [Google Scholar]
  • 582. Jolly P, Tamboli V, Harniman RL, Estrela P, Allender CJ, Bowen JL. Aptamer—MIP hybrid receptor for highly sensitive electrochemical detection of prostate specific antigen. Biosens Bioelectron 2016;75:188–195. [DOI] [PubMed] [Google Scholar]
  • 583. Xu Q, Davis JJ. The diagnostic utility of electrochemical impedance. Electroanalysis 2014;26(6):1249–1258. [Google Scholar]
  • 584. Pawar D, Jaganathan KS. Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: Enhancement of mucosal and systemic immune response. Drug Deliv 2016;23(1):185–194. [DOI] [PubMed] [Google Scholar]
  • 585. Zoidl M, Gonzalez Santana A, Torvisco A, Tysoe C, Siriwardena A, Withers SG, Wrodnigg TM. The Staudinger/aza‐Wittig/Grignard reaction as key step for the concise synthesis of 1‐C‐alkyl‐iminoalditol glycomimetics. Carbohydr Res 2016;429:62–70. [DOI] [PubMed] [Google Scholar]
  • 586. Zelli R, Longevial J‐F, Dumy P, Marra A. Synthesis and biological properties of multivalent iminosugars. New J Chem 2015;39(7):5050–5074. [Google Scholar]
  • 587. Orecchioni M, Cabizza R, Bianco A, Delogu LG. Graphene as cancer theranostic tool: Progress and future challenges. Theranostics 2015;5(7):710–723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 588. Dong H, Dai W, Ju H, Lu H, Wang S, Xu L, Zhou SF, Zhang Y, Zhang X. Multifunctional poly(L‐lactide)‐polyethylene glycol‐grafted graphene quantum dots for intracellular microRNA imaging and combined specific‐gene‐targeting agents delivery for improved therapeutics. ACS Appl Mater Interfaces 2015;7(20):11015–11023. [DOI] [PubMed] [Google Scholar]
  • 589. Huffman JE, Pučić‐Baković M, Klarić L, Hennig R, Selman MHJ, Vučković F, Novokmet M, Krištić J, Borowiak M, Muth T, Polašek O, Razdorov G, Gornik O, Plomp R, Theodoratou E, Wright AF, Rudan I, Hayward C, Campbell H, Deelder AM, Reichl U, Aulchenko YS, Rapp E, Wuhrer M, Lauc G. Comparative performance of four methods for high‐throughput glycosylation analysis of immunoglobulin G in genetic and epidemiological research. Mol Cell Proteomics 2014;13(6):1598–1610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 590. Reusch D, Haberger M, Falck D, Peter B, Maier B, Gassner J, Hook M, Wagner K, Bonnington L, Bulau P, Wuhrer M. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc‐glycosylation profiles—Part 2: Mass spectrometric methods. mAbs 2015;7(4):732–742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 591. Reusch D, Haberger M, Maier B, Maier M, Kloseck R, Zimmermann B, Hook M, Szabo Z, Tep S, Wegstein J, Alt N, Bulau P, Wuhrer M. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc‐glycosylation profiles—Part 1: Separation‐based methods. mAbs 2015;7(1):167–179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 592. Ito H, Kaji H, Togayachi A, Azadi P, Ishihara M, Geyer R, Galuska C, Geyer H, Kakehi K, Kinoshita M, Karlsson N, Jin C, Kato K, Yagi H, Kondo S, Kawasaki N, Hashii N, Kolarich D, Stavenhagen K, Packer N, Thaysen‐Andersen M, Nakano M, Taniguchi N, Kurimoto A, Wada Y, Tajiri M, Yang P, Cao W, Li H, Rudd P, Narimatsu H. Comparison of analytical methods for profiling N‐ and O‐linked glycans from cultured cell lines. Glycoconj J 2016;33(3):405–415. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Medicinal Research Reviews are provided here courtesy of Wiley

RESOURCES